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Abstract 
Growth hormone variant (GH-V) is expressed in the human placenta. Placental GH-V 
is not produced in rodents, but pituitary GH production is increased in pregnancy. In 
both cases, pulsatile GH secretion is replaced by a more continuous GH pattern. The 
placenta also expresses GH receptors, so it itself could represent a target tissue for 
direct GH action. GH effects are mediated in part via the JAK/Stat5b pathway, and 
detection of phosphorylation and nuclear translocation of Stat5b can be used to 
identify cells responding directly to GH in vivo.  I have now tested whether the rodent 
placenta shows Stat5b responses to GH in vivo. This has been studied under basal 
conditions, following continuous GH replacement, and during fasting, with or without 
insulin injection.  Following a single iv injection of recombinant bovine GH (bGH) in 
female dwarf rats or GHRH-M2 GH-deficient mice, tissues were processed for 
phospho-Stat5 (pYStat5) immunocytochemistry. As expected, both non-pregnant and 
pregnant animals showed marked hepatic pYStat5 responses. Notably, pYStat5 
responses were also seen in placental syncytiotrophoblast cells in response to 
injections of GH but not saline. GH exposure during pregnancy is continuous, and it 
has previously been shown in male dwarf rats that continuous GH exposure is much 
less effective in inducing hepatic Stat5 phosphorylation, and blunts the pYStat5 
response to a GH pulse. Pregnant rats receiving continuous bGH, showed an increased 
cellular pYStat5 staining compared to saline controls. However, like in the male rats, 
the response to GH was blunted following continuous exposure. Fasting is known to 
impair GH effects, with lower pYStat5 responses in target tissues. GH-induced 
pYStat5 responses were reduced in fasted animals, a single injection of insulin was 
able to restore the response to GH during the continuing state of fasting, however, this 
was variable depending on the extent of endogenous GH. GH deficiency was also 
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associated with reduced litter size, average pup and placental weights. A preliminary 
microarray analysis was carried to identify potential GH target genes in the placenta. 
A few well known GH target genes or placental genes containing potential Stat5b 
response elements showed no change in response to GH or a change in secretory 
pattern. However, some novel genes were identified as GH-responsive and might be 
important in growth during pregnancy. In conclusion, my results show that the 
placenta is a direct target for GH, but what role this plays in placental function or fetal 
growth remains to be determined. 
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1. Introduction 
 
 
 
1. General Introduction 
 
Growth hormone (GH) is the central endocrine regulator of postnatal growth and 
involved in the coordination of a wide range of biological processes. GH is also 
required for fetal nutrition and may have some indirect effects on fetal growth. The 
human growth hormone gene family is encoded within a 48-kilobase (kb) cluster on 
the long arm of chromosome 17. This cluster spans 66.5 kb and is made up of five 
genes, each of which is found within close proximity of each other [1]. The genes are 
highly related, owing probably entirely to gene duplications, having between 91% and 
99% sequence homology [2]. The genes encode pituitary growth hormone (native 
GH, GH-N gene), placental growth hormone (GH variant, GH-V gene), and three 
chorionic somatomammotrophins (hCS-A, hCS-B and hCS-L genes), also called 
lactogens, [3]. The GH gene is approximately 3 kb long, consists of 5 exons and 4 
introns, and encodes a 217-amino-acid precursor protein [2]. An amino-terminal 
signal peptide is subsequently removed by proteolytic cleavage yielding a mature 
single-chain polypeptide that contains 191 amino acids with a molecular mass of 22-
kDa [4, 5]. A 20-kDa form of GH has also been found to be secreted by the pituitary 
and is produced by alternative splicing of the GH precursor mRNA [6].  
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Genes encoding rat and mouse GH have been shown to be situated on chromosome 10 
[7] and 11 [8] of the rat and mouse genomes respectively. Mouse GH is encoded by a 
single copy gene located in a highly conserved region between mouse chromosome 11 
and human chromosome 17. Other genes from the PRL/GH family, including the 
genes encoding for mouse PRL, and placental lactogens have all been mapped to 
chromosome 13 [8]. Like in the mouse and in humans, PRL genes are located on 
different chromosomes, with rat PRL located on chromosome 17 [7]. 
 
1.1 GH, regulation, action and secretion. 
Pituitary GH is known to be under neuronal, hormonal and metabolic control. GH is 
synthesized and secreted by the somatotroph cells in the anterior lobe of the pituitary 
gland [2, 4]. GH secretion from somatotrophs is a calcium dependent event, during 
which an increase in cytosolic calcium is required for the release of GH [9]. GH 
synthesis and secretion is regulated by two hypothalamic peptides, growth hormone 
releasing hormone (GHRH) [10] and somatostatin (SMS) [11], via their opposing 
effects on intracellular calcium concentration [12, 13]. GHRH elicits an increase in 
intracellular calcium via its G-protein-coupled receptor, in part by stimulating an 
increase in the level of cellular cAMP [14]. SMS has an opposing effect on 
intracellular calcium concentration and inhibits GH synthesis and secretion [14]. 
A class of molecules known as GH-releasing peptides [15] also stimulates GH 
release. The GH-releasing peptides are a group of short synthetic peptides that 
stimulate GH release via binding to the GH secretagogue receptor (GHS-R) [16]. The 
GHS-R cDNA encodes a seven-transmembrane G protein-coupled receptor of 364 
amino acids and is highly conserved between rats, human, and pig [16]. Kojima et al 
(1999) [17] identified and purified the endogenous GHS-R ligand termed ghrelin, a 
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28-amino-acid peptide that can stimulates the release of GH both in vitro and in vivo. 
The identification of ghrelin whose primary source is the stomach, suggests that GH 
release can be regulated by peripheral signals, as well as of those generated by the 
hypothalamus. GH exerts its biological actions by binding to a specific cell surface 
receptor, the growth hormone receptor (GHR). The GHR belongs to the class I 
cytokine receptor superfamily that includes receptors for PRL, erythropoietin, leptin, 
interferons, granulocyte colony stimulating factor, and the interleukins [18]. These 
receptors are singlepass transmembrane proteins that contain an extracellular region, a 
single hydrophobic transmembrane domain of 24 amino acids, and an intracellular 
signaling region. The human GHR (hGHR) gene is localized on the short arm of 
chromosome 5 in the region p13.1-p12 [19].  
 
The mouse GHR (mGHR) gene is similar in size and sequence to the hGHR gene but 
contains two additional exons [20]. These include an exon 4B, which is downstream 
of exon 4, and an exon 8A, which is upstream of exon 8. Exon 4B encodes an eight-
amino-acid segment of the extracellular domain of the receptor and is present in all 
known mGHR transcripts. Exon 8A serves as an alternative splice site for the mGHR 
and rat GHR gene [20, 21], to generate a soluble binding protein. This is also present 
in humans, and is derived by proteolytic processing of the extracellular domain of the 
human GHR. The GHRs are a single polypeptide chain that range from 614 – 626 
amino acids in length with a predicted molecular mass of approximately 70 kDa [22, 
23]. The extracellular region of GHR contains seven cysteine residues and five 
potential N-linked glycosylation sites that are highly conserved between species, [23]. 
GHRs are present in many biological tissues and cell types, including liver, bone, 
kidney, adipose, muscle, eye, brain, and heart [24]. GHRs have also been identified in 
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immune cells including cultured human B cells [25] IM-9 lymphocytes [26], spleen, 
and thymus [27].Extensive work has been done to characterize the signaling pathways 
activated by GH-N [28, 29], and recent years have shown significant progress in 
elucidating the signaling pathways activated by the interaction of GH and GHR. An 
initiating event in this interaction is the activation of janus kinase 2 (JAK2), a GH 
receptor-associated tyrosine kinase [30].  
 
The original model of GH activation of JAK2 was the binding of GH to two GH 
receptors to induce dimer formation, which would lead to the increase in affinity of 
each GH-receptor for JAK2 [31, 32]. However, Waters et al (2006) [33] revised this 
original concept, using FRET based studies to show that GHRs already exist as 
dimers. It is thought that GH binds to these dimers causing rotation of one of the GH-
receptors, which results in GHR-JAK2 association, bringing JAK2 molecules into 
close proximity, leading to the phosphorylaton of the activating tyrosine sites on each 
JAK2 molecule, locking JAK2 in an active confirmation [34]. It is thought that 
activated JAK2 then phosphorylates itself and the cytoplasmic domain of the GH 
receptor on tyrosine residues [29]. These tyrosines are thought to form high-affinity 
binding sites for a variety of signaling proteins that contain phosphotyrosine binding 
domains, such as the signal transducers and activators of transcription (Stat) family of 
transcription factors. Activated GH-JAK2 can phosphorylate at least four members of 
this family (Stats 1,3,5A and 5B), leading to their dimerization, nuclear translocation, 
DNA binding and activation of transcription [35].  
The most important member of this family is Stat5, as has been shown with targeted 
disruption of Stat5a and Stat5b genes. A study by Udy et al (1997) [36] evaluated the 
importance of Stat5b in the physiological effects of GH pulse using a mouse gene 
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knockout model. The disruption of the Stat5b gene led to the loss of multiple, sexually 
differentiated responses associated with the sexually dimorporhic pattern of GH 
secretion. Both male characteristics of body growth rates and male-specific liver gene 
expression were decreased to wild-type female levels. The findings of this study and 
other in vivo studies [37] suggest that Stat5b may be the major Stat protein that 
mediates the sexually dimorphic effects of GH pulses in the liver. This is further 
emphasized with the highly homologous Stat5a being unable to substitute for Stat5b 
[38]. An elegant study by Rowland et al (2005) [39] reported knock-in mouse models 
that express GHRs with deletions of specific intracellular domains of the receptor. 
These mice displayed progressive impairment of postnatal growth, furthermore, Stat5 
phosphorylation was substantially decreased for some of the mutant models and 
absent from others, correlating with loss of IGF-1 expression and reduction in growth. 
They also showed however, that an additional pathway important in GH regulated 
gene transcription is the mitogen-activated protein kinase pathway (Ras-MAP). The 
Ras-MAP kinase pathway has also been shown to initiate GH regulated fos gene 
transcription [40, 41]. The GH-JAK2 activated complex also interacts with other 
pathways activated by other hormones such as insulin and IGF-1. GH is known to 
have both insulin-like and anti-insulin-like effects. The insulin-like actions include, 
glucose and amino acid transport, lipogenesis and protein synthesis. GH and insulin 
are thought to converge on common signaling pathways, as GH stimulates the 
phosphorylation of the insulin receptor substrates 1, 2 and 3 (IRS-1, 2 and 3), (Fig 
1.1).  
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Important regulators of GHR-JAK2 signaling are a family of cytokine-inducible 
genes, termed suppressors of cytokine signaling (SOCS), and cytokine inducible 
subunit (CIS) [42]. GH induces the expression of eight members of the SOCS family, 
SOCS 1, 2, 3 and CIS in the rat liver [43]. SOCS proteins are thought to inhibit 
signaling by binding to JAK2 directly [44]. Transgenic mice constitutively expressing 
CIS have reduced body weights [45] presumably because of decreased GH-induced 
activation of JAK2. Mice deficient in SOCS2 however, are giant, suggesting that 
SOCS2 might be important for terminating signaling by GH or IGF-1 [46]. 
 
 
Figure (1.1) Growth hormone activated signal transduction cascades 
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1.2 GH secretory patterns 
 
The secretion pattern of pituitary GH is characterized by multiple episodic bursts 
commonly referred to as GH pulses [47]. However, a notable sex difference in the 
pattern of GH secretion is evident in most mammalian species [48] and [49]. This is 
particularly striking in rodents; secretory profiles recorded in male rats are shown to 
be characterized by high-amplitude GH bursts at regular 3- to 4-hr intervals, separated 
by prolonged (1-2hr) periods of mostly undetectable plasma GH levels [47]. 
 In contrast, female rats exhibit irregular, more frequent, lower amplitude GH pulses 
superimposed on an elevated GH baseline [50], (Figure 1.2). These distinct sex 
differences in the temporal pattern of GH release are of biological significance, as 
they evoke a number of male-female differences in, (i) body growth, (ii) GH 
intracellular signaling pathways, and (iii) liver enzyme expression.  
 
Figure (1.2) GH secretory profiles for normal male and female rats 
 
An automatic method for repetitive microsampling of blood from conscious animals was used to 
obtain detailed GH-secretory profiles, for the first time, Clark et al., 1987. 
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1.2.1 GH secretion pattern and Body Growth 
Early studies by Tanner (1963) [51] and Eden (1979) [52] have shown that body 
weight and composition begin to differ in male and female rats from around the onset 
of puberty. The sex differences in the pulsatile profile of circulating GH, along with 
the amplitude of GH, is likely to be the major contributing factor to the differences 
shown in the growth of rodents [53]. Male rats infused with GH at a constant rate 
show steady increases in growth rate and circulating IGF-1 levels, however, in the 
same rats, a constant GH infusion was shown to be more effective in increasing 
hepatic GH-binding protein concentrations, than infusion of the same GH dose as a 
series of pulses [50, 54-56]. In contrast, pulsatile infusion is much more effective in 
promoting statural growth [57]. Gevers et al (1996) [78] confirmed that growth 
responses in the rat are more sensitive to stimulation by the pulsatile component of a 
GH infusion, whereas hepatic GH-receptor and plasma GH-binding protein 
concentrations are more sensitive to a continuous component. This and other studies 
point to the greater amplitude of intermittent GH pulses in male rats, as most effective 
component in stimulating growth in GHD animals than the type of profile observed in 
female rats. Note however, that females do grow in response to continuous GH, just 
less rapidly. If female rats are given GH pulses they will grow more like males. 
 
There is also a sexually dimorphic pattern of GH secretion in humans: mean 24 –hr 
serum concentrations of GH are significantly higher in females, than in males [58]. In 
a study by Pincus et al (1996) [59] blood sampling in a small cohort of young women 
and men showed that the females exhibited an increased irregularity in their GH 
pulsatility, compared to males. These alterations in the pattern of GH signal in 
humans, is thought to have similar effects on body composition as shown in rodents. 
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Furthermore, Hindmarsh et al (1997) [60] demonstrated that peak and trough GH 
concentrations have different associations with the IGF axis, body composition and 
metabolic parameters in adult males. They concluded that peak values of GH 
concentration profiles were mostly responsible for influencing the IGF axis, whereas 
trough values may affect body composition and metabolic parameters of GH action. 
  
1.2.2 GH secretory pattern and intracellular signaling 
In the adult male mouse or rat, GH pulses stimulate an intracellular signaling pathway 
that is dependent on JAK2, and Stat5b [36, 61]. This sex-dependent plasma GH 
pattern to activate Stat5b determines distinct, sex-dependent patterns of gene 
expression in the liver (discussed below). From studies in hypophysectomized rats, 
the importance of the time interval between each plasma GH pulse has also been 
highlighted [50, 62, 63]. The time between each pulse is critical in determining the 
ability of liver cells to reset their signaling systems to respond to subsequent GH 
pulses. A study by Waxman et al (1991) [64] further emphasized the ideas of a 
minimum GH “off time” for hepatocytes to express the masculinizing effects of 
pulsatile GH. Hypophysectomized rats given rat GH subcutaneously, required at least 
2.5 hours between each interpulse trough to give rise to distinct patterns of male liver 
gene expression. These findings suggest that male rat hepatocytes may become 
refactory to subsequent GH pulses until a minimum recovery period has lapsed.  
 
Furthermore, an in vitro study carried out by Gebert et al (1999) [65], using CWSV-1 
liver cell lines, showed that the level of Stat5b tyrosine phosphorylation was reduced 
to 10-20% of the maximal GH pulse-induced Stat5b signal, within 3 hours of 
continuous GH exposure. Thus, GH-responsive cells reduce their response following 
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continuous GHR occupancy. Several studies have also shown that the targeted 
disruption of Stat5b leads to major loss of multiple, sexually differentiated responses 
associated with pulsatile GH secretion [36, 66]. Thus, GH signaling is critically 
impaired in animals with Stat5b disruption, and thus has been confirmed by the 
observation of severe short stature in patients with Stat5b mutations [67, 68]. A study 
carried out in hypophysectomized Stat5b deficient mice, showed no changes in the 
body weight, following GH pulse replacement, compared to wild-type mice, which 
showed dramatic resumption of body weight [69]. Furthermore, a study by Klove et al 
(2007) [70] presented evidence to show the importance of skeletal muscle Stat5 in 
postnatal growth and suggested that this is conveyed by the production of localized 
IGF-I. To investigate the role of Stat5 in skeletal muscle, mice with skeletal muscle 
specific deletions of both combined Stat5a and Stat5b genes (Stat5MKO) were used. 
These mice showed a reduction of 60% in IGF-I mRNA levels in muscle tissue. At 8 
weeks despite a reduction of only 15% in circulating IGF-1 levels, mice showed a 
20% reduction in body weight, accounted for by a reduction in lean mass. Finally, the 
skeletons of the Stat5MKO mice were also found to be smaller than controls, 
indicating that the defect was not restricted to skeletal muscle alone. These findings 
provides strong evidence that Stat5b has a role in mediating body growth, stimulated 
by the male pattern of pulsatile plasma GH. 
 
1.2.3 Sexually dimorphic liver expression 
The sex dependent plasma GH pattern has been shown to lead to sex-dependent 
patterns of gene expression in the liver, the major target of GH action [71]. This is 
exemplified by the patterns of transcription of sex-dependent steroid hydroxylase 
P450 genes. The male intermittent pattern of GH secretion stimulates the expression 
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of male specific steroid 16α- and 2α-hydroxylase P450 CYP2C11 [64, 72, 73], while 
the female continuous plasma GH profiles up regulate steroid disulfate 15β-
hydroxylase P450 CYP2C12 [74]. This suggests that GH can initiate intracellular 
signaling pathways via the GH-receptor, with very different opposite effects on some 
targets, which are determined by the temporal pattern of plasma GH stimulation. 
 
Studies in hypophysectomized rats given tailored patterns of GH have further 
confirmed that steroid metabolism in the liver can show feminization or 
masculinization depending on the mode of GH administration [75]. Furthermore, 
Wells et al (1994) [76] showed that sex differences in steroid-metabolizing enzymes 
could still be found in dwarf rats with low GH secretion, as it still remains dimorphic, 
small pulses in males and low continuous GH levels in females. In this study, male 
dwarf and normal rats given continuous intravenous infusion of very low doses of 
human GH, showed a dose-dependent decrease in male specific cytochrome P450s, 
and an increase in female specific cytochrome P450s, with no effect on IGF-1 and 
minimal effects on growth. This shows the high sensitivity of hepatic cytochrome 
P450 transcripts to GH. The correlation between Stat5b tyrosine phoshorylation and 
GH pulses, have also implicated in directly determining the expression of male-
specific liver genes, with the finding that some GH pulse-regulated, male specific 
liver P450 genes contain Stat5b response elements, for example the CYP3A10 gene 
[77]. 
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The sexually dimorphic pattern of GH secretion has also been shown to be important 
in functions other than steroid metabolism, some of these include, GH- binding 
protein expression in the liver [78] and major urinary protein secretion [79], 
suggesting that many GH targets are sensitive to the pattern of GH. The significance 
of this for my work is that there are two conditions in humans in which the normal 
pulsatility is converted to a high continuous physiological GH secretion, namely 
fasting and pregnancy. In fasting, this high GH exposure is accompanied by a 
desensitization to the effects of GH, with low IGF-1 levels. In pregnancy however, 
this is not accompanied by fasting, so I predict it is likely to be related to increase GH 
signaling. Modeling fasting in rodents doesn’t help as fasting reduces GH secretion in 
rodents (unlike in humans) [80]. However rodent pregnancy is also associated with 
increased GH secretion [81]. I felt it was therefore an excellent model to study the 
physiological relevance of continuous GH. 
 
1.3 Actions of GH, GH-V, IGF-I and Insulin 
 
1.3.1 Role of GH 
GH physiological role is pleiotropic and affects several tissues including, bone, liver, 
fat and muscle. As its name implies, a major role of GH is to stimulate longitudinal 
bone growth, and growth of other tissues, actions of GH are summarized in Table 1.1. 
GH directly stimulates prechondrocytes in the growth plate followed by a clonal 
expansion caused both by the GH-induced local production of IGF-1 and by a GH-
induced increase in circulating levels of IGF-1 [82]. During the process of 
longitudinal bone growth, prechondrocytes in the germinal cell layer differentiate and 
thereafter undergo limited clonal expansion in individual chondrocyte columns in the 
growth plate [83]. Several hormones are necessary for the expansion of normal 
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postnatal longitudinal bone growth, but it is generally accepted that GH is the most 
important stimulatory hormone in this respect. GH stimulates growth of cartilage and 
other tissues by both increasing the number of cells and by increasing cell size [84], 
though the latter may also include an indirect effect via IGF-1. 
 
Table (1.1) Biological actions of GH 
 
 
Stimulates                                                                                Inhibits 
 
Longitudinal bone growth &                                                      Insulin action 
Bone remodeling                                                                        IGFBP-1 synthesis 
Chondrocyte proliferation                                                          IGFBP-2 synthesis 
Osteoblast proliferation and bone deposition 
Osteoclast proliferation and bone reabsorption 
Type I collagen synthesis 
 
Skeletal muscle growth (fiber, strength) 
Liver growth 
 
Deiodination of T4 to T3 
Lipolysis 
Ketogenesis 
Gluconeogenesis 
Protein synthesis/turnover 
Total body nitrogen balance 
Lactation 
 
IGF-I synthesis 
ALS synthesis 
IGFBP-3 synthesis 
Serine protease inhibitors (SPI) 2.1 and 2.2 
 
Immunomodulation 
(endocrine, autocrine-paracrine) 
B and T cell proliferation 
Natural Killer cell activity 
Macrophage activity 
Neutrophil activity 
Immunoglobulin production 
Cytokine production 
 
Adapted from Le Roith et al., 2001 
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A widely discussed question during the last two decades has been whether GH acts on 
tissues directly, or whether the effect is mediated by a liver-derived growth factor, 
initially called sulfation factor [85], later renamed somatomedin, and subsequently 
shown to be identical to IGF-1. According to the original somatomedin hypothesis, 
GH stimulates skeletal growth by stimulating liver production of somatomedin, which 
in turn, stimulates longitudinal bone growth in an endocrine manner [86]. This was 
because in early studies it was very difficult to demonstrate any effects of GH in vitro.  
 
However, in the early 1980s the somatomedin hypothesis was challenged by a 
landmark study demonstrating that injection of GH directly into the rat tibia growth 
plate stimulated longitudinal bone growth at the site of injection [87], in one leg, but 
not in the control injected leg. This initial observation has subsequently been 
confirmed and extended, and it is now well documented that GH stimulates growth of 
many different tissues directly [88, 89]. However in agreement with the original 
somatomedin hypothesis, IGF-I- null mice fail to respond to GH treatment, suggesting 
that IGF-I is essential for GH-stimulated postnatal growth. However, experiments 
carried out in the liver specific IGF-1 deficient (LID) mice [90] showed that normal 
growth and development could proceed despite low circulating IGF-1 levels, 
suggesting that other mechanisms besides hepatic production of IGF-I may be 
involved in growth. Although 75% of circulating IGF-1 is liver-derived, normal 
growth and development is possible even in the complete absence of liver IGF-1 
production [91]. Taken together, these studies allow to hypothesize that GH mediates 
somatic growth both directly and via local IGF-1 production, acting in a 
paracine/autocrine fashion in different tissues. Liu et al (2000) [92] treated LID mice 
with exogenous GH and studied postnatal growth (in response to long-term injections) 
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and extra hepatic IGF-1 expression (following acute injections). They demonstrated 
that recombinant human GH stimulated local tissue IGF-1 production under 
conditions of complete liver IGF-1 deficiency, particularly so in adipose tissue. These 
results provide further support to the notion that exogenous GH accelerates somatic 
growth through stimulation of local production of IGF-1, as well as by direct 
mechanisms, via a Stat5b phosphorylation.  
 
The importance of GH in longitudinal bone growth and bone formation is obvious in 
isolated GH deficiency, in which bone mass and length is also reduced [93]. However, 
the low IGF-1 levels caused by GHD, will also contribute to the reduction in bone 
mass. Again, these studies emphases that whilst GH plays a major role in the 
longitudinal bone growth an inter-relationship with IGF-1 is evident and difficult to 
disentangle. To reconcile this, a dual theory concerning the roles of both GH and IGF-
1 was suggested, in which, GH stimulates the specific differentiation of cell types, 
while IGF-1 stimulates their clonal expansion, [94]. However, there have also been 
disputes of the dual action theory for GH and IGF-1. Although GH has been 
confirmed to have direct effects on the differentiation of growth plate germinal cells, 
the further proliferative effect of IGF-1 on chondrocytes has been disputed [83]. Both 
Shiner et al (1993) [95] and Wang et al (1999) [96] were unable to detect IGF-1 
mRNA in the growth plate chondrocyte of rats and mice of any age. Nevertheless, 
IGF-1 clearly has an important role in human and rodent longitudinal bone growth, 
since IGF-1 gene deletions result in dwarfism in mice and short stature in humans [97, 
98].  
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Furthermore, IGF-1 treatment of children with Larons syndrome produces an increase 
in bone growth, demonstrating that IGF-1 can work independently of GH, as GHR is 
inactive in this syndrome [99]. 
 
The availability of GH to the tissues is also modulated by growth hormone binding 
proteins (GHBPs). Growth hormone binding proteins were first detected in the serum 
of pregnant mice by [100] and were then reported in human serum [101, 102]. 
Following the cloning of the GH-receptor, an identity between GHBPs and GHR was 
demonstrated [22, 103]. GHBP in humans originates by specific proteolysis of the GH 
receptor [104]. However, in rodents the GHBP is produced by alternate messenger 
RNA splicing of the eighth exon and contains a unique hydrophilic carboxy terminus 
[105]. The concentration of GHBP in serum has been reported to be higher in females 
than in males and is oestrogen- dependent. This is the case in humans [103, 106], and 
rats [107-109]. Since the GH binding domain of the high affinity GHBP is identical to 
GH binding domain on the membrane associated GHR, the binding of GH to GHBP 
could reduce its availability for interaction with the GHR, and it has been calculated 
that at low GH levels, as much as  30-50% of GH circulates coupled to the GHBP 
[110]. However in practice it is a much smaller proportion, when measured directly 
by half-life measurements [111] of larger amounts of GH. 
 
Pregnancy in rodents is the only physiological state in which there is a dramatic 
change in serum GHBP concentration. An upregulation was initially observed in mice 
by Peters (1977) [100] and subsequently by Smith (1988) [112] suggesting a role for 
GHBP in normal pregnancy. Furthermore, Sanchez et al (1990) [113] showed that 
hypophysectomy of mice on day 11 of gestation resulted in down regulation of GHBP 
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mRNA and circulating GHBP. The mechanism is obscure but may relate to induction 
of estrogen [114]. In contrast, in humans, although there is a several fold increase in 
maternal GH concentration from week 18 onwards [115], after an initial increase in 
GHBP concentration, they decrease. Such a concomitant decrease in GHBP would 
tend to increase the proportion of bioavailable GH for GHR signaling, but this has not 
been directly demonstrated in humans. 
 
GH is not just a hormone for growth. It also has several important metabolic effects in 
adulthood, a major one being the induction of protein synthesis in muscle tissue, 
which in turn is also responsible for the regulatory control of the mobilization of 
nitrogen reserves, used to provide further amino acids to various organs [116-118]. 
GH enhances the uptake of amino acids into skeletal muscle. The importance of this 
effect of GH is evident in GH-deficient individuals, who show a marked reduction of 
lean body mass and skeletal muscle mass, compared to healthy individuals [119, 120], 
whilst GH replacement therapy results in the increase of muscle mass [121, 122]. 
GHD adults receiving GH replacement increase their total lean body mass by as much 
as 11% [123] and thigh muscle mass by 5-8% [124, 125]. Again it is possible that 
some of the effects of systemic GH on muscle protein metabolism may also be a 
result of increasing circulating and / or local IGF-1 production. 
 
In this context, several studies have looked at the acute and long-term actions of GH 
administration on whole body metabolism, and have demonstrated that GH has direct 
effects on increasing anabolic actions via the inhibition of amino acid oxidation and 
stimulation of whole-body protein syntheses [126]. Systemic GH may enhance local 
production of IGF-1 and IGFBP-4 in muscle. IGF-1 is shown to stimulate satellite 
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myoblasts to express myogenin, which mediates the differentiation of myoblasts to 
myotubes and to mature myocytes [127-129]. It is also possible that GH may directly 
increase the total number of myocytes or may stimulate mature myocytes to increase 
autocrine expression of IGF-1.  
 
GH also has important lipolytic effects. It enhances the utilization of fat by 
stimulating lipolysis and fat oxidation [130]. GH brings about its lipolytic action by 
inhibiting lipoprotein lipase, an enzyme involved in lipid accumulation in adipocytes 
[131, 132] and represents a major effect of GH on metabolic intermediates. GH 
exhibits both insulin-like and insulin antagonizing actions on both glucose and lipid 
metabolism in adipose tissue [133]. The insulin like effect is an acute antilipolytic and 
lipogenic effect, causing a temporary insulin-like effect on stimulating glucose 
uptake. This acute insulin-like activity of GH on carbohydrate metabolism seen both 
in vivo and in vitro appears to be independent of both circulating IGF-I and insulin, 
since these effects have also been observed in isolated tissue preparations and in 
cultured cells [134]. It may therefore represent another direct effect of GH.  
 
Insulin-antagonizing effect of GH include inhibition of lipogenesis and glucose 
transport, and the increase of lipoysis [132], which predominates with chronic GH 
treatment. GH administration also causes mild reductions in low-density lipoprotein 
(LDL) cholesterol levels and small elevations in high-density lipoprotein (HDL) 
cholesterol [135]. The clinical significance of these effects is reflected in the 
increased adiposity in GH deficiency and reduced fat mass in acromegaly [136, 137] 
and in GHD individuals given GH replacement therapy. Studies in animal models of 
GH deficiency models have also recorded increased fat mass, and that treatment with 
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GH decreases adipose mass, and increases increased lean body mass [138]. In obese 
dwarf rats, GH treatment induces a dose-regime-dependent effect on lipolysis, with 
GH in the presence of IGF-1 showing anti insulin actions causing a powerful net 
lipolysis [139]. Chronic exposure to GH, however, showed insulin resistance 
associated with hyperinsulinemia that seems primarily due to a post receptor defect in 
insulin signaling [140].  
 
1.3.2 Effects of GH-excess and GH-deficiency in insulin signaling 
In both humans and animals an excess of GH causes the impairment of insulin 
sensitivity. This results in glucose intolerance, insulin resistance and hyperinsulinemia 
[133, 141-143]. In contrast, GH deficiency leads to increased insulin sensitivity, 
decreased secretion of insulin and hypoglycemia [144, 145]. 
The mechanism of this cross-talk between GH and insulin signaling pathways is 
unclear, but both in vitro and in vivo studies show GH promotes tyrosine 
phosphorylation of IRS-1 and IRS-2 and their association with PI 3-kinase [146] 
[147-149]. These results suggest a direct way for GH to interact with signaling 
molecules used by insulin. Such potential crosstalk between the GH and insulin 
signaling pathways is further emphasized in studies carried out in GHR-knock out 
mice. A study by Dominici et al (2000) [150] showed that the absence of GHR was 
associated with increased IR abundance, insulin-stimulated IR tyrosine 
phosphorylation, and normal efficiency in IRS-1 phosphorylation, and activation of 
PI-3 kinase by insulin. Furthermore, a more recent study of Dominici et al (2002) 
[151] looked at the effects of combined GH, PRL, and thyrotrophin (TSH) deficiency 
on insulin signaling in Ames dwarf mice. These showed metabolic alterations 
associated with a change in insulin signaling, increased protein levels of IR, IRS-1 
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and IRS-2, insulin-stimulated association of p85 with IRS-1 and IRS-2, and increased 
insulin induced AKT activation through a PI3-kinase independent mechanism. These 
findings suggest that the deficiency of GH, PRL, and TSH is associated with 
increased insulin sensitivity, Furthermore, metabolic alterations are also associated 
with changes in insulin signaling. However, whether these compensatory changes in 
insulin signaling have an important role in the phenotype of Ames mice is not entirely 
clear [150]. Interestingly, these animals also live much longer than their normal 
siblings [152] and paradoxically reductions in insulin signaling (or in homologous 
pathways in other species) have been associated with increased longevity [153]. 
 
1.3.3 The effects of nutritional restriction on GH and Insulin signaling 
As mentioned above, Growth hormone secretion is affected by fasting differently in 
different mammalian species [80, 154-156]. In humans, nutritional deprivation is 
associated with an increase of circulating GH [157] and a decrease in IGF-1[158]. 
The increase in GH secretion is thought to be linked to an increase in pituitary 
sensitivity to GHRH and a decrease in pituitary sensitivity to somatostatin. In contrast 
to humans, fasted rats show a dramatic decline in pulsatile GH release [80, 159]. This 
decrease is thought to be associated with the decrease of hypothalamic GHRH 
expression [159, 160]. However, consistent with humans, IGF-1 levels decrease in 
food deprived rats [161]. Furthermore, fasting is also shown to induce some form of 
GH resistance, a study by Beauloye et al (2002) [162], showed the reduced IGF-1 
levels were not restored by GH administration. This state of GH resistance is thought 
to be associated with the decrease of GHRs, as evident by reduced GH binding [163, 
164]. The consequence of this is the possible impairment of the JAK-STAT signaling 
pathway, in concert with induction of suppressors of cytokine signaling (SOCS), 
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particular SOCS3 [162]. Unfortunately however, the very different responses to 
fasting between rodents and humans, makes it difficult to study mechanisms relevant 
to GH and human fasting, in rodent models. 
 
1.4 IGF family 
 
The insulin-like growth factors (IGFs) are integral components of multiple systems 
controlling both growth and metabolism. The IGF family consists of two ligands 
(IGF-1 and IGF-2), six major and several minor IGF binding proteins, and cell surface 
receptors that mediate the actions of the ligands (IGF-1 receptor and the IGF-2 
mannose-6-phosphate receptor) and the insulin receptors which can be activated to 
some extent by IGFs [165, 166]. In circulation, almost all the IGFs are present as 150 
kDa ternary complexes comprising of one molecule each of IGF, IGF-binding 
protein- (IGFBP)-3 (the predominant IGFBP in serum) or to a lesser degree IGFBP-5 
[167, 168] and an 85-kDa glycoprotein, the acid-labile subunit (ALS) [169, 170]. 
 
ALS is primarily a plasma protein, which serves as a reservoir of systemic IGFs by 
sequesting the majority of these within ternary complexes from which the IGF is 
slowly released, principally after limited proteolysis of IGFBP-3 within the complex 
[167, 171]. The ALS complex may also enhance long-term body growth by 
maximizing the bioavailability of systemic IGFs. Short-term studies using IGF-1 
[172, 173] were carried out in GH-deficient animals, but all components of the ternary 
complex are decreased in GHD, making it difficult to outline the separate roles of 
ALS, IGF-I and IGFBP-3. An ALS-null mouse model has been generated, in which 
the ternary complexes were absent due to the inactivation of the ALS gene [174]. Null 
ALS mice show dramatically reduced circulating IGF-I and IGFBP-3 concentrations 
compared with their wild-type siblings (62 and 88% reductions respectively). These 
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changes occurred despite the absence of any reductions in IGF-I or IGFBP-3 
synthesis, as expression of both these genes in liver, the predominant site of synthesis, 
was normal, proving ALS is necessary for the normal serum levels of both IGF-I and 
IGFBP-3 [175, 176]. However, despite disturbances in the circulating IGF system, 
null ALS animals show only a 13% growth reduction by adulthood [177-179]. This is 
consistent with the observation that abrogation of IGF-I synthesis only in liver, 
resulting in a reduction of plasma IGF-1 similar to that of the null ALS mice, does not 
alter postnatal growth [90, 91]. However, double gene disruption of IGF-1 and ALS 
by crossing IGF-1 deficient (LID) and ALS knockout mice resulted in further 
reductions in serum IGF-1 levels and a significant reduction in linear growth, 
suggesting that some threshold concentration of circulating IGF-1 is necessary for 
normal bone growth [180] to occur. Again, interpretation is complex, since with low 
circulatory IGF-1, negative feedback is reduced and GH levels become very high. 
IGFs bound to the 50 kDa binary complexes, can cross the vascular endothelium, but 
formation of the ternary complexes restricts the IGFs to the circulation, prolongs their 
half-lives and allows them to be stored at high concentration in plasma, facilitating 
their endocrine actions. It may also help to minimize the effects of intrinsic insulin-
like activities, such as hypoglycaemia [172]. 
 
1.4.1 IGF-1 physiological role in growth and metabolism 
IGF-1 has an important role in both embryonic and postnatal growth. This is 
demonstrated in mouse models carrying null mutations in the IGF-1 gene, which are 
born small, compared to wild-type and continue to grow poorly postnatally [97] [177, 
181]. Furthermore, infusion with IGF-1 will enhance body weight and length, 
showing that circulating IGF-I can stimulate growth [182]. 
 42 
IGF-1 has insulin-like metabolic actions as well as unique actions of its own. A 
unique action is displayed in its involvement in the increase of protein synthesis as 
well as inhibition of proteolysis [183]. However, as insulin acts primarily to inhibit 
proteolysis, these findings also suggest that IGF-1 works via the IGF-1 receptor and 
not the insulin receptor in the muscle. An obvious insulin-like action of IGF-1 is the 
enhancement of glucose uptake in peripheral tissue [184]. Furthermore, insulin-like 
effects of IGF-1 replacement have been shown with patients with type 1 and type-2 
diabetes. Plasma glucose concentrations in these patients decrease following acute or 
chronic administration of IGF-1 [185, 186]. Similar findings with a decrease in 
glucose levels in conditions of insulin resistance and mutations of insulin receptor has 
also been reported following short term IGF-1 treatment [187-189]. The mitogenic 
and anabolic actions of IGF-1 are believed to be mainly mediated by signaling 
through the IGF-1 receptor [190]. The IGF-1 receptor shares high degree of homology 
with the insulin receptor, both receptors having the same heterotrameric structure 
formed from two α- and two -β subunits; the homology extends to 85% in the 
cytosplasmic tyrosine kinase domain, which is thought to initiate intracellular events 
involved with receptor signaling, [191]. 
 
1.4.2 Pathological conditions of IGF-1 
IGF-1 is important for intrauterine growth, as IGF-1 and IGF-1 receptor knockout 
mice show a reduction in birth weight of 45%, compared to normal pups [97, 177, 
181]. The effects of IGF-1 are mediated by the IGF-1R, knockout mice for IGF-IR 
and IGF-1 show a reduction in weight (40% of normal) [97]. IGF-1 gene deletions 
and mutations also have compromising effects in humans. IGF-1 deletion results in 
severe intrauterine growth restriction and postnatal problems in growth [98]. 
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Furthermore, low IGF-1 levels in cases of IGF-1 promotor region polymorphisms, are 
associated with a reduction in birth weight and length [192, 193]. 
 
1.4.3 Insulin and Insulin signaling 
Insulin induces a wide range of growth and metabolic responses, a major role is its 
regulation of glucose, lipid and protein metabolism in known GH target organs 
including liver, muscle and fat [194]. Insulin signaling begins with the binding of 
insulin to the α-subunit of the insulin receptor (IR), a protein tyrosine kinase. This 
initiates the autophosphorylation of tyrosine residues in the intracellular β-subunit 
region of the insulin receptor, and several intracellular proteins, including insulin 
receptor substrate (IRS)-1 and IRS-2 [195]. These substrates are crucial in 
coordinating the effects of insulin, [196-198] and IR substrates also provide docking 
sites for several SH2 (scr homology 2) domain-containing proteins.  SH2 domains 
typically bind phosphorylated tyrosine residues, linking IR to other intracellular 
signaling cascades [195], such as phosphatidylinositol (PI) 3-kinase, a well-
characterized SH2 domain-containing protein. Following the tyrosine phosphorylation 
of IRS-1 and IRS-2, binding of these proteins to the p85 regulatory region of P1 3-
kinase occurs, resulting in the  activation of the enzyme [199]. A downstream target 
for P1 3-kinase is protein kinase B (Akt), Akt is activated by phospholipid binding 
and phosphorylation at two regulatory sites [200], and is thought to mediate many 
insulin responses, such as insulin induced glucose uptake and glycogen synthase 
activation [201]. 
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1.5 Growth Hormone Variant 
 
Over 20 years ago the discovery of the growth hormone variant (GHV) meant a new 
addition was made to the human growth hormone gene family making a total of five, 
[202]. The discovery identified a “new” gene called the growth hormone variant (GH-
V) the interest of this thesis, is that  this GH-V has a unique source of production in 
the placenta, [115]. 
 
1.5.1 The GHV gene, its expression, protein product and measurement 
The GH- V gene, yields an 800-nucleotide mRNA [203] and a 1250- nucleotide 
mRNA resulting from alternative splicing [204]. The 800-nucleotide mRNA codes for 
the 22 kDa GHV, GHV contains the same total number of amino acids as GH-N but 
differs at 13 positions and, moreover, exists in a minor, glycosylated form [205] 
[206]. Specific expression of the GH-V gene in the placenta has been demonstrated by 
in situ hybridization [207] and by immuno-histochemical localization [208]. More 
recently, GH-V gene expression has also been demonstrated in the extravillous 
cytotrophoblast, which invades the uterus in early pregnancy, as well as 
choriocarcinoma cell lines [209, 210]. Notably, the expression of GH-V mRNA was 
observed in a patchy appearance, i.e. in only some of the syncytiotrophoblastic cells, 
from as earlier as 9 weeks of gestation [207, 211] GH-V has somatogenic activity (at 
least in rodents), equal to GH-N [212-214]. Furthermore, transgenic mouse lines 
expressing hybrid gene, mouse metallothionein-1 (MT)/human placental GH variant 
display greater increases in adult body weight compared to normal mice [215] 
showing systemic effects of this GH-variant. Thus, the human placenta produces an 
active GH isoform. 
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1.5.2 Measuring Placental Growth Hormone 
In the absence of a specific antibody for GH-V, the initial method used to measure 
growth hormone variant was performed indirectly using a GH immunoassays, both 
based on monoclonal antibodies (MAbs); one recognizing both the placental and 
pituitary GH form (MAb 5B4), and the other recognizing only the pituitary GH form 
(MAb K24). By subtracting the paired hormone concentration values obtained from 
each assay in each serum sample, the difference remaining was assumed to represent 
the placental form of GH in serum samples [216]. However, this method was indirect, 
as the assay couldn’t distinguish directly between GH-N and GH-V and other GH 
isoforms. More accurate, specific assays have since been developed. The first assay 
developed to determine specific GH-V serum levels was based on a solid-phase 
immunoradiometric assay. This assay used non-glycosylated 22kDa recombinant GH-
V expressed from Escherichia coli as a calibrator, and to determine the total amount 
of GH-V, mouse MAbs were used [217]. However, more recently this assay has been 
replaced by an enzyme-linked immunosorbent assay (Biocode) where its 
manufacturers claim that little cross-reactivity is seen from either 20-22kDa GH-N, 
human placental lactogens, prolactin or human chorionic gonadotropin (hCG). In 
2004, the Strasburger group developed a non-isotopic GH-V assay, using mouse 
MAbs raised against the glycosylated variant of GH-V [218].  
 
1.5.3 Secretion pattern, action and regulation of GH-V 
Serum profiles of growth GH-V have been recorded for 24 hours in women at 
different stages of normal pregnancy [219]. In this study, two monoclonal antibodies 
directed against different epitopes, unaffected by human placental lactogen were used 
in radioimmunoassays to distinguish the pituitary 22kDa-GH-N from the placental 
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GH variant. GH-V was detected as early as 5 weeks of pregnancy. From there on GH-
V levels gradually increased to peak values of around 25µg/L at week 34-37 of 
gestation. These are significant quantities of GH, not unlike those seen in mild 
acromegaly. The episodic peak activity of GH-N in non-pregnant and first trimester 
pregnant women was shown to dramatically reduce into a more continuous and stable 
secretion during late pregnancy, this change first observed at 17 weeks gestation. This 
study concluded that during the second half of pregnancy, serum measurements of 
GH reflect a major contribution from a non-episodically secreted placental GH variant 
and a concomitant suppression of pituitary GH [219, 220]. Other studies have also 
reported the non-pulsatile secretion of GH-V and how it dominates in the third 
trimester of pregnancy, down regulating and suppressing the pituitary source of GH, 
[221, 222]. Upon delivery of the placenta, the source of GH-V disappears and the 
serum concentrations start to decline immediately, with a reported half-life of 13 
minutes [223]. In the course of pregnancy, serum GHBP levels follow a bell shaped 
curve. Increasing levels are seen in the first half of pregnancy, and then a decline is 
observed [224]. It is assumed that GH-V will bind to GHBP, which may facilitate 
accumulation in the circulation. Plasma GH levels have also been measured in female 
rats during late pregnancy. An early study, by Sauders et al (1976) [225] measured 
GH levels in rats during the last week of pregnancy. GH was measured in blood 
samples collected via chronic intra-atrial cannulae, every 15 minutes. The results 
indicated that there was an increase in GH levels in the last 3-4 days of pregnancy. 
GH levels have also been determined in late pregnant rats by Klindt et al (1981) 
[226]. Blood samples were collected over a 4-h period at 15-min intervals on days 18 
and 19 of gestation. From days 18-19, GH levels increased 2-fold [226].  
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Plasma GH patterns have been also analyzed more extensively using a pulse analysis 
computer program (PULSAR), to analyze data from automated repetitive blood 
sampling from conscious pregnant animals. Mean GH levels were about twofold 
higher in pregnant females on days 15, 18 and 22 of gestation than in age-matched 
non-pregnant females [81]. The basal plasma GH levels were also increased, while 
there was no change in GH pulse amplitude or frequency. The augmentation of GH 
release was even more pronounced on day 20 of gestation, with a fourfold increase in 
mean plasma GH levels compared with those in non-pregnant females. This increase 
reflected an increase in both basal plasma GH levels and GH pulse amplitude, but 
there was no increase in pulse frequency. In female rats that delivered on day 22 of 
gestation, the basal and mean plasma GH levels increased during parturition. This is 
the most complete study in rodents to date and demonstrates an increase in basal 
plasma GH levels during late pregnancy, and a marked increase in both basal plasma 
GH levels and GH pulse amplitude on day 20 of gestation. Since hypophysectomy of 
the pregnant rats results in undetectable GH levels, the high levels of GH during rat 
pregnancy arise definitely from the pituitary source [81], and that there is no rodent 
placental source of GH-N, nor any evidence for a rodent GH-V.  
 
To date there has not been a specific GH-V receptor identified that may mediate the 
actions of GH-V. However, GH-V displays very similar characteristics, including a 
high affinity for hepatic GH receptors, as GH-N [227]. Therefore, it is reasonable to 
think that GH-V may also act through the same GHR as GH-N. In situ hybridization 
and northern blot hybridization using complementary radioactive DNA probe 
encoding part of the extracellular domain of the GHR has been carried out. GHR gene 
was expressed in all human tissues studied, including the placenta [228]. Evidence for 
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the expression of the GH receptor (GHR) gene in the placenta was also obtained by 
northern blot analysis by a study by Frankenne et al (1992) [229]. GH receptor have 
been detected as early as 8 weeks gestation in syncytial layers of the placenta and shown 
to be maintained until term [230]. In addition, Frankenne et al (1987) [227] have 
detected GHR poly A+ RNA in RNA from cultured trophoblastic cells, but not from 
placenta fibroblasts. There was a low but significant specific binding of pituitary GH-
N and placental GH-V to placenta plasma membranes. Both variants were shown to 
bind to the same receptor, which is present in the first trimester as well as in the term 
placenta. These early findings suggest the provocative notion that in humans GH-V 
may have paracrine or autocrine functions in the placenta as well as potential 
endocrine functions in maternal blood stream. GHRs have also been detected as early 
as 15 weeks in the syncytiotrophoblast cells of rat placenta. Receptor expression was 
localized by immunohistochemistry with specific monoclonal antibodies in several 
tissues including decidual and trophoblastic cells of the placenta [231]. Furthermore, a 
study by Ymer et al (1989) [232] also identifies binding sites for growth hormone in 
both fetal and maternal compartments of rat placenta. All these studies again suggest 
the idea that GH may have a role in placental metabolism in the rodent. 
 
1.5.4 Regulation of GH-V 
GHRH, which stimulates GH-N synthesis and secretion in the pituitary somatotrophs, 
is mainly expressed in the hypothalamus. However it is also expressed in 
extrahypothalamic sites, such as the placenta. In particular, it has been reported that 
the GHRH gene is actively transcribed in rat [233] and mouse [234] placentae. In both 
species, expression of the GHRH gene in placenta is regulated during gestation, 
increasing from mid- pregnancy to term [235]. The placental GHRH transcript and its 
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peptide products appear to have the same size as their hypothalamic counterparts, 
while the site of its placental GHRH synthesis is the cytotrophoblast [236, 237]. 
However, administration of GHRH to pregnant women does not to alter GH-V 
concentrations. Furthermore, addition of GHRH to the media of cultured trophoblastic 
cells from early and term human placenta, did not stimulate GH-V release [238]. 
Since that GHRH does not affect GH-V secretion, the physiological role of placental 
GHRH during pregnancy thus remains unclear [239]. Meigan et al (1988) [240] 
detected no immunoreactive GHRH in the rat maternal circulation suggesting that 
placental GHRH does not affect the maternal hypothalamic pituitary axis. The 
presence of high molecular weight immunoreactive GHRH in rat placenta but not in 
the median eminence also suggests that posttranslational processing of the GHRH 
precursor molecule may be different in the two organs [240]. Several studies suggest 
that glucose levels may play a part in regulating GH-V production. In vitro studies 
have shown that low glucose concentrations in culture media can lead to an increased 
liberation of GH-V from cultured placental explants [241]. More recent studies report 
an inverse relationship of maternal BMI and GH-V serum levels, implicating 
metabolic factors could possibly regulate GH-V [242, 243].  
 
1.5.5 Physiological effects of GH-V 
In rodents GH-V is a more “somatogenic” hormone as it has the same potency in 
binding to GHR as does GH-N, but has lower lactogenic bioactivity [213].  The 
ability of GHV to bind to somatogen or lactogen receptors was investigated in rabbit 
and rat liver microsome cell lines [214]. GH-V was found to displace 125I-ovine 
prolactin bound to rat liver microsomes (lactogen binding) and to displace 125I-hGH 
bound to rabbit liver microsomes (somatogen binding). Therefore, human GH-V is 
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predicted to display both somatogenic and lactogenic bioactivity in animals, a dual 
specificity previously thought to be unique to GH-N. However, a 7.4-fold difference 
in this ratio was observed for GH-V compared to GH-N, suggesting significantly 
greater selectivity by GH-V in binding to the rabbit somatogenic receptor. MacLeod 
et al (1991) [213] also showed that GH-V could bind to both somatogen and lactogen 
cell surface receptors in vitro and that the ratio of its somatogen to lactogen receptor-
binding affinities was substantially higher than that of GH-N.  
 
The somatogen bioactivity of GH-V was also assayed by stimulation of weight gain in 
hypophysectomized rats, and lactogen bioactivity was assayed by the mitogenic 
response of the Nb2 lymphoma cell line [213]. The average increase in rat body 
weight in response to a fixed concentration of hormone was comparable using either 
GH-V or GH-N, whereas the mitotic response of the lactogen-inducible Nb2 cells was 
significantly less for GH-V. The comparable somatogenic, but lower lactogen, 
bioactivity of GH-V relative to GH-N parallels the previously reported receptor 
binding profiles of the two hormones. While this can suggest that GH-V could have 
the potential to perform a unique role during human gestation, it is difficult to 
extrapolate because the specificities of the receptors for rodent and human GH 
isoforms differ. For example Goodman et al  (1981) [244] investigated the biological 
properties of GH-N and GH-V. GH-N and GH-V activities were examined on rat 
adipocytes or epididymal fat segments. Both GH-N and GH-V were quite similar in 
their ability to bind specifically to intact fat cells and were virtually indistinguishable 
in their ability to increase glucose oxidation (an insulin-like response), induce 
refractoriness to insulin-like stimulation, and induce lipolysis in the presence of 
glucocorticoid. These findings suggest that placentally expressed GH-V has a 
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spectrum of metabolic activity comparable to pituitary GH-N and may contribute to 
regulation of carbohydrate and lipid metabolism during pregnancy. Some studies of 
GH-V have used human GHR-expressing cells for example, Silva et al (2002) [245] 
investigated GH-V signaling in IM-9 human lymphocytes. Human placental lactogen 
did not activate signaling in these GH receptor-expressing cells. Moreover, like GH, 
signaling by GH-V was inhibited by the GH antagonist (G120K). These findings 
confirm that GH-V can activate target cells expressing human GH receptors.  
 
1.5.6 Physiological effects of GH-V during pregnancy 
The direct function, if any, of GH-V during pregnancy is unclear, however, its 
continuous secretion appears to have important implication in the control of maternal 
IGF-1 levels. Studies in normal and pathological pregnancies have shown that IGF-1 
values in the maternal plasma correlate with corresponding GH-V values, regardless 
of complications and gestational age. The Cauifriez group [222, 246] obtained blood 
samples from 93 healthy pregnant women at various gestational stages. IGF-1 and 
human placental lactogen (hPL) was measured by radioimmunoassay. Pituitary GH 
was estimated by a two monoclonal antibody-based radioimmunoassay, the K24 
assay, which recognizes only GH-N, and the 5B4 assay, which reacts with all known 
pituitary as well as placental GH variants. GH-V was then distinguished from the 
main pituitary GH through its differential immunoreactivity. The results obtained 
showed that the mean plasma IGF-1 levels remained relatively stable until 29-30 
weeks of gestation, and then began to progressively increase from 164.0±44.6µg/L to 
a maximum of 331.6±63.7µg/L by 35-36 weeks. Regardless of gestational age, IGF-1 
values exhibited a positive correlation with GH-V values, whereas no significant 
correlation was found between IGF-I and hPL. 
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The regulation of IGF-1 with GH-V is also apparent in a study of pregnant women 
with acromegaly. Despite the high levels of GH-N and high basal IGF-1 
concentrations observed, maternal IGF-1 levels were nevertheless shown to increase 
further during pregnancy, following the pattern of GH-V secretion [247]. Moreover, 
the description of progressive elevations of IGF-1 in pregnant PIT-1 deficient women 
(and hence pituitary GHD women) further supports the theory of GH-V as being a 
prime regulator of IGF-1 during pregnancy [248]. The actions of GH-V are most 
likely to be mediated indirectly by IGF-1, since GH-V does not cross the human 
maternal/fetal barrier [239]. Pregnant rats injected with 125I-hGH hormone on 
gestational day 20 also showed no detection of radioactivity in fetal tissue, confirming 
no transfer of hGH from mother to fetus in the rat. The involvement of local IGF-1 
production in fetal development was suggested from early studies [249, 250], with 
evidence that the secretion of IGFs from maternal decidua may play a role in the 
control of growth process. However, clear mechanisms have never been shown. A 
role for human IGF is supported by studies showing a direct correlation of maternal 
IGF-1 and birth weight [251, 252].  
Further support for the coupled importance of GH-V and IGF-1 maternal 
concentrations come from studies that show decreased levels of both GH-V and IGF-1 
in cases of intrauterine growth retardation (IUGR) [221, 253]. Chowen et al (1996) 
[254] evaluated GHV mRNA expression in placenta taken from normal and IUGR 
babies. There was a significant decrease GH-V mRNA expression in placentae of 
babies with IUGR compared to normal placentae. They suggests that in IUGR the 
decreased levels of GH-V in the maternal circulation may not result exclusively from 
the reduced size of the placenta, but also from abnormal placental tissue development 
and/or from abnormal regulation of GH-V synthesis. In addition, data from Larcoix et 
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al (2002) [255] has demonstrated the expression of GH-V in invasive extravillous 
trophoblasts suggesting that the physiological role of GH-V might also include a 
direct influence on placental development via an autocrine or paracrine mechanism 
[255]. 
 
1.5.7 GH-V in pathology 
GH-V levels have been shown not to differ in the maternal circulation in cases of fetal 
anencephaly, supporting the independence of GH-V regulation from the fetal pituitary 
axis [253]. Women with a total deletion of the CS-A-B-GH-V gene locus (also 
resulting in the absence of circulating hPL) show uncomplicated pregnancies with 
normal newborns [256]. A further two reports of children with a GH-N, GH-V, CS-A 
and CS-L gene major deletion have also been published [257, 258]. The first of the 
cases lack accurate documentation, the second study, however, reported that the four 
affected newborns were short. These cases of deletion provide some evidence that the 
viability of human fetuses is not crucially affected by the lack of placental synthesis 
of GH, but this could contribute to defective fetal or placental growth  
Other studies have pointed to a possible modification of GH-V expression in diabetic 
pregnancies. A study by Hu et al. (1999) observed a higher GH-V/CS-L mRNA ratio 
compared to normal term placenta [259]. Furthermore, McIntyre et al. (2000) [224] 
showed a strong correlation between GH-V and glycemia at 28–30 weeks of gestation 
and they suggest that in long-term regulation, GH-V levels in diabetic pregnancy may 
be driving increased glycemia [224]. Although rodents show no GH-V-like activity, it 
has been reported in other species like the sheep placenta [260]. In this study the 
ovine trophoblast and syncitium was shown to produce an ovine placental growth 
hormone (oPGH). This hormone is produced between day 30 and 60 of pregnancy, 
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peaking at day 55. As well as the production of oPGH in sheep placenta, GH 
receptors were also found to be expressed in sheep placental trophectoderm [261]. 
Golos et al (1993) [262] showed that Southern blots of rhesus genomic DNA probed 
with a human CS cDNA demonstrated mRNA levels of mCS1 and mGH-V, being 
most abundant and increasing from the first to second trimester and then remaining 
relatively constant.  
 
1.5.8 Relationship of GH-V with Human Placental Lactogen (hPL) 
Human placental lactogen (hPL), is a single polypeptide of 191 amino acids also 
called human chorionic somatomammotropin and the product of the two chorionic 
somatomammotrophin genes (hCS-A, hCS-B) [263]. hPL is related to the pituitary 
growth hormone and prolactin with which it shows 85% and approximately 30% 
amino acid sequence homology, respectively [264]. hPL is also synthesized by the 
syncytiotrophoblast of the human placenta [265] and is detected from an early stage 
of pregnancy. hPL has been shown to act in concert with GH-V in the stimulation of 
IGF-1 production, this result in the increase in the availability of glucose and amino 
acids to the fetus [266, 267].  A study by Pilistine et al (1984) [268] demonstrated that 
the administration of hPL to fasted pregnant rats increased maternal and fetal plasma 
IGF concentrations and stimulated fetal weight gain. Such findings lead to the 
proposal that PL could play a part in the regulation of IGF during pregnancy. A 
correlation has also been shown between birth weight and maternal levels of hPL 
[269]. Pregnant rats infused with hPL between days 14 and 21 showed a significant 
increase in fetal weight on day 19 of gestation [270]. Furthermore, Spellacy et al. 
(1976) [271] have shown that in comparison with normal pregnancy, women with 
complications of IUGR during pregnancy have shown significantly lower hPL values, 
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which positively correlates with both placental and fetal weights. With these findings, 
as well as hPL being secreted into both the maternal and fetal circulations after the 
sixth week of pregnancy [267], hPL may have direct as well as indirect effects on the 
fetal growth. Furthermore, Freemark and Cormer (1989) [272] documented a unique 
placental lactogen receptor in maternal and fetal sheep liver. These studies strongly 
suggest that the biological actions of placental lactogen in fetal tissues are mediated 
through binding of the hormone to a distinct and unique placental lactogen receptor.  
 
Although hPL levels measured in maternal serum follow a similar pattern to GH-V 
and serum levels are measured to be 200-300 fold higher, two studies have now 
compared the relationship of GH-V, hPL and IGF-1, and hPL was shown to be only 
weakly associated with the third trimester IGF-1 values [222, 246]. Although hPL 
may be involved in the adaption to pregnancy, however, its potency over GH-V to 
regulate IGF-1 production is less, as the affinity of hPL GHR is >2000 fold weaker 
than for GH, whereas it has for binding to PRL-R [273]. Although hPL bears 
similarities to GH-V in placental production and implications in IGF-I regulation, the 
receptor binding properties imply different roles for hPL. There additionally seems to 
be no relationship between high or low glucose concentrations and hPL production, as 
shown for GH-V [241]. 
 
 
 
 
 
 
 56 
1.6 The placenta 
The survival and growth of a fetus is crucially dependent on the placenta, as it forms 
an interface between the maternal and fetal circulation, facilitating metabolic and gas 
exchange as well as fetal waste disposal. In addition, the placenta produces hormones 
that alter maternal physiology during pregnancy and forms a barrier against the 
maternal immune system [274]. The number of hormones produced by the placenta, 
vary between species. In both humans and rodents, the fully developed placenta 
consists of three distinctive layers, the outer maternal layer, which includes decidual 
cells of the uterus as well as the maternal vasculature, which brings blood to and from 
the implantation site. A middle region, known as the junctional zone in rodents only, 
which attaches the fetal placenta to the uterus and contains fetoplacental (trophoblast) 
cells, that invades the uterine wall and maternal blood vessels. Lastly, an inner layer is 
composed of highly branched villi that are designed for efficient nutrient exchange 
[275]. 
 
Structural homologies and dissimilarities between mouse and human placenta are 
fairly well recognized. Although the gross architecture of the human and mouse 
placenta differ, their overall structure and the molecular mechanisms underlying 
placental development are thought to be similar [275]. Comparison of placental 
development in mouse and human is summarized in Table (1.2). 
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Table (1.2) Comparison of pregnancy and placentation in mouse and human 
 
 MOUSE  HUMAN  
Implantation  Secondarily interstitial Primarily interstitial 
Trophoblast invasion 
of uterine arteries  
Shallow, limited to 
proximal decidua 
Extensive: reaching 
myometrial vessels 
Transformation of 
uterine arteries  
Dependent on maternal 
factors (uterine natural 
killer cells) 
Dependent on trophoblast 
Placental exchange 
area  
Labyrinthine Villous 
Trophospongium  Extensive Absent 
Interhaemal layer  Three trophoblast layers; 
outer one cellular, inner 
two syncytial 
Single layer of syncytial 
trophoblast (Langhans 
layer not part of barrier) 
Placental hormones  Placental Lactogens Chorionic gonadotrophin 
(hCG),  
chorionic 
somatomammotrophin 
(hPL),  
placental growth hormone 
(GH-V), Progesterone, 
Relaxin, IGFs. 
Gestation  Three weeks Nine months 
Adapted from Hans and Carter, 2000 
 
 
1.7 Placental cell lines 
A number of placental lines have been used to investigate several aspects of placental 
function. There are three main types of cell lines derived from human placenta; those 
that have arisen from spontaneously from cultured cytotrophoblast in vitro, those that 
have been immortalized by in vitro transfections with viral genes, and those from 
spontaneous choriocarcinomas, which have been maintained in vitro [276]. Defining 
the cell lines as representative of trophoblastic cell types has come from reports 
showing the production of hCG and hPL from cell lines [277, 278]. 
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Spontaneous cell lines of placental origin have had some assessment of endocrine 
function [279]. Transfected cell lines on the other hand have been generated by 
specific transfection with viral gene, all of which are positive for at least one of hCG 
or hPL [280]. The drawback of transfected cell lines is that the alteration to the 
genome may result in an alteration of endocrine function, rendering them as less 
useful models for functional studies [276]. BeWo and Jar1 are well established human 
cell lines, derived from choriocarcinoma which are malignant tumors of epithelial 
origin, they are thought to be representative of trophoblastic cells, and shown to 
undergo fusion and morphological differentiation similar to the formation of 
syncytiotrophoblast by the cytotrophoblast in the placenta [281]. There is evidence to 
suggest that chorionic somatomamotrophin (hCS-A and hCS-B) and growth hormone 
variant gene expression, although relatively low, occur in BeWo cells, with relative 
expression is greater in BeWo cells than Jar-1 cells [282]. Treatment of BeWo cells 
with thyroid hormone results in a 6-fold increase in messenger RNA from placental 
members of the hGH gene family [283]. Studies have been carried out to compare 
chorocarcinoma cell lines compared to one another, to gain insight into how normal 
trophoblast cells might function. These have more similarities then differences, 
suggesting that these can be good models of the human trophoblast lineage [284] 
There are some differences however. For example Mandl et al (2002) [285] showed a 
difference in proliferative response to insulin and IGF-I in BeWo, Jar-1, and JEG-3 
cell lines. 
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1.8 Aims of the thesis 
Although human placenta makes growth hormone GH and its receptor GHR, but the 
physiological roles and potential interaction are based on circumstantial evidence. 
Now we have tools for studying direct effects of GH on tissues, the main aim of my 
thesis was to investigate whether the placenta could be shown to be direct target of 
growth hormone. I began by initially investigating the production of GH-V and 
expression of GHR in placental cell lines, with the hope of establishing a system I 
could use to study GH-V storage and regulation. However I mostly wanted to study 
an in vivo model in GHD to obtain direct evidence for the placenta as a direct target of 
GH. 
 
To see an effect of GH, in vivo I used the approaches of giving GH to GHD animals. 
There were a number of GH-deficient animal models that were available to me for 
this project, including a dw/dw dwarf rat, as well as the GH-deficient GRF-M2 
transgenic mouse. The advantage of using GH deficient animal models is to observe 
the direct effect of GH administration in a number of tissues without the interference 
of endogenous pituitary GH. A notable change that occurs during human pregnancy is 
the change in GH secretory pattern from the pituitary. This would be eliminated in a 
GH-deficient model, whilst I could administer different patterns of GH in pregnant 
GHD animals. I planned experiments to observe the effects of food deprivation on GH 
response under conditions of minimal endogenous GH alteration, and compared them 
with responses in normal animal models. 
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When I began my work I was promised mice from Carole Mendelson whose group 
produced a transgenic mouse (for other purposes) with human growth hormone 
expressed in the placenta. The objectives of this group were to investigate the placenta 
specific transcriptional factors conserved between humans and rodents. They 
introduced the 501 bp of CYP19 exon I.1 5’ flanking sequence, which mediates 
placenta specific expression of aromatase, and used human growth hormone simply as 
a reporter in their transgenic mice. Expression of the CYP19 (I.1):hGH fusion genes 
was shown to be placenta specific. I envisaged I could examine placental responses to 
endogenous (transgene) hGH in isolation, by crossing these mice with our GHD mice 
strains, which would then lack pituitary GH, generating the first mouse model to have 
only a placental source of GH. Unfortunately, due to a variety of circumstances (loss 
of mice, huricanes and floods) these mice never arrived. I therefore decided to 
concentrate on GH administration studies, and used both rat and mice GHD models 
instead. To compensate, I also performed some preliminary studies of potential GH 
gene targets in placenta using microarray, to investigate preliminary downstream 
targets of GH in the placenta.  
 
In summary, the objectives of this study is to (i) investigate whether the placenta is a 
direct target of GH, (ii) whether the secretory pattern of GH and other factors i.e. 
restriction of nutrition alters the response to GH, and finally (iii) to seek preliminary 
evidence for potential downstream targets responsive to GH and sensitive to GH 
secretory pattern in the placenta. 
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Materials and Methods 
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2. Materials & Methods 
 
2.1 Animal physiology experiments 
2.1.1 Animal models  
GRF-M2 transgenic mice were generated by Paul Le Tissier. These mice have their 
GHRH neurons ablated using a modified H37A variant of the influenza virus and M2 
protein [286]. The mice show GH deficiency, secondary to GHRH deficiency, and 
develop dwarfism following weaning.  
Dwarf rats (dw/dw) were originally characterized by Charlton et al (1988) [300] but 
since have been bred as a homozygous colony in the SPF unit at NIMR. The dwarf rat 
mutation is autosomal recessive, and arose spontaneously in a breeding colony of 
Lewis wild-type rats. The mutation has not been identified, but causes a profound, but 
not total specific GH deficiency, with over 90% reduction compared to normal AS 
rats. 
 
2.1.2 Animal stocks 
Mice were bred and housed in the Laidlaw Blue animal unit of the NIMR, maintained 
according to local and national ethical animal welfare guidelines with a 12hr 
light/12hr dark cycle. Unless otherwise stated animals were allowed free access to a 
standard chow diet (3.4% fat, 18.8% protein, 3.7% fibre, 3.8% ash and 60% 
carbohydrate). Tap water was provided as drinking water. Animals were housed 
usually, in groups of 2-4. On completion of experiments, animals were anaesthetised 
using isoflurane, weighed, and then decapitated to collect truncal blood. Blood was 
collected in tubes containing 50U of heparin (Leo Laboratories Ltd), centrifuged at 
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200g for 10 minutes and plasma supernatant aliquoted into 0.5mL microfuge tubes 
and stored at -20oC until further use. Tissues were collected, weighed, frozen on dry 
ice and stored at -80oC or fixed where appropriate in 4% paraformaldehyde (Sigma) 
for 16 hours before being transferred to 70% ethanol. 
 
2.2 Genotyping 
To identify transgenic pups within litters, ear punches were taken from 2-week-old 
mice and DNA isolated for genotyping. Each sample was digested overnight in 250µL 
lysis buffer (50mM Tris pH 8.0, 100mM NaCl [Sigma-Aldrich], 100mM EDTA, 1% 
SDS [Bio-Rad], in dH2O) containing 0.4mg/mL proteinase K (Roche) at 55oC. DNA 
was extracted by adding 80µL of saturated NaCl solution to precipitate proteins and 
cell debris by centrifugation, followed by the addition of isopropanol (Fisher 
Scientific) to precipitate DNA and washed in 70% ethanol (Fischer Scientific) to 
remove salt. DNA was resuspended in 50µL water (Molecular biology grade, Sigma) 
and kept at 4oC until further use. 
 
2.2.1 Polymerase Chain Reaction (PCR) 
Amplification of DNA fragments was performed by PCR. DNA (1-2µL) was 
amplified by using 40 cycles of denaturation, annealing and extension conditions of 
94oC/40 seconds, 58oC/40 seconds, 72oC/120 seconds. A total reaction volume of 
25µL was used, consisting of 200µM dNTP mix (GE Healthcare), 0.2µM primers, 1x 
reaction buffer IV (ABgene), 1.5mM MgCl2 (ABgene), 2U Taq Polymerase 
(ABgene).  
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Table 2.1 lists the primers used to genotype GRF-M2 mice, and are directed against 
specific 3’ and 5’ sequences of human GH in the GRF-M2 transgene, which provides 
upstream cloning sites in GHRH and a polyA site, Le Tissier et al (2005) [286]. 
 
Table (2.1) Oligonucleotides used to genotype transgenic mice. 
PRIMER  DIRECTION  SEQUENCE  
GH12 hGH 5’ UTR AACCACTCAGGGTCCTGTGGACAG 
GH13 hGH 3’ UTR ATGATGCAACTTAATTTTATTAGGACAA 
 
Products were separated using electrophoresis through a 1.2 % agarose gel in 1x TBE 
(10x stock: 89mM Tris-Base, 89mM boric acid, 2mM EDTA) with 5ng/mL ethidium 
bromide (Bio-Rad) for analysis. The product sizes expected for non-transgenic (NT) 
and transgenic (T) were 1523bp and 724bp, respectively. 
 
 
2.3 Animal treatments 
 
2.3.1 GH treatment 
Female transgenic mice, dwarf rats and their wild-type controls were set up for mating 
with males between 4-6wks of age. Date of assumed pregnancy was determined by 
daily plug checks. Pregnant mice and rats at day 16 were given a single intravenous 
injection of varying doses of recombinant bovine growth hormone (bGH) or saline 
through the tail vein. Animals were culled 25 minutes following injection and blood 
and tissues were collected as appropriate. Six animals were used for each group. 
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2.3.2 Continuous GH treatment 
Pregnant day 12 animals had osmotic minipumps (Alzet) inserted subcutaneously 
under isoflurane anaesthesia. Analgesic drugs were given immediately post-
operatively. Pumps delivered a daily dose of 200µg of bGH/bodyweight. After 7 days 
the animals were culled, and tissue and blood samples collected. 
 
2.3.3 Fasting experiments 
Pregnant day 16 animals were fasted for 48 hours. On the 48th hour the fasted animals 
were given a single intravenous injection of bGH through the tail vein. Another group 
of fasted animals were given an additional single subcutaneous injection of 10mU/g 
of insulin (Humulin) at the 40th hour into the fast was followed by a single injection of 
bGH at the 48th hour of the fast through the tail vein. All animals were culled 25 
minutes after the final injection. 
 
 
 
2.4 Immunocytochemistry of paraffin embedded sections. 
 
Dissected tissues were stored in 4% PFA in PBS for 15 hours at 4oC before being 
transferred to 70% ethanol. All tissues were embedded in paraffin and sectioned 
(6µm) and stored at 4oC until use. I am grateful to Wendy Hatton (histology services, 
NIMR) who performed this. Tissue sections were dewaxed using histoclear (National 
Diagnostics) for 5 minutes to remove paraffin, followed by rehydration in descending 
concentrations of ethanol (2 minutes each in 100%, 70%, 30%, dH2O). To minimize 
background due to endogenous peroxidase activity, sections were incubated in 1% 
H2O2 diluted in 40% methanol. To enhance antigen retrieval, sections were incubated 
in 0.05% pepsin (Sigma) in 10mM HCl at 37oC for 7 mins or 0.05% trypsin in 0.1% 
CaCl2 (Sigma) for 15 minutes. Non-specific binding was blocked by incubating 
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sections for 1 hour at room temperature in TNB blocking solution (0.1M Tris-HCl 
(pH 7.5), 0.15M NaCl, 0.5% Blocking Reagent (PerkinElmer, 0.5% Triton x100). The 
primary antibody was diluted in blocking solution and incubated with sections at 37oC 
overnight. After overnight incubation, unbound primary antibody was removed by 
washing with TNT (0.1M Tris-HCl, 0.15M HCl, 0.05% Tween-20) 3x for 5 minutes. 
Sections were then incubated with secondary antibody at 37oC for 45 minutes. 
Sections were washed twice for 5 minutes in TNT and once in TN (lacking tween) to 
terminate antibody reaction. This was then followed by an Avidin-biotin step (ABC 
Elite Kit, Vectorstain) for which the sections were incubated for 30 minutes at room 
temperature. Some sections were then treated with biotinylated tyramides 
(PerkinElmer) for 15 minutes at room temperature in the dark to amplify the staining 
reaction. Sections were then washed 3x for 5 minutes with PBS before being 
incubated for 1 minute in diaminobenzidine (Sigma) to visualize peroxidase labelled 
antibodies, and then counterstained in Methyl Green (pH 4.5). 
 
2.5 Hormone analysis 
 
2.5.1 Tissue collection and preparation 
 
Pituitaries were then dissected and homogenised on ice in 1mL cold PBS. 
Homogenates were stored at -20oC until assayed. 
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2.5.2 Radioimmunoassay (RIA) 
 
RIA Solutions 
PBS   50mM NaH2PO4, 100mM NaCl, 0.6mM Thimerosal, pH 7.4 
Tris Buffer  100mM Tris-HCl (pH 8.4), 0.6mM Thimerosal. 
18% PEG  2mL 10%Trition x100, 1.5g γ-globulins, 330mL Tris buffer,  
667ml 27% polyethylene glycol (PEG), water to 1L 
RIA Buffer  PBS-0.3% BSA. 
 
2.5.3 Hormone Iodination 
Hormone iodination was performed using the iodogen method adopted by Danielle 
Carmignac in our lab, this was followed by the separation and elution of iodinated 
hormone from unbound iodine-125, carried out on 0.6 x 26cm Sephadex G75 columns 
(Amersham Bioscience). Prior to use, the columns were equilibrated with PBS/BSA 
(0.3% w/v BSA). Hormones for iodination were stored at -20oC in 0.2M sodium 
phosphate solution (pH 7.4) as 10µg aliquots. Immediately prior to iodination, a 
further 10µg of 0.2M sodium phosphate solution was added to the hormone solution. 
Iodine-125 (125I, Amersham) was stored at 4oC in 20MBq aliquots. An aliquot was 
diluted by the addition of 15µL of 0.2M sodium phosphate immediately prior to use. 
Hormone was added to the diluted 125I, and the mixture transferred to a glass tube 
containing 5µg of dried iodogen (1,3,4,6-teracholride-3α,6α-diphenylaglycouril; 
Sigma), and incubated at room temperature for 5 minutes. A total of 220µL of 0.2M 
sodium phosphate solution was then added and incubated for a further 2 minutes. This 
mixture was then added to the top of the column and eluted using PBS containing 
0.3% w/v BSA. Fractions (1mL) were collected manually and the radioactivity 
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counted. The middle fraction with the highest MBq count containing the labelled 
hormone was diluted into aliquots and stored at -20oC. 
 
2.5.4 Standard Curve 
The standard curve was prepared in triplicates in PBS/BSA. Total counts (T), 
antibody blank (ABL) and non-specific binding (BO) were used as controls were as 
follows: 
• T- 100µL iodinated hormone (diluted to give 5000-10,000cpm) only. 
• ABL- 200µL PBS/BSA + 100µL iodinated hormone. 
• Bo- 100µL PBS/BSA + 100µL antibody +100µL iodinated hormone. 
 
Standards were set up in triplicates as two-fold serial dilutions from a top standard of 
5ng hormone in PBS/BSA in a volume of 100µL per tube. Samples were set up as 
duplicates, also in two-fold serial dilutions. An antibody solution (100µL) and 100µL 
of iodinated hormone were then added to each tube. Antibody concentrations and 
standards are shown in Table 2.3. Tubes were shaken and incubated at room 
temperature for 24 hours. After incubation the antibody-bound hormone fraction was 
precipitated using 600µL 18% PEG-IGG solution. Tubes were allowed to stand at 4oC 
for 30 minutes, before being separated by centrifugation at 3000g for 12 minutes at 
4oC. The supernatant was then aspirated and the tubes capped and placed in a gamma 
counter to measure the radioactive 125I in the pellets. Counts were averaged over 3 
minutes. The percentage Bo was then calculated for each triplicate averaged and 
compared to the standard curve. A typical standard curve for mouse IGF-1 is shown 
in Fig 2.1, a best line of fit shown for the triplicate values obtained for each standard. 
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Figure (2.1) Typical mouse IGF-1 RIA standard curve. 
                                50% Bo=0.39698ng, ABL=5.19%, Bo-26.06% 
Each standard was run in triplicate, and values between Bo 30-80% on the standard curve were 
read. The readings would then be multiplied according to dilution factor to generate ng/mL serum as 
plasma. 
 
 
2.5.5 Pituitary samples: GH and PRL 
Standards and samples were always run together in each assay. Two-fold serial 
dilutions of the samples were set up in duplicate in PBS/BSA with 100µL final 
volume. Antibody solution and iodinated hormone were added and incubated at room 
temperature for 24 hours. After incubation the bound hormone fraction was 
precipitated using 18% PEG solution. The percent Bo was then calculated for the 
average of each set of duplicates (using a RIA plot program), to determine the mean 
ng of hormone per duplicate. This was then converted to µg per pituitary. 50% Bo 
values for GH, PRL and IGF-1 RIAs are shown in Table 2.2, indicating the mid point 
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on the respective standard curves. All the samples were rapidly measurable in these 
assays. 
 
 Table (2.2) 50% BO values for GH, PRL and IGF-1 RIA for mouse and rat. 
GH and PRL measured as pituitary content. IGF-1 measured from plasma. 
 
 
2.5.6 IGF-1 RIA 
In order to separate IGF-1 from its binding proteins prior to assay, plasma samples 
were extracted on the day of assay using a previously published protocol 
(Ebensperger et al 1998, [287]). Briefly, the samples were diluted 1:4 in acid-alcohol 
(87.5% ethanol, 12.5% 2M HCl), vortexed, and incubated at room temperature for 30 
minutes. These were then separated by centrifugation at 0.8g for 10 minutes at 4oC. 
The supernatant was removed and mixed in a 5:2 ratio with 0.855M Tris base to 
neutralise the solution. This was vortexed and incubated at -20oC for 1 hour. 
Following the incubation, samples were separated by centrifugation at 0.8g for 30 
minutes at 4oC. The supernatant (20µL) was then used for the assay and made up to 
100µL assay volume with PBS/BSA. Tubes were incubated and processed as for the 
pituitary extracts. Results were converted to ng/mL.  
 
 
 
RADIOIMMUNOASSAY MOUSE RAT 
GH 0.126ng 0.158ng 
PRL 0.431ng 0.290ng 
IGF-1 0.397ng 0.116ng 
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Table (2.3) Antibodies and standards used for RIA 
 
 
2.6 DC Protein Assay (detergent compatible) 
The detergent free protein assay (Bio-Rad) DC Protein was used to measure protein 
concentration following detergent solubilization. The reaction is similar to the well-
documented Lowry assay [288], but is faster and the color is more stable. A standard 
curve consisted of 3 - 5 dilutions of a top protein standard containing 1.5mg/mL to 
about 0.2 mg/mL of protein. Each of these standards as well as samples  (5 µL) was 
pipetted into a microtiter plate followed by addition of manufacturers reagents. The 
plate was mixed for 5 minutes on a plate mixer and the absorbance was read at 750 
nm.  
 
 
 
 
ASSAY  ANTIBODY  FINAL ANTIBODY 
CONCENTRATION  
STANDARDS  STANDARD 
RANGE  
mGH  Monkey 
alpha-rat GH 
NIDDK 
1:1,500,000 mGH 
NIDDK 
10ng-10pg 
mPRL  Rabbit alpha-
mouse PRL 
NIDDK 
1:400,000 mPRL 
NIDDK 
5mg-20pg 
mIGF1 
& 
rIGF1  
DSL 1:168,000 mIGF1 & rIGF1 
DSL 
10ng-10pg 
RGH  Monkey 
alpha-rat GH 
NIDDK 
1:300,000 rGH 
NIDDK 
10ng-10pg 
RPRL Rabbit alpha- 
mouse 
NIDDK 
1:400,000 rPRL 
NIDDK 
 
10ng-10pg 
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2.7 Western Blot protocol 
Liver and placental primary tissue was homogenised in with RIPA buffer (50mM 
Tris-HCL (pH 7.6), 150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 
protease inhibitor cocktail tablet (1x 25U tablet/10mL, Roche), and stored at -80 oC 
until further use. Loading buffer (100uL; 50mM Tris-HCL (pH 6.8), 100mM DTT, 
2% SDS, 0.1% bromophenol blue, 10% glycerol) was added to each sample. Samples 
were denatured at 95oC for 5 minutes, then loaded onto a miniture 10% 
polyacrylamide gel (Biorad) and separated by electrophoresis at 150V in a buffer 
solution (25mM Tris Base, 250mM glycine, 0.1% SDS; in dH2O). Samples were 
transferred to Nitrocellulose membrane (Hybond) for 2 hours in 1x transfer buffer 
(30mM glycine, 48mM Tris Base, 0.0037% SDS, 20% methanol; in dH2O), which 
was then incubated with primary antibody overnight at 4oC. Non-specific binding of 
the antibody to membranes was blocked by incubation in blocking buffer (5% milk 
powder in TBS-T (0.1% Tween20 in TBS). After washing in TBS-T, the membrane 
was incubated with mouse HRP-conjugated secondary antibody (1:10,000) in 
blocking buffer for 1 hour at room temperature. Specific antibody binding to 
membrane was detected by incubation with Supersignal® Chemiluminescent 
Substrate (Pierce) for 5 minutes before exposing to film. 
 
2.8 Microarray 
2.8.1 RNA Isolation 
Total RNA from rat placenta was isolated using a TRIzol reagent protocol (Life 
Technologies). Tissue samples were homogenized in 1mL of TRIzol reagent per 50-
100mg of tissue and incubated for 5 minutes at 15-30oC to ensure the dissociation of 
nucleoprotein complexes. This was followed with the addition of 0.2mL of chloroform  
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per 1mL of TRIzol reagent, and incubation at 15-30oC for 3 minutes. The aqueous 
phase formed was removed and transferred to fresh tubes with 5mL of isopropanol 
per 1mL of TRIzol reagent originally used. Samples were then incubated at 15-30oC 
followed by centrifugation at 2-8oC for 10 minutes. The supernatant was then 
removed and the remaining RNA precipitate was washed with 75% ethanol, 1mL of 
ethanol per 1mL of TRIzol used. Samples were centrifuged at 7500x g for 5mins at 
8oC, and the RNA pellet was then air dried for 5-10 minutes. 
 
2.8.2 Microarray experimental protocols 
A quantity of 500ng of total RNA was subjected to the Affymetrix small sample two- 
cycle protocol (Affymetrix GeneChip® Two-Cycle cDNA Synthesis Kit, Affymetrix 
Inc, Santa Clara, CA, USA). This protocol is designed to prepare labelled cRNA from 
as little as 100ng of total RNA. The resultant biotin labelled cRNA was then used to 
hybridize to GeneChip® arrays. Before hybridization the labelled cRNA product was 
assessed in a 2100 Bioanalyser (Agilent Technologies, Palo Alto, CA, USA), 
followed by fragmentation of 12µg of the labeled cRNA products following 
Affymetrix protocols. Each sample from the different experimental conditions was 
then processed and run on a separate rat gene chip. The fragmented cRNA products 
were firstly hybridized to GeneChip Test3 gene arrays to assess cRNA quality, and 
then to rat 230 2.0 array (900505) GeneChip array (Affymetrix), for 16 hours at 45o C 
following standard Affymetrix protocol. Following the 16-hour hybridization, bound 
biotinylated cRNA was then targeted by fluorophore conjugated-streptavidin. The 
signal amplified by the use of biotinylated anti-streptavidin antibody.  
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Following washing and staining, the arrays were then scanned on the Affymetrix 3000 
7G scanner. Data files from generated gene transcript levels were then determined 
using the PLIER algorithm and Genespring (version 9) by Abdul Sesey. 
 
 
2.9 In vitro Analysis of human placental choriocarcinoma cell lines 
 
2.9.1 Tissue culture 
Human BeWo and Jar1 placenta choriocarcinoma cell lines were obtained from 
American Type Culture Collection (ATCC). Cells were maintained as a monolayer in 
modified culture medium recommended and obtained from ATCC. For the BeWo cell 
line, F-12K (Kaighn’s modification of Ham’s F-12 Medium) was used. RPMI-1640 
medium was used for the Jar1 cell line. Hep2 cells were maintained in DMEM 
medium. All medium was supplemented with 10% fetal calf serum and 50mg/mL 
gentamycin (Invitrogen). 
 
2.9.2 Cell line transfections 
(i) Nucleofection 
Cell lines were cultured as normal and passaged two days prior to nuclear transfection 
using electroporation. Cells were transfected at 70% confluency using nuclear 
transfection kits (Amaxa). Table 2.4 shows a summary of the optimal conditions used 
for the given cell lines using nuclear transfection.  
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Table (2.4) Conditions used to transfect Jar1, BeWo and Hep2 cells 
CELL 
LINE  
AMAXA 
ELECTROPORATION 
PROGRAMME  
BUFFER DNA 
TRANSFECTED  
AMOUNT 
OF DNA 
(µG)  
Jar1  A20 L GHR/GFP/Stat5bGFP 1 
BeWo  A20 V GHR/GFP/Stat5bGFP 1 
Hep2  I-13 R GHR/GFP/Stat5bGFP 1 
 
Transfected cells were plated on polylysine-coated coverslips (Sigma) and maintained 
in growth medium at 37oC and 5 % CO2 for the period of the experiment, usually 
48hrs. 
(ii) lipofection  
Cells were plated in 24-well plates on polylysine-coated coverslips. After 24 hours the 
cells were transfected using Lipofectamine 2000 (Invitrogen) as described in 
manufacturer’s reagent protocol. Briefly, 1µg of DNA was diluted in 50µL of serum 
free medium and mixed gently. Lipofectamine 200 (2µL) was diluted in 50µL of 
serum free medium, mixed and incubated at room temperature. After 5 minutes, the 
diluted DNA and lipofectamine 200 were mixed together and incubated at room 
temperature for 20 minutes. The DNA–Lipofectamine mix was then added to each 
well containing cells and medium (500µL serum free), and the plates rocked gently at 
37oC for 5 hours. The transfected medium was then replaced with growth medium and 
returned to the 37oC incubator for the remainder of the experiment. 
 
2.10 Immunofluorescence 
Cells on coverslips were removed from growth medium and placed in 4% PFA 
(Sigma) and fixed for 15 minutes. This reaction was quenched and the cells 
permeablized using 50mM NH4Cl and 0.02% (w/v) saponin (Sigma) for 15 minutes. 
Cells were then placed in PGAS (0.2% gelatin (Sigma), 0.02% saponin) for 5 minutes 
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before incubating with the primary antibody (in PGAS) for 45 minutes. Primary 
antibody was removed by washing with PGAS and then the cells were incubated with 
secondary antibody for 30 minutes. Cells were washed in PBS followed by dH2O and 
mounted using Mowiol (100% glycerol [Sigma], 40% [w/v] Mowiol 4-88 
[Calbiochem] in ddH2O), ± DAPI (4’, 6-Diamidino-2-phenyindole, Dilactat). All 
incubations were carried out in the dark at room temperature. 
 
 
2.11 Imaging 
 
2.11.1 Image capture and analysis 
Light microscope images were captured on an AxioPlan2 microscope using Openlab 
software, version 5. Fluorescent images were captured using a Leica TCS SP. All 
images were captured both at high magnification  (x 40) and low magnification (x 
10). All light microscope images were quantified using a module of the Java-based 
image-processing programme, ImageJ (Wayne Rasband). 
 
2.12 Statistical analysis 
Unless otherwise stated, all results were presented as mean ± S.E.M and statistical 
analysis was carried out using Instat 2.01. Where two groups were compared, 
statistical analysis was performed with unpaired Student t-test. Where multiple groups 
were compared, analysis of variance (ANOVA) followed by post-testing of selected 
pairs with Dunnetts, Bonferroni, or Newman Keuls tests was used to determine the 
groups showing significant differences.  Significance values are shown as: * P<0.05, 
**P<0.01, *** P<0.001 in this thesis. 
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3. Models of GH signaling in the placenta in vitro and in vivo 
 
 
 
3.1 Human choriocarinoma cell lines and their use in studying GH signaling  
 
Cell lines considered to be representative of the human trophoblastic lineage were 
readily available at the outset of my studies. Whilst waiting for the transgenic animals 
from the Mendelson lab, I thought I would see if I could establish a GH-signaling 
system in human placental cell lines. How representative these different types of cell 
lines really are of the human placenta is a point of debate and discussed in chapter 1. 
Direct effects of GH are notoriously difficult to obtain in vitro (hence the 
somatomedin hypothesis) but I felt it important to utilize the availability of such tools, 
to see if I could use in vitro to models to establish responses to GH, for later 
application in vivo.  
I used two different choriocarcinoma cell lines, BeWo and Jar1 [289, 290] derived 
from spontaneous choriocarcinomas. These cell lines have been available for over 30 
years with a large literature. Both cell lines are reported to be representative of the 
human trophoblast lineage owing to their reported production of placental hormones, 
including reports of the growth hormone variant [283]. 
Owing to the similarity between the protein sequence of GH and GH-V, an existing in 
house radioimmunoassay (RIA) using a polyclonal sheep hGH antibody was used to 
measure GH in the two cell lines. This RIA detected very small amounts of GH for 
the BeWo cell line, but no measurable amounts of GH for the Jar1 cell line, (data 
obtained was < 40pg in 100µL of sample). One explanation for the detection of such 
low levels of GH in the cell lines may have been due to the lack of sensitivity of the 
RIA, I therefore attempted to make the assay more sensitive by the late addition of 
tracer, however, no measurable difference in GH was detected in either cell line.  
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Furthermore, I also tried a ELISA assay kit specific for GH-V. Results from this assay 
also showed no measurable amounts of GH-V for either cell line. The ELISA assay 
was designed to typically measure GH-V levels in blood samples, which may have 
accumulated higher levels than produced in vitro from cells. Nevertheless, with the 
assays I had, neither of the cell lines was going to be useful for measuring regulation 
of the production of GH-V, I thought this could mean they might be useful to study 
the effects of endogenous GH. I therefore carried out a number of 
immunofluorescence experiments on both cell lines to visualize the expression of GH 
receptors.  Interestingly, faint immunofluorescent staining was present, though 
variable in the BeWo cells, but undetectable in the Jar1 cells (Figure 3.1).  
 
Figure (3.1) Immunofluorescent staining for GHR in Jar1 and BeWo cells 
 
 
 
 
 
Jar1 
BeWo 
  GH -1°Ab 
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3.2 Transfection studies in placental cell lines 
Given the faint staining in these cultured placental cell lines I wished to try to 
improve detection and use these as a basis for introducing components of the GH 
signaling cascade i.e. the GHR into the cell lines, by transfection. To clarify whether a 
transfected GHR was functional, cells were exposed to GH, and then I attempted to 
detect a GH-GHR interaction by visualization of phosphorylated Stat5, as has been 
successfully achieved in chondrocytes and liver [291]. I used lipofection to introduce 
GHR to the placental cell lines, with a GHR construct (GHR-YFP) with a fluorescent 
tag in order to assess transfection efficiency, as previously used by Gevers here in the 
lab (2009) [291]. Although, this lipofection method has been previously used to 
transfect BeWo cells and been successful [292] I could not rescue viable placental 
cells following lipofection with this construct.  
 
I therefore switched to nuclear transfection, using a kit from Amaxa, which uses 
nuclear electroporation to introduce constructs. To my knowledge, this method, quite 
new at the time, had not been previously used to transfect placental cell lines, but 
several members of our lab had used this method to transfect a variety of other cell 
types, including endothelial cells, achieving high levels of viable transfected cells.  I 
therefore tested several of the buffers and protocols supplied by the manufacturers, 
transfecting both GHR and GFP (as a positive control) for the individual placental cell 
lines. This was somewhat more successful than lipofection, and viable cells following 
transfections could be identified under a fluorescence microscope, and the 
transfection efficiency calculated by counting fluorescent cells from five randomly 
selected fields.  
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However, few placental cells remained viable following nuclear transfection with 
GHR under most conditions, so the combination of the highest transfection efficiency, 
with the lowest cell death, in reference to both GFP and GHR transfected cells was 
sought. These conditions were program A20, with buffers V and L, for BeWo and 
Jar1 cell, respectively. The details about the buffers and programs are kept 
confidential by the manufacturers, so it is difficult to suggest why these specific 
conditions were more optimal for transfection efficiency.  
 
The conditions outlined above were then used to transfect cells with a range of 
construct concentrations, to determine an optimal amount of DNA for transfection, 
measuring randomly selected fields over a time course of 6-48 hours. I found the 
optimal amounts of GHR DNA to transfect were 1µg and 6µg, for BeWo and Jar1 cell 
lines, respectively, with an incubation time of 24  hours. Figure 3.2 illustrates cells 
from both placental cell lines transfected with GHR and GFP under optimal 
conditions. GFP was bright; GHR-YFP was dimmer but a few YFP positive cells 
were clearly visible under the microscope. Both Jar1 and BeWo cells illustrated in 
Fig.3.2 were transfectable but stronger signal was seen for GFP, compared to the 
GHR construct. 
 
 
 
 
 
 
 
 
 82 
 
 
 
Since the fluorescence signal from GHR-YFP was faint, I used immunofluorescent 
staining in an attempt to improve the visualization of the few GHR transfected cells 
more clearly, however, the level of signal observed for the GHR transfected cells 
remained low, even with confocal microscopy. Nevertheless, I incubated some of 
these cells with GH to try to stimulate Stat5 phosphorylation, in case this would give 
amplification. However, the level of GHR was either too low, or in too few cells, to 
see a significant Stat5b response. One reason for the poor success of GH signaling  
could be that many components of several signaling pathways may be compromised 
in the placental cell lines due to their pathological origin. For example low 
endogenous expression levels of GHR could also be accompanied with low levels of 
Stat5 after many passages. I therefore attempted to carry out double transfections with 
GHR and a Stat5b tagged construct (Stat5bGFP, a kind gift provided by Carter-Su et 
Jar1
GHR-YFP     GFP
BeWo
Placental cells transfected with GHR-YFP and GFP
Figure (3.2) Jar1 and BeWo cell transfected with GHR-YFP and GFP 
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al (1999) [293]. The placental cell lines were transfected with Stat5bGFP or double 
transfected with GHR-YFP and Stat5bGFP, cultured in GH, and then stained for 
phosphoStat5. This time I included control cells of non-placental origin to check 
whether the lack of signal was due to my poor technique or bad reagents causing these 
negative results. Hep2 cells, derived from squamous cell carcinomas were used. These 
cells express interferon alpha-receptors, like GH, a member of the cytokine nuclear 
receptor family. Upon ligand (interferon alpha) binding to its receptor, members of 
the Stat family are shown to be phosphorylated and translocated to the nucleus in 
these cells [E.Gevers in our lab, personal communication]. I therefore felt that cells 
known to be capable of initiating the phosphorylation of Stat5, without the need of an 
exogenous supply of Stat5 would be a good positive control. With the successful 
transfection of the Stat5bGFP construct in these cells, I would also expect to be able 
to track the translocation of phosphorylated Stat5bGFP upon IFNα stimulation.  
 
This would provide good evidence that the transfected Stat5b construct was capable 
of being phosphorylated, the stimulation worked and would indicate the viability of 
cells following transfections using this construct. Figure 3.3, illustrates the results 
obtained for the Hep2 control cells, Figure 3.4 (a) and (b) illustrates 
immunofluorescent staining for pYStat5 for both Jar1 and BeWo cell lines, 
respectively.  
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Figure (3.3) Hep2 cell lines transfected with Stat5bGFP, +/- IFNα treatment 
 
 
 
The top panel of images show Hep2 cell transfected with Stat5bGFP; image (1) 
shows fluorescent staining for GFP part of the Stat5bGFP (2) shows the 
fluorescence observed for the GFP without immunofluorescent staining (3) nuclei 
stained by DAPI, (4) Immunofluorescent staining for Hep2 cells following no 
treatment with IFNα . The lower panel shows the same groups, treated with IFNα . 
Images were created on a confocal microscope, x100 
 
 
The confocal images shown in figure 3.3 clearly indicate that Hep2 cells are 
transfectable with the Stat5bGFP construct. Furthermore, the Dapi staining of the 
cells confirm the survival of cells during the transfections. Transfected Hep2 cells can 
be clearly identified by the fluorescence shown by the GFP part of the construct 
alone, as well as by immunofluorescent staining for GFP.  Most importantly, 
administration of IFNα clearly shows the translocation of the fluroscence to the nuclei 
of cells, when compared to controls, thus verifying the phosphorylation of the Stat5b 
construct upon IFNα stimulation. This was encouraging as it suggested that my 
technique and reagents were functioning in these control cells, but suggested the 
          Control 
        IFNα 
  Anti GFP   GFP    DAPI    Anti  pYStat5 
(1) (2) (3) (4) 
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placental cell types were less good models for this in vitro approach, as my technique 
and reagents were the same.  
 
Figure 3.4 (a) Jar1 (b) BeWo cells transfected with GHR or GHR/Stat5bGFP 
 
(a) Top panel shows images for Jar1 cells; image (1) Stat5bGFP transfected Jar1 
cell immunostained for the GFP part of construct, (2) fluorescence from a Jar1 cell 
for the GFP part of the construct, (3) Sta5bGFP transfected Jar1 cells 
immunostained for pYStat5, (4) immunofluorescent staining for double transfected 
(Stat5bGFP/GHR-YFP) Jar1 cells. Lower panel shows the same images but for 
cells treated with GH. Fig.3.4 (b) Shows images for the same conditions but for 
experiments carried out in BeWo cells.  
 
        Control 
             GH 
  Anti GFP      GFP 
 
Anti pYStat5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Anti pYstat5 
 Stat5bGFP Stat5bGFP Stat5bGFP/GHR-YFP 
(a) 
 
(b) 
 
   Anti-GFP   GFP 
Stat5bGFP Stat5bGFP Stat5bGFP/GHR-YPP 
Anti pYStat5 Anti pYStat5 
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Confocal images shown in both Figure 3.4 (a) and (b) show that the Jar1 and BeWo 
placental cell lines could be transfected with the construct Stat5bGFP, although the 
number of cells were much fewer than Hep2 cells. As with the Hep2 cells the GFP 
part of the construct could be visualized with use of fluorescent microscopy as well as 
with fluorescent immunostaining for GFP. Unlike the Hep2 cells both Jar1 and BeWo 
cells showed no translocation of the construct upon GH stimulation. This was a 
disappointment as it suggested that any undetected endogenous GHR as well as the 
few GHR transfected cells remain unresponsive to GH even through the supply of 
exogenous signaling components. Given the primary aim of my thesis was to pursue a 
GH response in vivo, I didn’t embark on any further attempts to set up a cell-line 
system based on these cells, and concentrated on rodent placental responses in situ. 
As will become apparent in chapter 4, this proved a more fruitful approach. However, 
it is important to note that other placental cell lines might be better suited to this 
approach. 
 
3.3 Discussion 
It seemed reasonable to look first at placental cell lines to see if they could reflect the 
human placenta, at least in terms of investigating the effects of GH and GHR 
signaling. Studies by Frankeene [229] show GH production and GHR expression in 
the syncytiotrophoblast cells of the human placenta, and BeWo and Jar1 cells have 
been documented for being representative of the syncytial population [283] so there 
was reason to believe that these cells might also show GH production and endogenous 
GHR expression. My attempts to measure GH production from the placental cells 
lines proved difficult, with both methods employed being able to only show small 
amounts of GH production from one cell line. It is probable that assay sensitivity may 
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not have been sensitive enough to detect very low levels of GH production, and with 
hindsight, I could have established this with more sensitive methods like in situ 
hybridization. However this could not have given me the experimental system I 
needed, and paradoxically, the lack of endogenous GH could be a benefit for studying 
signaling in response to exogenous GH. 
 
Following immunofluorescence staining for GHR, very little flurorescent staining was 
observed in BeWo cells, (and not very convincingly specific) compared to antibody 
controls. As with GH production, no GHR staining was observed in the Jar1 cells, 
further emphasizing the variation in the properties of the two placental cell line. 
With the tumourous origin of the cell lines in mind, it is highly likely that the 
morphological and functional state of the cell lines may be altered when compared to 
that of normal human placenta. But in any event, the cell lines did not serve my 
purpose. Even when transfected with both GHR and Stat5b constructs, these cell line 
did not mount good Stat5 responses to GH; even after extensive optimization trials, 
very few cells were successfully transfected with GHR-YFP or Stat5bGFP. The 
number of transfected cells wasn’t overly convincing, and for those with signal, the 
Stat5 response to GH was rather inconclusive, especially when compared to the robust 
IFNα responses in the control Hep2 cells.  
 
In conclusion, despite the exogenous addition of two major components of the GH 
signaling cascade, I could not reconstitute responses to GH in these cell lines.  
The placental cell lines could be lacking in a number of other components required for 
GH signaling cascade, but the combination of endogenous absence of GHR, the low 
transfection efficiency (eg. JAK kinase), and the inability of the cells to show function 
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through transfected GHRs and Stat5s made me decide to not pursue this route further 
in in vitro models for the study of GHR activated signaling. It should be remembered 
that many studies in many different tissues have also found it difficult to obtain 
reliable robust GHR signaling, hence the somatomedin hypothesis, though there are 
now some successful GH-responsive cell lines (Gevers et al 2009) used in the lab. 
 
Having spent a lot of time on this, and with no guarantee that the placental cell lines 
would generate any results, I felt it more constructive to move on to a different model 
to observe the possible effects of GH on the placenta, I therefore decided to utilize the 
GH deficient rodent models available in my division. Whilst this has the advantage of 
an in vivo approach, it does loose the advantage of human system that the cell lines 
offered. This was a feature I needed to bear in mind in the following rodent studies 
presented in this thesis. 
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3.4 GH-deficient rodent models 
 
3.5 Introduction 
Even though GH is produced in the fetus from around the third month of gestation in 
humans [294] and from embryonic day 16-19 in rodents [295, 296] most available 
evidence suggests that pituitary GH does not have a direct role in fetal growth and 
development. For example fetal sheep made GH deficient by hypophysectomy are of 
normal birth weight [297]. Similarly, human infants with congenital GH deficiency 
show only a small reduction in birth length [298]. This has also been confirmed in 
newer studies with Laron Dwarfs, which show normal birth weights despite having 
defective GH receptors [299].  
 
Despite this, there are high levels of circulating GH in the later terms of both human 
and rodent pregnancy. The role of this remains unclear, however, a potential indirect 
role could be considered, via effects on other processes like metabolism, not as 
obviously reflected in skeletal growth as it is in post-natal life. In the experiments 
described in this part of chapter 3, my specific aims were to (i) briefly describe the 
characteristics of GHD rodent models used, and measure their pituitary hormones in 
pregnant vs non-pregnant states, which has not previously been reported and (ii) to 
observe whether there is a change in some pituitary hormones during pregnancy in 
these models. All measurements were taken at approximately day 16 of both rat and 
mouse pregnancy, with all animals being set up for mating after 4-6 weeks of age.  I 
also tested whether GH-deficiency during pregnancy in these models would affect 
such outcomes as the weight of mother, pups, and number  
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of pups born to each mother. Differences if any in these parameters between GH-
deficient and normal mothers would of course also reflect possible consequences of a 
small mother on fetal growth, which might imply a possible indirect role of GH status 
in pregnancy, as well as other factors relating to uterine size, not directly depending 
on GH. 
 
3.6 Hormone analyses in pregnant Dwarf and AS rats 
 
Our lab was the first to identify the dwarf rat model used in my experiments. These 
dwarf rats (dw/dw) have an inherited autosomal recessive mutation (as yet 
uncharacterized) resulting in a severe but sub-total GH deficiency [300, 301]. 
Chromosomal location studies (Le Tissier, unpublished) have excluded all the known 
candidates genes affecting the GH axis but the locus close to a centomere has proven 
difficult to clone. The initial characterization of the dwarf (dw/dw) strain showed that 
post weaning growth was retarded, 3 month old male and female rats showed weights 
approximately 40% less then their normal litter mates, and continued to grow at a 
slower rate. Pituitary GH concentrations were approximately 10% of normal in male 
and 6% in female rats, all other anterior trophic hormones (LH, TSH, prolactin and 
ACTH) were within the normal range [300]. Since these initial observations by the 
Charlton group, several other studies have measured the same hormones, as well as, 
carried out more detailed work to characterize the dw/dw model further [301, 302]. 
Studies in dw/dw rats have shown their acute response to GH secretagogues such as 
GH-releasing hormone (GHRH) or growth hormone releasing peptide-6 (GHRP-6) as 
being reduced in proportion to their pituitary content [300, 303]. One defect appears 
to be an inability to generate a cyclic AMP response to the administered GHRH, 
which results in a failure to build pituitary stores. A compensatory effect of their 
 91 
somatotroph hypoplasia appears to be an increase in prolactin (PRL) and PRL cell 
number [304, 305]. Subsequent measurements have shown significantly higher 
pituitary PRL content in adult dw/dw animals, although their basal plasma PRL levels 
were normal [305, 306]. The pituitary content for GH and PRL has never been 
measured in pregnant dwarf rats, so as well as providing new data, my proposed 
studies would address the question of whether pregnancy changes the magnitude of 
GH deficiency or prolactin excess observed in non-pregnant dwarfs, compared to 
pregnant normal Albino Swiss (AS) rats. I also measured IGF-1 plasma levels in the 
same groups of animals, as a more general index of GH activity.  
 
Table 3.1 shows pituitary GH contents from pregnant and non- pregnant dwarf and 
(AS) rats. As expected, the pituitary GH content in non-pregnant rats was profoundly 
reduced in dwarfs (3.2±0.7), compared to normal AS rats (181.2±23.8), P<0.001. My 
new findings were a similar significant reduction in the pituitary GH content in 
pregnant dwarfs (3.0±1.7) vs AS rats (186±34.4), P<0.001. However, I noted that 
when comparing the pituitary GH content of non-pregnant with pregnant rats, no 
significant differences were found within either strain. Since fasting in rodents 
induces a state of GH resistance and reduced GH levels [80], and I planned to use 
fasting in later experiments, it was also of interest to measure the pituitary GH 
contents of fasted pregnant rats. Measurements of pituitary GH contents in an 
additional group of pregnant 48 hour fasted, normal and dwarf rats (Table 3.1) 
showed no significant differences in pituitary GH, when compared to the non-fasted 
pregnant groups. Importantly, fasting did not build up GH stores in dwarf rats. 
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Table (3.1) Pituitary GH content measured for normal (AS) and dwarf 
(pregnant and non-pregnant) rats. 
 
 
RAT MODEL NON-PREGNANT PREGNANT PREGNANT/FASTED 
AS        181.2±23.8 186±34.4 186±29 
Dwarf          3.2±0.7***     3.0±17*** 3.8±1.7 
Pituitary contents shown for (6wk +) old animals at day 16 of pregnancy 
 
 
An increase in the baseline circulating GH concentrations is evident in pregnant 
rodents [81] and recent data suggest that the increase in GH levels during pregnancy 
is likely to be a result of increased secretory activity [307]. Since I found no change in 
GH contents between pregnant and non-pregnant rats, this could imply that the 
production of pituitary GH would also be increased during pregnancy, to match 
increased secretory activity. Dwarf rats show no intrinsic impairment in responding to 
GRF treatment with GH secretion, however, the amount of GH secreted is much 
lower than normal rats, reflective of their reduced pituitary GH content [303]. I thus 
feel is reasonable to assume that any increase in GH secretion during pregnancy in the 
dwarf rat will not make a significant contribution to plasma GH, and it certainly does 
not restore the GHD state to normal. 
 
 
3.6.1 Pituitary prolactin content in non-pregnant and pregnant dwarf and AS 
rats 
 
During pregnancy and in preparation for lactation there is a progressive increase in 
hypophysial PRL secretion, with an extensive modification of lactotrophs, increase in 
the synthesis and secretion of prolactin (PRL) [308]. As mentioned above, dwarf 
dw/dw rats are unusual in having relatively high PRL contents despite having low GH 
[309] but again, PRL measurements had not been made in pregnant dw/dw rats, so I 
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wanted to measure the PRL pituitary contents during pregnancy in AS and dw/dw rats 
(Fig 3.5). I found a significantly higher level of pituitary PRL content in non-pregnant 
dwarfs (29.81±4.0), compared to non-pregnant AS rats (14.3±1.9), P<0.001. The 
original findings from Charlton et al (1988) [300], in which pituitary PRL content 
measured in small groups of dwarf rats, found no differences, but the same group later 
analyzed larger groups of animals on the same genetic background, and found larger 
differences. My results support these later findings, confirming that dw/dw dwarf rat 
have increased pituitary PRL contents, (AS vs dw/dw, P<0.01) [304]. Interestingly, in 
pregnancy, there appears to be no significant change in AS pituitary PRL content, 
when compared to non-pregnant AS rats. Dwarf rats showed a mean reduction in PRL 
content from (29.8±4.0) in non-pregnant, to (21.3±2.4) in pregnant rats, and although 
this remained higher (21.7±2.4) than in pregnant AS rats (14.4±2.1), the difference 
was no longer statistically significant. This further suggests that the dwarf rat model 
has an unusual increased pituitary PRL content, but that it isn’t maternally altered 
during pregnancy, remaining higher than in AS rats. Of course these are only content 
measures, so it is possible there are differential effects as secretion vs release in dwarf 
rats. Since the mechanism for increased PRL is unclear in dwarfs, it is difficult to 
speculate on mechanisms for this in pregnancy in rats. 
 
I also tested whether this high pituitary PRL content in pregnant and non-pregnant 
dwarfs would be affected by fasting during pregnancy. Pregnant 48 hour fasted AS 
rats showed no significant difference in pituitary PRL content, when compared to 
non-pregnant or non-fasted pregnant AS rats. Pregnant fasted dwarf rats, showed 
higher pituitary PRL content, than non fasted pregnant dwarf rats though the contents 
didn’t exceed those in non-pregnant dwarfs, and pituitary PRL content in pregnant 
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fasted dwarfs was much higher (29.3±2.9), compared to pregnant fasted AS rats 
(13.4±1.9). These results indicate that the high PRL content recorded for dwarf rats is 
maintained during conditions of fasting, compared to non-fasted and normal rats. 
 
 
Figure (3.5) Pituitary PRL content measured for AS and dwarf non-pregnant 
and pregnant rats. 
 
ANOVA followed by Student Newman Keuls, *** P<0.001 
 
 
 
 
3.6.2 IGF-1 plasma levels in dwarf and AS pregnant rats during pregnancy 
 
Circulating IGF-1 concentrations change in pregnancy in a variety of species. 
In women, maternal serum levels of IGF-1 rise progressively throughout pregnancy, 
[250, 310] and its levels are associated with mean levels of GH-V. In contrast, there 
are several studies that show in rats that IGF-1 levels continue to decrease during the 
later part of pregnancy [173, 311, 312]. Gargosky et al (1994) [173] showed that 
maternal rat serum IGF-1 levels increased from early to mid-pregnancy, after which 
IGF-1 levels declined. Conversely, as IGF-1 levels declined, pituitary rat GH 
increased two-fold. This coincides with a decrease in IGF binding protein 3 (IGFBP-
3) and the appearance of an IGFBP protease, which cleaves BP3, increasing free IGF-
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1 levels. IGF-1 plasma levels are low in dwarf rats, but I measured IGF-1 levels in 
dwarf (and AS) rat plasma in pregnancy, as these has not previously been compared. 
IGF-1 plasma levels measured in dwarfs and AS rats are shown in Figure 3.6. As 
expected non-pregnant dwarf rats showed much lower plasma IGF-1 levels 
(160.0±11.3) than non-pregnant normal rats (323.9±50.8). Both 16d pregnant dwarf 
and AS rats showed a significant decrease of IGF-1 plasma levels, when compared to 
non-pregnant rats, (49.7±7.0 and 160.0±11.3 compared to 191.0±32.7 and 323±50.8; 
both P<0.01), respectively. As expected, there was also a significant decrease in IGF-
1 plasma levels measured in both pregnant fasted AS and dwarf rats, compared to 
non-fasted counterparts (21.9±2.3 and 20.5±1.7 compared to 160.0±11.3 and 49.7±7; 
both P<0.01, respectively). The reduction in IGF-1 plasma levels shown in the fasted 
rats support the previous findings of Bornfeldt et al (1989) [161] which also showed a 
reduction in IGF-1 levels in fasted rats. My data shows this is also the case in food 
deprived pregnant rats, and in the dwarf strain.  
 
Figure (3.6) IGF-1 plasma levels measured in AS and dwarf, non-pregnant and 
pregnant rats. 
 
ANOVA followed by Student Newman Keuls, ***P<0.001, ** P<0.01 
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The decline in IGF-1 levels in fasting is thought to be due to, at least in part, to a 
lower hepatic synthesis of IGF-1 [313].  High levels of IGF-1 are known to inhibit 
pituitary GH synthesis and secretion by acting on the sommatotrophs [314]. 
Therefore, it can be expected that diminished negative feedback as a consequence of 
decreased IGF-1 may contribute to the increase of plasma GH during late pregnancy. 
This of course will be much more pronounced in normal rats than in dwarf rats, which 
are already IGF-1 deficient, but which cannot increase their GH levels significantly. 
 
 
3.7 Measurement of pituitary GH, PRL content and IGF-1 plasma levels in GHD 
 
(GRF-M2) and non-transgenic pregnant and non-pregnant mice. 
 
There have been few studies that have measured changes in the hormone content of 
the pituitary in mice and, none adequately monitoring plasma levels during 
pregnancy. The latter is not surprising considering the size of mice and the difficulty 
in obtaining serial blood samples from them. I therefore wished to establish some 
baseline data for our GRF-M2 mouse model [286]. As well as, being able to compare 
the results from one rodent GH deficient model to another, these comparisons would 
help draw further conclusions to whether any changes observed are common to at 
least two deficient GHD rodent models of primary and secondary dwarfism. As 
described in materials and methods, GRF-M2 transgenic mice lack GHRH neurons 
[286] show GH deficiency, secondary to GHRH deficiency, and develop dwarfism 
post weaning. 
I confirmed that GRF-M2 mice show dramatically lower pituitary GH contents 
(2.2µg/pit), when compared to their non-transgenic counterparts (19.6µg/pit), Figure 
3.7. Also apparent is a trend in slightly higher pituitary GH contents in pregnant non-
transgenic mice, compared to a non-pregnant group (23.3±0.9 compared to 19.5±1.5) 
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but this did not reach statistical significance. Interestingly, pregnant GRF-M2 mice 
showed a significantly lower (0.41±0.09) pituitary GH, when compared to non-
pregnant mice (2.1±0.4), P<0.001. Given this lack of GHRH, one possibility is that 
they are unable to respond to increased demand for pituitary GH during pregnancy by 
increased GHRH drive to stimulate GH synthesis. As in the GHD rat model, I was 
interested to see whether fasting during pregnancy would change the pituitary GH 
content in GHD mice or whether this change would differ in the mouse, compared to 
the rat. The pituitary GH content measured for pregnant wild-type mice fasted for 48 
hours was obviously much higher (26.1±1.6), compared to GRF-M2 pregnant fasted 
mice (2.1±0.4). However, significantly higher pituitary GH contents were found in 
both pregnant non-transgenic and GRF-M2 fasted mice, compared to pregnant non-
fasted groups (26.1±1.6 and 2.1±0.4, compared to 19.5±1.5 and 1.6±0.1, P<0.01 and 
P<0.001, respectively). Fasting in these animals may have more indirect effects on 
GH. This is suggested by the increase recorded in the pituitary contents of both 
groups of fasted mice. One possible mechanism may be a reduced feedback of IGF-1 
during fasting conditions, thus resulting in the increase of pituitary GH content as 
IGF-1 has direct negative effects on GH synthesis, and wouldn’t regulate an intact 
GHRH axis to regulate GH contents. It is also important to bear in mind that the GRF-
M2 mice have secondary GH deficiency, unlike dwarf rats, therefore their pituitary 
somatotroph population has no intrinsic defect, and should be responsive to feedback 
mechanisms, providing it excludes the requirement of increased GRF, which is 
lacking in these GRF-M2 mice. 
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Figure (3.7) Pituitary GH content measured for non-transgenic (wild-type) and      
GRF-M2  non-pregnant and pregnant mice. 
 
ANOVA followed by student Newman Keuls, **P<0.01, or ***P<0.001. 
 
 
3.7.1 Pituitary PRL content measured in non-transgenic and GRF-M2 non- 
pregnant and pregnant mice 
Unlike the dwarf rats, and like most GHD models, GRF-M2 mice show low PRL in 
the non-pregnant state [286], so it was interesting to find out whether there was be an 
increase in PRL during pregnancy. Figure 3.8 confirms the amount of pituitary PRL 
measured for GRF-M2 mice was markedly lower (0.6±0.03) than that in non-
transgenic mice (6.6±02), similar to the pituitary GH comparisons (Fig 3.8 vs Fig 
3.7). A significantly increased pituitary PRL content was observed in pregnant non-
transgenic mice (9.7±06), compared to the non-pregnant group (6.6±0.2, P<0.001). 
This differed from my results in normal rats, in which no significant difference in 
pituitary PRL levels was observed between any groups. Unlike their wild-type 
littermates, GRF-M2 pregnant mice showed a further reduction in PRL-pituitary 
content, when compared to non-pregnant mice (0.61±0.03 compared to 0.42±0.01, 
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P<0.001). This supports the paper describing the GRF-M2 model, in which the 
potential mechanism for disruption of lactotrophs (secondary to GH loss) is discussed 
[286]. Figure 3.8 also shows that fasted pregnant non-transgenic mice have higher 
pituitary PRL contents (8.5±0.6), compared to the GRF-M2 group (1.05±0.03), which 
in turn was higher than PRL contents in the non-fasted pregnant group (0.42±0.01, 
P<0.001).  
 
 
 
Figure (3.8) Pituitary PRL content measured for non-transgenic (WT) and GRF-
M2 non-pregnant and pregnant mice. 
 
ANOVA followed by student Newman Keuls, ***P<0.001. 
 
 
3.7.2 IGF-1 plasma levels measured in GRF-M2 and wild type mice during 
pregnancy 
As in dwarf and AS rats, IGF-1 plasma levels (Fig 3.9) are significantly reduced in 
the pregnant GRF-M2 and non-transgenic mice, when compared to non-pregnant 
groups, (19.3±0.4, 113.0±8.9 compared to 33.7±2.5 and 179.1±7.5, both P<0.001, 
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respectively). Figure 4 also shows a significant reduction of IGF-1 plasma levels in 
the fasted pregnant GRF-M2 group (18.4±0.9) compared to non-pregnant mice 
(33.7±2.5, P<0.001). This adds strength to the notion that GHD in pregnant rodents 
show reduced IGF-1 production, unlike in humans.  
 
 
 
Figure (3.9) IGF-1 plasma levels measured in GRF-M2 and non-transgenic 
(Wild type) non-pregnant and pregnant mice 
     
                                   ANOVA followed by student Newman Keuls, ***P<0.001. 
 
 
3.8 Difference in weight gain observed in pregnant and non-pregnant GHD 
rodents and normal Wild-Type controls 
Figure 3.10 shows the weights recorded for day (16) pregnant vs non-pregnant dwarf 
and AS rats. Figure 3.10 shows that, non-pregnant dwarf rats weigh one third less 
(107.2g±2.55) than to non-pregnant AS rats (155.0g±4.03; P<0.001), in line with 
observations made by Charlton et al (1988) [300]. Figure 6 also shows that this 
relative dwarfism persists in pregnancy, since pregnant dwarf rats weighed 
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significantly less (180.3g±6.25) than pregnant AS rats (255.0g±5.88; P<0001). 
However, it was interesting to see whether pregnant dwarf rats gained less weight 
than normal pregnant AS rats, e.g. by expressing this relative weight gain as a 
percentage. Dwarf rats gained 40% weight during the 16 days of pregnancy, whilst 
AS rat’s weights increased by 39%, i.e. identical between dwarf and AS rats. 
Neglecting for the moment, pup weight and number, the overall weight gain of 
mothers would differ if the GH-deficient mothers tissues continue to be affected by 
GH deficiency as would be expected from my hormone data.  
 
Figure (3.10) The weight of non-pregnant and pregnant dwarf and AS rats 
Student t-test, ***P<0.001 
 
 
The same measurements were made in 16 day pregnant GH-deficient, GRF-M2 and 
non-transgenic mice. Figure 3.11 shows an increase in the weight of pregnant GRF-
M2 and non-transgenic mice (24.3g±1.8 and 34.0g±1.8) compared to non-pregnant 
groups (11.0g ±1.0 and 20.1g±0.4, both P<0.001). As in the dwarf rats, GRF-M2 mice 
show post weaning dwarfism; non-pregnant female GRF-M2 mice weighed 
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13.8g±0.5, compared to non-transgenic females 23.1g±1.8 [286]. However, GRF-M2 
mice show a pregnancy related percentage weight gain of 54% relative to its weight, 
compared to 41% weight gain showed by the non-transgenic mice. This indicates that 
the GRF-M2 mice do not show any apparent impairment in weight gain during 
pregnancy, gaining over half of their relative body weight. Of course this does not 
distinguish between pup weight and litter number, vs maternal growth, and the former 
could have a relatively larger numerical effect in these tiny GRF-M2 mothers. 
 
Figure (3.11) Weights of pregnant and non-pregnant GHD (GRF-M2) and non-       
transgenic wild-type mice. 
Student t-test, ***P<0.001 
 
 
3.8.1 Differences observed in the number of pups born to normal vs GHD 
pregnant rodents 
Previous work has shown that GH may have a role in determining litter size. A study 
using GH receptor knockout mice showed a marked reduction in the litter size born to 
these animals. GHR KO mice showed a reduction in litter sizes in GHR KO 
 103 
homozygous mating (1.6±0.4 pups per litter vs. 6.3±0.9 for wild-type mating vs. 
3.2±0.5 for heterozygous mating), but there are many possible reasons for this, not 
least being strain differences [315]. It was therefore interesting to determine whether 
similar effects on the number of pups per litter would be seen in the GH-deficient 
models used in my experiments, when compared to normal rodents of the same strain. 
Figure 3.12 records the number of pups observed for 40 individual litters in dwarf and 
AS rats. The most frequently occurring litter size in dwarfs was 8, compared to 10 in 
AS rats, on the same genetic background. Figure 3.13 shows a similar scatter graph 
for GRF-M2 and non-transgenic mice, revealing a reduced average litter size in GRF-
M2 mice, most frequently 5, compared to 10 in non-transgenic mice. These results, 
showing that a reduced number of pups are born to both GRF-M2 and dwarf rats, 
compared to normal rodents, do suggest that GH-deficiency and dwarfism impairs 
litter size, and this will exaggerate the differences observed earlier in total weight 
gain. 
 
It is difficult to determine whether the absence of GH is directly responsible for the 
reduction of pups per litter or this reflects a secondary phenotype of dwarfisim. 
Nevertheless, there is data in the literature, which shows maternal GH to be involved 
in oocyte maturation, ovulation rate and folliculogenesis [316, 317]. It is thus possible 
that GH may have a possible role in determining litter size. (see page 110 for 
discussion).  
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Figure (3.12) The number of pups born per litter in dwarf and normal AS rats. 
 
 
Figure (3.13) The number of pups born per litter to GRF-M2 mice and normal 
Wild-Type mice. 
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3.8.2 Differences in the weight of pups and placenta in GHD vs normal rodents  
Unlike littersize effects, Figure 3.14 shows no significant difference in the weight of 
individuals pups born to dwarfs, compared to that of AS rats, which further supports 
the idea that most of the difference in maternal weight gain is due to effects in the 
mother, and on total litter size. 
 
Although, no study has shown the direct affects of maternal GH on fetal growth, a 
study by Spencer et al (1994) [318], shows that disruption of rat GH during 
pregnancy can lead to the retardation of fetal and placental weights, suggesting that 
the effects of GH during pregnancy are more likely to be indirect. Furthermore, GH 
treatment throughout pregnancy of GHD rats, in the same study, resulted in 
significantly bigger pups, compared to pups from untreated mothers. In contrast, in 
humans lack of GH-receptors causing complete GH insensitivity (as in Larons 
syndrome), is not associated with any changes in birth weight [319] suggesting that 
GH signaling is not important for fetal growth in humans. From these observations, it 
appears that whilst GH-deficiency in dwarf rats somehow reduces the number of pups 
successfully coming to term, the weight of these pups remain similar to weights of 
pups born to normal rats, despite them being developed in a dwarf uterine 
environment. Whether this reflects a trade-off between uterine size, and nutrient flow 
appropriate for a smaller total litter, remains to be determined. 
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In this context, Figure 3.14 showed that there is a significant reduction in the 
individual placental weights measured in dwarfs, compared to AS rats (0.34±0.06 
compared to 0.43±0.09; P<0.001). There are very few studies related to GH status and 
placental weight, though a relationship between rodent placental size and IGF-1 
levels, has been reported [224]. McIntyre et al [224] showed in rats that reduced IGF-
1 plasma levels during pregnancy, were associated with reductions in placental size. 
Since plasma IGF-1, in pregnant dwarf rats in my experiments, also showed a decline 
compared to non-pregnant rats, this is consistent with an indirect effect of GHD on 
placental weight, via lower IGF-1 levels. 
 
Figure (3.14) Pup and placental weights in dwarf and AS rats. 
 
 
***P<0.001, student t-test. 
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It was also interesting to test whether pup and placental weights varied in the same 
way in pregnant normal and GHD mice. However, in addition, in these experiments, 
pups from these litters were also individually genotyped to record whether there was 
any difference in weight between the transgenic and non-transgenic pups, carried in 
the same mother. This was possible in mice, as the phenotype is expressed in 
hemizygous animals, (whereas the rat dw/dw mutation is recessive, heterozygotes 
being normal, and there is no genetic PCR maker for dw/dw). Figure 3.15 shows that 
the mean pup weights recorded for GRF-M2 litters were significantly smaller 
(0.51±0.03), than the mean pup weights in wild-type litters (0.80±0.04, P<0.001). The 
difference in mean pup weights between transgenic and normal wild type pups 
suggests in mice, that the mothers GHD-status may play a part in determining the 
weight of its pups, however, the mechanism involved is unclear. Again, it is quite 
possible that this simply reflects constraint imposed by the smaller uterus, as well as 
the reduced levels of IGF-1, which in turn may limit the nutritional supply to pups.  
 
Figure 3.15 shows that there is a significant reduction in the mean weight of 
transgenic pups, compared to non-transgenic pups born to the same litter (0.393±0.05 
compared to 0.84±0.06; P<0.001, respectively), but no significant difference between 
the weights of non-transgenic pups, compared to wild type pups. These results suggest 
that the absence of maternal GH doesn’t have a direct effect on fetal growth, as non-
transgenic pups from the same litter as transgenic pups, grow normally, when 
compared to normal pups born to normal mothers, it does raise the surprising notion 
that the lack of GHRH may have some effect on the transgenic pups in utero. Since 
GH does not seem to play a role in the fetus, per se, it may point to other effects of the 
GHRH gene in fetal life. 
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Interestingly, despite these differences in pup weights the mean placental weights 
recorded for both GRF-M2 and wild-type litters were not different (Figure 3.16), nor 
were there significant differences in mean placental weight from transgenic vs from 
non-transgenic pups (Figure 3.16). The study describing the GRF-M2 mouse 
mentions the potential for the expression of GRF-M2 ablating transgene in the mouse 
placenta, which silenced and ablated virtually all GHRH cells in the hypothalamus 
[286].  
No defects were observed in this study, suggesting that (i) the mouse placenta isn’t 
affected directly by this model of secondary GH deficiency, and (ii) any GHRH 
release from the placenta probably doesn’t affect pituitary GH secretion. Furthermore, 
no correlation was observed with pup GH-status and placental weight for either 
transgenic or non-transgenic pups (data not shown). Nevertheless the effect of 
genotype on fetal weight remains to be explained, and the most economical 
hypothesis is that there may be adverse effects in individual pups carrying the M2 
transgene. 
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Figure (3.15) Pup weights recorded for GRF-M2 and wild-type litters, as well as 
(genotyped) transgenic and non-transgenic pups 
Pup weights recorded for GRF-M2 litters are shown in the (red) bar, the light red bar shows the weights of pups 
of which are transgenic from the same litters, as the light blue bar shows the weight of those that are non-
transgenic.  The pup weights of non-transgenic (WT) pups are shown in the (blue) bar, ANOVA followed by 
student Newman keels test, ***P<0.001. 
 
Figure (3.16) Placental weights recorded for GRF-M2 and wild-type litters, as 
well as placental weights for pups known to be transgenic or non-transgenic. 
 
The color code follows the same format as above, except in this case the weights are shown for placenta for 
individual mice 
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3.9 Discussion 
 
 
Unsurprisingly, pituitary GH contents in both dwarf rats and GRF-M2 mice were 
confirmed to be significantly lower, compared to normal rodents. However, my new 
observations were the measurements of pituitary GH contents in both models during 
pregnancy. Neither the dwarf rats nor the normal rats showed changes in pituitary GH 
content, during pregnancy, and they remained low, when compared to normal rats.  
The number of papers that have recorded endogenous GH plasma levels during rat 
pregnancy is scarce, however, Carlsson et al (1990) [81] showed the plasma GH 
levels increased with the progression of pregnancy. Since I only measured GH in the 
pituitary, lack of change in the pituitary content does not necessarily imply there to be 
no change in serum levels, for which I would need to perform serial micro sampling. 
It is thus possible that both synthesis and secretion increased with no overall change 
in content, but this rarely occurs in experiments where others have previously 
measured both in my lab (Robinson, personal communication). Such information is 
only available for the rat, as serial sampling is rarely performed in mice. 
 
The GRF-M2 model as described before has GHRH neurons ablated, using the 
modified H37A variant of the influenza virus M2 protein expressed in these neurons 
[286]. A few GH cells remain in these mice but the anterior pituitary shows marked 
hypoplasia, with greatly reduced GH content and reduced release of GH.  
During pregnancy an increased secretory pattern of GH might also be expected in 
mice. In these GRF-M2 mice, disruption of GHRH neurons would result in such an 
increased demand not being met. The further reduction in pituitary GH content 
observed in pregnancy could be a result of non-hypothalamic mechanisms, such as 
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changes in IGF-1 affecting GH synthesis in these mice. It should also be remembered 
that the somatotrophs in these mice (unlike in dwarf rats) have no intrinsic defects, so 
would normally respond to other secretagogues and metabolic factors. Pituitary 
prolactin contents measured for both GH-deficient rodent models produced interesting 
contrasting observations. The dwarf rats showed a higher significant pituitary 
prolactin content, compared to normal (AS) rats. This observation confirmed previous 
reports that dwarf rats have elevated levels of pituitary prolactin, compared to normal 
rats [305, 306]. With the combination of immunocytochemistry and fluorescence-
activated cell sorting [309], Tierney et al measured GH-PRL cell numbers in dwarf 
rats and despite the evident somatotroph hypoplasia, they showed an increase in 
lactotroph number and increased prolactin stores. It was therefore interesting to find 
in my studies that the pituitary prolactin content during pregnancy decreased 
compared to non-pregnant rats in both dwarf and AS strains.  
 
Escalada et al (1996) [320] showed that early pregnancy in normal rats is associated 
with high prolactin plasma levels and low pituitary prolactin content, but this reverses 
in late pregnancy. My observations taken at day 16 of both rat and mouse pregnancy 
may not support these findings, but to accurately show the changes in pituitary 
prolactin levels in dwarf rats, both plasma and pituitary prolactin levels would need to 
be observed throughout pregnancy, and then compared to normal rats. I did not follow 
this up as it wasn’t important for the main aim of my work, especially as the GRF-M2 
mouse showed in contrast to the dwarf rat, a reduction in pituitary prolactin content in 
both non-pregnant and pregnant mice, when compared to non-transgenic animals.  
This was no surprise as Le Tissier et al (2005) [286] has previously reported prolactin 
deficiency in the GRF-M2 model, like in most other model of somatotroph hypoplasia 
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[321] as GH cells share a common lineage with prolactin cells. One possibility arising 
from my data is that PRL cells could be differentially sensitive to low IGF-1 levels in 
these two models of primary and secondary GHD. 
 
Of more relevance for GH secretion, IGF-1 serum levels in both pregnant dwarf rats 
and GRF-M2 mice were reduced when compared to non-pregnant counterparts. This 
is in contrast to what happens in human pregnancy, in which IGF-1 plasma levels are 
shown to increase with the increase of placental GH [115]. However, it is in 
agreement with other authors [173, 311]. A possible cause of the decline in plasma 
IGF-1 levels could be a result of a reduction in IGF-1 mRNA levels driven by GH in 
the liver [311] and a further contribution may be the consequence of a decrease in 
GH-dependent IGFBP-3 [322] leading to the decrease in the half-life of serum IGF-1. 
Another possibility could be an increased insulin resistance in pregnancy, lowering 
hepatic IGF-1 production. The reduction of IGF-1 levels could also offer an 
explanation to the increase of GH plasma levels in rat pregnancy. Circulating IGF-1 
inhibits pituitary GH synthesis and secretion by somatotrophs [314] so diminished 
negative feedback from decreased IGF-1 levels, may contribute to the increase of 
plasma GH synthesis and release during late pregnancy.  
 
 
Both dwarf rats and GRF-M2 mice gained similar amounts of weight as normal 
pregnant rodents, with both dwarf rats and GRF-M2 mice showing almost doubling of 
their total weight during pregnancy. In both dwarf rats and GRF-M2 mice, there were 
a reduced number of pups born per litter. This also suggests a likely indirect effect of 
the mothers GH-deficiency in affecting the number of pups per pregnancy. There is 
evidence from others to suggest that the lack of GH and functioning GH-receptor can 
 113 
affect oocyte maturation and ovulation rate, which in turn, alter the number of pups 
per litter in various species. GHRs are present in ovarian granulosa cells, corpus lutea 
and oocytes in rats [323] and humans [324]. GH is able to induce ovarian IGF-1 
synthesis and to increase granulosa cell LH receptor number [316]. GH treatment 
increases the number of mature follicles in the rat [316] and rabbit [325] largely as a 
result of decreased apoptosis and atresia of preantral follicles [326] increased 
granulosa cell estradiol production [327] and the gonadotrophin potentiating actions 
of IGF-1. 
 
GH is also known to have substantial stimulatory effect on oocyte maturation in vitro, 
in the cow [328], rat [329], rabbit [325], and human [330] this occurs with the 
accelerated breakdown of the germinal vesicle and accelerated passage to metaphase 
II. This may be a direct action of GH, mediated by local IGF-1, since germinal vesicle 
and metaphase II oocytes express GHR mRNA [331]. Moreover, there may be other 
factors independent from number of oocytes, which may contribute to determining the 
number of pups per litter. GH may also play a role in modulating endometrial 
secretion and receptivity, since GH-receptors have been reported in endometrial 
glands and have been shown to increase in gland density in response to maternal GH 
[332] 
 
There was no significant difference in the weight of pups born to dwarf rats, 
compared to those born to normal rats, suggesting that the GH-deficiency of the 
mother or the presence of the mutation in the fetus does not play a major role in 
regulating the weight of the pups directly. Laron dwarfs with inactivating GHR 
mutations are born slightly (up to 2 SD) shorter then normal [99] and congenitally 
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GH- deficient newborn babies are also shorter [298], however, their birth weights are 
usually normal. Unfortunately my observations didn’t include measurement of the 
length of the pups, which could have shed light on these differences. Note also that 
these results differed in mice; the weight of pups born to GRF-M2 mice were shown 
to be significantly smaller, compared to normal mice, and when genotyping was 
performed, the transgenic pups alone showed a significant reduction of weight. Thus, 
in contrast to my findings in the rat, these results suggest that the maternal GH status 
or transgene expression in the fetus can exert greater effect on birth weight. A study 
by Danilovich et al (1999) [315] suggests that the fetal length and weight of GHR KO 
mice are reduced by 20-25% at E17, furthermore, weight at birth being reduced by 
17%. I need to bear in mind that the mechanism of GHD is indirect in my mouse 
model, and cannot exclude a role of GHRH itself.  
 
How maternal GH may influence fetal growth and birth weight indirectly is far from 
clear, however, some studies suggest that maternal GH may regulate the availability 
of substrates to the fetus [32]. Maternal GH may have an influence on birth weight 
through its regulatory actions to make glucose, available as a metabolic substrate for 
the fetus [333]. However, my data are informative since the pups that showed 
reduction in birth weight in GRF-M2 mice were only those that were genotyped to be 
transgenic, suggesting an effect in the fetus itself. The reduction in the size of the 
transgenic pup could reflect its ability to utilize its substrate supply, and it would be 
difficult to imagine how the supply of important substrates could be selective between 
pups, depending on genotype. However, if the supplier of substrates to each pup, the 
placenta, was also globally affected by the GH-status of the mother, then perhaps the 
amount of substrates being extracted by each pup would be different and an 
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assortment of birth weights could be seen. However, it doesn’t appear to be simply 
due to differing placental weights, as placental weights from GRF-M2 mice were no 
different to those recorded for normal mice. Another speculation would be an effect 
mediated on placental GHRH mediated via the transgene selectively in the fetus. 
 
Dwarf rats also showed a significant reduction in placental weights compared to 
normal rats. The placenta is comprised of both maternal and embryonic tissues, 
therefore a difference in maternal GH-status could affect this contribution to the 
placenta and thus influence the process of fetal growth. However, despite differences 
in placental weight, the dwarf rat pup weights were within normal ranges. The 
conflicting findings of differences in placental weights between rats and mice, makes 
it difficult to draw any general conclusions from my studies, other then to record that 
GHD can have significant effects on the feto-placental unit in rodents. I found 
reduced IGF-1 levels in these models, confirming previous findings. This provides an 
easy explanation for the increased GH plasma levels reported in normal pregnant rats, 
but not in GHD rats, who cannot respond further. Although IGF-1 levels are lower in 
rodent pregnancy, IGF-1 still seems the most likely candidate to be mediating the 
indirect effects of maternal GH in fetal growth, given that manipulation of IGF 
expression in mice and/or signals has been used to establish the role of the IGFs in 
feto-placental growth (reviewed by Esfstratiadis, 1998). Deletion of either the IGF-1 
or IGF-2 gene in mice results in retardation in fetal growth to similar extents, with a 
40% reduction in birth weight compared to wild-type littermates [177, 334]. 
Furthermore, double knockouts of both IGF-1 and IGF-2 exhibit an additive growth 
retardation of 80%. Disruption of the IGF-1 receptor in mice also leads to a 55% 
decrease in birth weight, which is less than in the double (IGF-1/IGF-2) knockouts, 
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[335]. The additional loss of IGF-1 in IGF-IR knockouts does not appear to show any 
further decrease in birth weight, suggesting that IGF-1 functions solely via the IGF-
1R. Finally, IGF-2 and IGF-1R knockouts show greater growth retardation than in 
single IGF-1R knockouts, suggesting that IGF-2 functions via another receptor during 
fetal growth [336]. Interestingly, in mice, deletion of the IGF-2 gene has more severe 
effects on the placenta, resulting in a 40% reduction in size, compared to deletions of 
the IGF-1 or IGF-1R [335].  
 
Placental growth in mice is normal in the absence of both IGF-1R and insulin 
receptor, suggesting that IGF-2 may, as mentioned above, act through a unknown 
placental specific receptor [178]. Taken together it appears that IGF-1 affects fetal 
growth directly, whereas the growth promoting actions of IGF-2 maybe indirectly 
mediated via changes in the growth and nutrient transfer in the placenta, [178]. Direct 
administration of IGF-1 to sheep and monkeys show an increase in the weight of 
specific fetal organs as well as skeletal maturation [337] suggesting the direct 
anabolic actions of IGF-1 on fetal metabolism. Nutrient restriction also shows a more 
pronounced effect on circulating levels of IGF-1 than IGF-2, similarly, there is a 
greater reduction in tissue abundance of IGF-1 than IGF-2 mRNA during nutrient 
restriction in fetal rats and sheep [338, 339]. These observations are consistent with 
the findings that birth weight is more closely correlated with plasma IGF-1 than IGF-
2 in several species [340].  Reports of rare case studies in IGF-1 deficiency in humans 
have shown phenotypes of severe intrauterine growth restriction as well as mental 
retardation [341, 342]. Furthermore, cases of IGF receptor deletions in children have 
also reported similar severe pre and post-natal growth retardation [343, 344]. 
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Collectively, these findings support the importance of IGFs during fetal growth with 
different roles for the IGFs in bringing about their growth stimulatory effects. 
 
In summary, the effects of having a GH deficient mother is far from understood but 
my observations in the reduction of number of pups per litter and the weight of pups 
suggest some indirect influence. However, the underlying mechanism, the 
involvement of other factors such as IGFs, and their autocrine/paracrine effects in 
these GHD rodent models during pregnancy remain to be elucidated. 
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4. Is the placenta a direct novel target for growth hormone? 
 
4.1 Introduction 
In chapter one I described the known target tissues for growth hormone (GH), and the 
evidence for the indirect effects of GH on growth and metabolism, through the local 
generation of IGF-1. The aim of the experiments described in this chapter is to test 
whether the placenta could be a direct target organ for GH. Moreover, it could be an 
autocrine or paracrine target in humans as the human produces a placental form of 
GH, growth hormone variant (GH-V) [202, 205]. The same placental form of GH is 
not produced during pregnancy in rodents, but there are marked similarities in the 
pattern of secretion of placental GH in humans and pituitary GH (GH-N) in rodents 
during pregnancy, suggesting that the same endocrine effect (increased continuous 
GH exposure) may be achieved by different means [2, 81]. Although the mechanisms 
appear different (pituitary pattern in rodents, continuous placental production in 
primates) in both cases, the end result is a switch from pulsatile to continuous GH 
exposure in pregnancy. I feel it reasonable to speculate that the switch in the pattern 
of GH secretion, from episodic to more continuous may be of some importance during 
pregnancy, rather than just the a change in source of the GH production, and that the 
role of continuous exposure, either of GH-V or GH-N may be common to several 
different species. However, this begs the question of what is the important target for 
continuous GH. Recent methodological developments have made it possible to 
identify target tissues responding directly to GH. The aim of this chapter is to use 
these methods to test whether the placenta could be a direct target for GH, using GH 
deficient rodent models which lack pituitary GH, and in which the placenta is not a 
source of GH-V, so that exogenous GH could be given. 
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There is good circumstantial evidence to believe that GH may act directly on the 
placenta. Firstly, GH-receptor (GHR) is expressed in the placenta and several studies 
have shown an increase in expression of GHR and growth hormone binding protein 
(GHBP) in both the liver and placenta of rodents throughout pregnancy [345, 346]. 
Secondly, placental human cell lines have been reported to be responsive to GH [283] 
though I found that difficult to reproduce. In the experiments described in this 
chapter, I used GH-deficient rats and mice (as described in methods), and a newly 
developed method to visualize the direct actions of GH on the placenta. For a control 
known direct target tissue for GH, I also studied the responses in maternal liver, 
which might also play an important role responding to placental GH, as it does to 
pituitary GH. 
As reviewed in chapter 1, GH-GHR interaction causes a number of phosphorylation 
events mediated via JAK2, resulting in the phosphorylation of signal transducers and 
activators of transcription (STATs). Recent papers by Rui et al (2008) [291] have 
exploited histochemical methods to show that cells in GH target tissues are responsive 
to a single injection of GH in GH-deficient animal models. In these studies, direct 
action of the GH signal transduction cascade was visualized by detecting GH-induced 
phosphorylation of Stat5 after a single injection of GH, at a time too soon to reflect 
any consequences of indirect GH action (e.g. IGF-1 generation). I used the same 
detection method to visualize responding cells in the placenta of pregnant rodents. It 
was important to use GHD animals for two reasons, firstly, because the signal is much 
clearer in the absence of endogenous pituitary GH, which could be secreted 
spontaneously, complicating the response observed. Secondly, because the method 
described is much more sensitive in GHD models (E.Gevers, personal 
communication). 
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4.2 Results: initial proof of concept 
Two groups of six pregnant dw/dw rats were given a single intravenous injection of 
either 100µg bovine growth hormone (bGH)/ bodyweight, or saline through the tail 
vein. All animals were culled 25 minutes later, blood samples and tissues were 
harvested and the latter processed for immunohistochemistry (see Methods). 
 
Figure 4.1 illustrates the result of staining for phosphorylated Stat5 (pYStat5) in tissue 
sections. In the liver (left panel), the majority of nuclei from GH-injected rats (a) 
showed intense staining for pYStat5, clearly different from liver sections (b) from 
saline-injected rats. This corresponds to the results described by Gevers [291] for non-
pregnant animals, and shown that hepatic cells respond directly to GH also in 
pregnant animals. The right panel shows the results obtained in random placental 
sections from the same animals. Numerous pYStat5 positive nuclei (stained dark 
brown) were evident after bGH injection but not in the saline injected animals. All 
sections were processed at the same time, using the same antibody and experimental 
conditions, and was encouraging as it suggested clearly that the placenta could be a 
direct target for GH, at least when the hormone is given an intravenous pulse, and 
pYStat5 is measured. 
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Figure (4.1) Liver and placental sections taken from a pregnant dwarf rat 
injected with a single intravenous injection of bGH or saline 
 
 
 
a) Immunohistochemistry for yPStat5 in liver and placental tissue of 16 day pregnant dwarf 
rats (n=6), that have received a single IV injection of bovine growth hormone, 100µg/100g 
body weight, 25 min before culling. b) Liver and placental sections from control animals 
injected with saline, and processed for Stat5 immunoreactivity. The chromogen used was 
DAB (diaminobenzidine), to give dark brown positive staining  (see methods). 
 
Note that the dark nuclear staining in hepatocytes (the top left of panel a, Figure 4.1) 
was intense and distributed quite homogenously throughout the section. In contrast, 
the dark nuclear staining in the right of panel a, Figure 4.1, showed distinct regions of 
the placental sections responded to bGH. This is the first report of such in situ 
staining, but from the location of the cells, it would appear that cells responsive to GH 
were mainly in the labyrinth zone of the placenta, though these were only random 
sections, so I could not exclude other regions that might contain responding cells in 
(a) 
(b) 
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this pilot study. The trophoblastic region of the chorionic villi consists of three types 
of trophoblastic cells, and is termed as trichorial, in contrast to the human placenta, 
which is monochorial [347]. The trophoblast layer lining the maternal blood spaces 
consists of mononuclear trophoblast cells (cytotrophoblast), and the middle and inner 
third layers are syncytiotrophoblastic. There are few antibodies available for specific 
trophoblast cell markers, particularly for the rodent placenta. One reason for this may 
be because of the multiple lineages of trophoblaslastic cells and the diversity of their 
location within all the regions of the rodent placenta.  
 
4.2.1 Image Analysis 
Although a positive cellular Stat5b response was obtained in pregnant rat tissues, it 
was quite variable in intensity. I realised I needed to develop an objective, 
quantitative method to analyse these stained sections in order to make statistical 
comparisons between responding and non-responding tissues (and saline controls) in 
subsequent experiments. This would also enable comparisons to be made between 
various experimental conditions, varying dose, pattern of bGH secretion, and the 
effects on the intensity of staining, and number of responding cells. 
 
4.2.2 Analysis of immunostaining: a semi-automated approach 
Histology-based results are often considered hard to quantify. A number of problems 
can arise which can be specific to the tissue being stained or the method being 
employed to visualise the staining. Using 3.3’-diaminobenzidine (DAB) as a 
chromogen (which creates a brown stained precipitation wherever there is secondary 
peroxidase labelled antibody) is a reliable and standard detection method.  
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However, depending on the tissue, DAB staining is particularly prone to non-specific 
and variable background staining, which can also vary from section to section within 
the same experiment. I aimed to quantify the level of response by assessing the 
intensity of the brown staining, as well as counting the number and proportion of cells 
in a responding tissue, using more objective methods than visual scoring. 
 
The method also needed to take into account variable background staining in different 
tissues, which contributes noise to the specific staining signal, and also recognise 
potential interference from non-specific staining, which could contribute as false 
positive or false negative signal during any semi-automated quantification process. 
The quantification method I chose was part of the java-based image-processing 
programme, “ImageJ”.  I chose ImageJ as it is designed with an open architecture that 
can provide the extensibility to devise custom made programmes via its built in editor 
and Java compiler. The advantage of this is that I could obtain a package customized 
specifically to my needs. However, I recognise that all packages have drawbacks with 
how rigid or flexible they are when assessing irregular objects in images using 
defined parameters. I worked with NIMR’s imaging software experts to develop and 
test a software method suitable for my images, but all the analyses were carried out by 
myself. What follows is a brief explanation of the process, with a series of images and 
worked examples, to illustrate the method in practice.   
 
To simplify the quantification process, I decided to use some existing parameters of 
Image J, to collect the relevant information for each experimental image, and then 
calculate the information of interest. A primary need is to identify the responding 
(brown stained) nuclei, using a cut-off for the hue value in the pixel image of a 
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defined range of size. This meant that objects possessing a different hue value (non-
specific, endogenous colour) could be discriminated and therefore not counted in the 
measurements. A secondary function was used to devise an estimate of the staining 
intensity of such identified objects (nuclei) using the “saturation” parameter in 
imageJ. Once the nuclei were localised in the image, they were counted in a standard 
grid area, so the data could then be expressed as mean number of responded nuclei 
and mean nuclei size (in pixels), in standard areas of section, in replicates. I set an 
additional parameter to allow flexibility in assessing non-specific and background 
staining, to minimise its input on the signals. This was achieved for each batch of 
sections analysed by choosing background measurements for saturation, and then 
subtracting them in an unbiased way from all the images, prior to analysis. It was 
therefore important to process batches of sections obtained stained, and processed 
together, before pooling results.  
 
The calculation of the mean size of nuclei enabled a value to be set as an upper and 
lower threshold for nuclear size. This allowed any non-specific staining of most other 
objects in the field to be identified and discarded, before final calculations were made 
for nuclei in each image. The disadvantage of this was that “positive” cells with 
partial staining of nuclei (restricted to the edges) that had a mean size outside of the 
set range were “falsely” discarded. I considered this an acceptable compromise 
considering the benefit of automatic processing of >4000 sections for more objective  
quantification of my results. In a typical experiment (Fig 4.2-4.8), I uploaded all 
images taken from an experimental group usually comprising 5 random field images 
taken each from the placenta and liver of six individual animals. To try to reduce (my) 
operator selection bias for a single image, and to gain a better representation of the 
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overall response in a given tissue, five semi-random, non-overlapping images were 
generated, and captured using the same microscope settings (Figure 4.2).  
 
I chose five images as suitable compromise between overload of sections and 
representation of the section, and found that such semi-random images did appear 
suitable for practicality to generate quantitative results and sufficient in statistical 
analysis, and gave results consistent with those obtained by visual inspection. Figure 
4.3 illustrates images taken from 5 semi-random fields in liver tissue, observed using 
an Axioplan microscope and captured with a digital camera on the microscope. The 
digitised image was then saved as an uncompressed TIFF file that retains all the pixel 
values of the image. The individual TIFF files were then uploaded as a batch file, into 
ImageJ.  Uploading of the images as batch files increased the speed of the analysis, as 
well as enabling the same settings to be applied to all images within the batch.  
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Figure (4.2) Schematic diagram of the method used to generate five semi- 
random images of liver and placenta section 
 
 
 
 
 
 
 
 
 
Slides with stained tissue section were placed on the microscope stage and secured firmly using clips. (X) marks 
the point of the tissue where it was brought into focus, and the start of the process of generating semi- random 
images. Each arrow represents a quarter (approx) turn of the stage dial in the direction shown. Each number 
represents the image field selected for analysis. 
 
 
Figure (4.3) Images of 5 fields taken from a pregnant dwarf liver 
 
a) Immunohistochemisry for pYStat5 in liver of 16-day pregnant dwarf rat that has received a single injection 
of bGH, 100µg/100g body weight, 25 min before culling. Images 1-5 are taken from the same animal (as 
described as above), x40. 
1 2 3 
 (x)   1   2 
  3 
  4   5 
(Left) 
        (Right) 
(Upward) 
Stage dial 
  
4 5 
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The file was then uploaded onto ImageJ and colour threshold set. Figure (4.4) 
illustrates the display of the example image (a) as seen in the colour threshold display 
algorithm. 
 
 
Figure (4.4) Distribution of Hue and Saturation using colour thresholding 
 
 
 
The ImageJ, “colour threshold,” parameter was used to display b) the distribution of 
hue and its value as part of the hue spectrum, and c) the distribution of saturation for 
the uploaded images. From here I recorded the hue value for “brown” nuclear staining 
for all the images and then set a mean threshold hue value and range (see later); all 
images from other experimental groups were then processed with these settings so 
that objects were identified according to this mean hue value. The background level of 
colour saturation was determined visually for one of the five random field images and 
then this value was subtracted from the remaining four. Images were next processed 
by applying threshold values for object (nuclear) size. The upper and lower range for 
a) 
 
b) 
c) 
Figure 4.4. a) An example image of 1 of the 5 random fields uploaded as a batch 
file, b) the distribution of colour (hue) and (c) saturation for this image. 
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non-specific staining size was set the same throughout the quantification of all other 
images. A working example of the quantification is illustrated in the following 
figures. 
 
4.2.3 Hue profile for image 
The hue profile for the example image using the colour threshold parameter is shown 
in (Figure 4.5b). Each peak of the hue spectrum corresponds to the mean number of 
pixels observed for the different parts of the hue spectrum in the example image. 
Using the hue spectrum to analyze colour, I was able to “gate” in the spectrum, where 
the brown nuclei are found. In this example the dark brown nuclear staining was 
distributed within the 1-30 hue range of the spectrum, which corresponds to colours 
ranging from brown to dark orange and red. There were also a number of other peaks 
observed in other parts of the hue spectrum, predominately due to the counterstain 
used in the immunostaining procedure. The counterstain in this case was methyl green 
(pH 4.6), and the distribution of colour observed was recorded in the 180-200 range, 
which corresponds to blue and green. The hue range was set to identify positive cells 
(brown) only, and ignore objects (pixels) with e.g. the 180-200 part of the colour 
distribution.  
 
In practice, the “brown” nuclear staining was set at 0-25, as 25 was the hue value 
obtained following the processing of all sections taken from animals given the 
maximum dose of bGH. This hue range was then used to process all experimental 
groups including the saline controls. Figure 4.5 shows the processing to objects 
identified using these hue settings (where the program displays only the objects of the 
selected “hue”).  
 
 129 
Figure (4.5) Brown positive cells identified using the hue range 0-25 
 
Figure 4.5. a) shows image after the selected hue range is applied. b) Shows the 
distribution of colour from the original image, shown in fig 5 and the selected 
range of the hue spectrum, 0-25 (black lines). 
 
 
By selecting this hue colour range, and checking by visual comparison with the 
original image, these settings were able to identify the vast majority of responded 
brown nuclei, identified by visual analysis. However, some fainter stained nuclei were 
not included if they fell out of this range, so I recognised that this method will 
moderately under estimate the response. However, I felt this would be similar across 
different sections, and thus not bias my results. 
 
4.2.4 Saturation profile for image 
Like hue, saturation is a measurement that relates to colour but refers to the intensity 
of a given colour, or, more simply, ‘brightness’. Figure 4.6 illustrates how saturation 
was measured, and then corrected for the example image. The objective of this was to 
remove background saturation signal that contributed to the intensity of overall 
staining, whilst discriminating positive (brown) nuclei. Again there are disadvantages 
to this step. Although most positive cells within the hue, gave a signal above 
background and saturation threshold ranges set, there were a small number of positive 
a) b) 
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cells that were fainter in their staining, presenting similar values to background. For 
this automated process to work effectively, I had to accept that some faint responding 
cells were likely to have been discarded as background, again underestimating the 
response. Although all the immunohistochemistry was conducted under the same 
condition, I still found that the level of background staining varied amongst the 
sections. For this reason I needed to modify the saturation parameters for each batch 
analysis, to take into account any differences. However, once set I allowed no 
variation of saturation amongst the 5 random field images that made up a batch file. 
 
 
Figure (4.6) Image of liver section, reduction of background noise 
 
Figure (4.6) a) example liver image with background reduced using the saturation 
tool bar, the saturation is set to ignore brightness of colour outside of the 58-255 
range, as shown in b). 
 
The hue and saturation range set using colour threshold parameters, as well as the 
upper and lower threshold for nuclei size, which varied very little in full section, were 
then entered into a final panel, Figure (4.7). All the remaining images of the given 
batch were then processed with the same settings.  
a) b) 
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Figure (4.7) Final panel displaying values used in the processing of a batch of five 
images 
 
Figure (4.7) a) Hue Bandwidth choice: pass, a setting that refers to the choice to 
run a set hue range, rather then analysing the image using the whole hue spectrum. 
Objects were identified in the hue range of 0-25. b) The lowest end of the hue 
spectrum used to analyse was zero c) the highest end of the hue spectrum used to 
analyse images, d) Saturation lower range, set as 58. e) Saturation upper range, set 
at 255. f) Particles less then 200 pixels were discarded and not analysed by the cell 
analyser. g) Particles over 2000 pixels were discarded. 
 
The results obtained from the quantification were then displayed as a number of 
images for each random field image, Fig (4.8) and also as a batch raw data file, table 
(4.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) 
b) 
c) 
d) 
f) 
e) 
g) 
e) 
2000 
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Figure (4.8) an example set of three quantified images produced for each image  
that made up the batch file 
 
 
 
 
 
 
 
a) Original example image of liver taken from a 
pregnant dwarf, before quantification is conducted. 
b) Mask image, refers to original image after 
background is subtracted using the saturation 
upper and lower values. 
c) edger image refers to the original image with 
identified and measured nuclei outlined in red, 
identified using all the parameters and settings 
described. 
→  
 
 
Note: Arrows indicate responded positive nuclei that have not been counted 
during the automated quantification process; this may be due to the hue of the 
nuclei not falling within the set hue range or the size of the nuclei being larger 
then the set upper threshold for object size. The boxes within images indicate 
areas within the section that the quantification process has discarded smaller and 
fainter stained objects. Cells may have been discarded as background or because 
of their size being smaller then the lower threshold set for object size. 
→  
 
→  
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Table (4.2) Summary of the calculated raw data for five random field images 
processed as a batch file for one animal 
 
          
 
Finally, a mean value was taken for each average of each section for one animal, for 
these parameters. In the following chapter’s results are presented for the response to 
GH observed in the GHD rat and mouse models using the automated quantification 
process described above. 
 
4.3 Response to GH follows a dose response pattern in both dwarf rat liver and 
placenta. 
Having established this method, I tested whether the response to GH seen in both liver 
and placenta was reproducible and whether lower doses would initiate a detectable 
cellular response to GH in these tissues. Figure 4.9 shows example single images for 
phosphoStat5 staining generated from groups of 6 pregnant dwarf rats given three 
different doses of bGH or saline as single intravenous tail injections.  
 
 
 
 
 
 
 
 
NUMBER 
OF 
ANIMAL 
NUMBER 
OF 
RANDOM 
FIELD 
NUMBER 
OF 
BROWN 
NUCLEI   
PERCENTAGE 
(PIXELS) 
AVERAGE 
HUE 
 
AVERAGE 
SIZE OF 
NUCLEI 
(PIXELS) 
AVERAGE 
SATURATION 
AVERAGE 
INTENSITY 
1 1 168 0.12 17 121 971 121 
 2 193 0.13 17 125 877 125 
 3 188 0.12 17 129 832 129 
 4 178 0.16 17 125 957 125 
 5 169 0.13 16 126 928 125 
Mean - 179 0.13 17 125 913 125 
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Figure (4.9) PhosphoStat5 Immunostaining for liver sections from dwarf rats 
treated with varying bGH doses, or saline 
 
Nuclear pYStat5 staining in liver tissue from pregnant dwarf rats treated with a single 
injection of (a) saline, (b) 2.5µg bGH, (c) 25µg bGH and (d) 100µg bGH/100g bodyweight. 
All images are shown at x40, (n=6) for each group. 
 
It is clear from Figure 4.9, panels b-d, that the number of nuclei showing staining for 
phosphoStat5 appear to increase with bGH dose, whereas animals injected with saline 
only, showed no evident Stat5b staining, suggesting in the absence of endogenous 
GH, other signals inducing Stat5b in the liver (e.g. Interferon) did not elicit significant 
signalling. Figure 4.10a and b summarises the level of staining intensity and the 
number of positive cells calculated for all the images generated from the liver of these 
animals in this experiment. 
 
 
 
 
 
 
 
 
 
a) b) c) d) 
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Figure (4.10) a) Nuclear staining intensity for pYStat5 b) number of positive 
(pYStat5) nuclei for liver from pregnant dwarf rats treated with varying bGH 
doses, or saline 
 
a) 
 
Saline vs varying bGH dose, ANOVA followed with 
Dunnett’s test, *P<0.05, **P<0.01 
 
 
 
 
b) 
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Figure 4.10a confirms that the liver from pregnant dwarf rats was responsive to bGH 
in a dose dependent manner, and that there was a small but significant difference in 
the mean staining intensity between the lowest dose tested (2.5µg bGH/100g 
bodyweight) of bGH (25.0±2.4) compared to the saline controls (15.1±0.2; P<0.05). 
This dose of GH was therefore able to produce a cellular response in the liver; it is 
possible that lower doses would also be effective, but it may prove difficult to 
distinguish this from background, though it is more clear for cell number than for 
staining intensity. The mean nuclear staining intensity increased with bGH dose; 25µg 
(99.0±4.4) and 100µg bGH (106.2±0.8) both gave significantly higher responses than 
the saline control injection (15.1±0.2; P<0.01 for both cases). The highest two doses 
of bGH had similar mean nuclear staining intensities, suggesting that this cellular 
signal had reached a plateau around 25µg bGH, and that higher dose of bGH would 
not cause any further response in my system. This does not necessarily mean it has 
reached maximum effectiveness, but would not exceed the maximum signal in my 
assay of Stat5b. Figure 4.10b shows a significant dose dependent increase in the 
number of positive pYStat5 cells, compared to saline injected animals, (P<0.01). 
  
 
4.3.1 The placenta also shows a direct, dose dependent pYStat5 response to GH 
The placenta was also immuno stained for phosphoStat5 in the same experimental 
groups. Figure 4.11 illustrates individual images for the placenta from the same dose 
response experiments, and again the results from all animals are summarized in Fig. 
4.12.       
 
 
+
* 
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Figure (4.11) PhosphoStat5 Immunostaining for placenta sections from dwarf  
rat treated with varying bGH doses, or saline 
 
Nuclear pYStat5 staining in placental tissue from pregnant dwarf rats treated with a single 
injection of (a) saline, (b) 2.5µg bGH, (c) 25µg bGH and (d) 100µg bGH/100g bodyweight. 
Example images shown at x40, (n-6) for each group. 
 
Strikingly, there was clearly a Stat5b response to bGH in the placenta. Again, a dose 
dependent increase in the level of staining intensity and number of cell responded was 
observed, similar to the situation described above in the liver. This confirms my 
ploted data, showing the placenta is clearly responsive to GH. Figure 4.12a shows that 
in the placenta there was a dose dependant increase in mean nuclear staining intensity, 
with a plateauing at the highest dose similar to the liver. All bGH injected groups 
were significantly higher than the saline group (P<0.01). This also shows that the 
mean nuclear staining intensity recorded for the placenta appeared higher than that of 
the liver. Figure 4.12b shows the mean number of positively stained cells in the 
placenta. A significant increase in the mean number of positive cells with increasing 
bGH dose was shown, when compared to saline controls (P<0.01). The highest 
number of positively stained cells recorded for the maximum dose in the placenta 
(102) was not as high as in the liver (211). This most likely explained in that staining 
in the placenta was obviously restricted to specific areas, and as such the staining was 
a) b) c) d) 
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not as homogenously distributed as in the staining in the liver. This makes direct 
comparison difficult, but it seems reasonable to conclude that the placenta is indeed a 
direct target of GH action, with strong response of Stat5 phosphorylation in regions of 
placental tissue in rats. 
 
Figure (4.12) a) Nuclear staining intensity for pYStat5 b) number of positive 
(pYStat5) nuclei for placenta from pregnant dwarf rats treated with varying 
bGH doses, or saline 
 
 
                   
Saline vs varying bGH dose, ANOVA followed by Dunnett’s test, **P<0.01 
b) 
a) 
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These experiments were carried out in GH-deficient pregnant rats, for technical 
reasons explained previously. However, I felt it important to see if this could also be 
shown in non-pregnant animals. Accordingly, I checked the pYStat5 response in the 
liver of non-pregnant dwarf rats, which received a single injection of bGH or saline 
(Figures 4.13, and 4.14a & b). Figure 14a clearly illustrates that in this case there are 
some positive cells in the tissue example for saline injected animals, nevertheless it 
appears that the number of positive cells, as well as the intensity of staining is higher 
in the pregnant dwarf animals that have been injected with bGH, (Fig, 4.14). 
 
Figure (4.13) PhosphoStat5 Immunostaining in liver sections from non-pregnant 
dwarf rat treated with saline or bGH 
 
 
Nuclear pYStat5 staining in liver tissue from non-pregnant dwarf rats treated with a single 
injection of (a) saline, (b) 100µg bGH/ 100g bodyweight. 
 Example images shown at x4o, (n=6). 
 
 
 
 
 
 
a) b) 
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Figure (4.14) a) Nuclear staining intensity for pYStat5 and b) number of positive 
(pYStat5) nuclei, in liver sections from non-pregnant dwarf rats treated with 
saline or bGH 
 
 
Saline vs bGH (100µ /100g bodyweight) injected animals, ***P<0.001 Student t-test. 
 
As summarized in Figure 4.14a, the mean nuclear staining intensity in the livers of 
non-pregnant dwarf rats injected with bGH (86.1±2.7) was significantly higher than 
that of saline group (48.7±4.5, P<0.001). This indicated that (i) I had a working 
positive control in non-pregnant GH-deficient rats, and (ii) that the observed response 
confirmed what has previously been observed by my colleague E.Gevers, in male 
dwarf rats [291]. Although it is risky to draw direct comparisons between experiments 
stained on different occasions, it appears that the liver of non-pregnant dwarf rats had 
a somewhat lower mean nuclear staining intensity compared to that of pregnant 
dwarfs injected with the same dose of bGH (86.1±2.7 vs 106.2±0.8, respectively), 
consistent with the idea that the liver becomes more responsive to GH during 
pregnancy (at least in the absence of circulating GH, that would rise in rats normally). 
Figure 4.14b shows that the mean number of positively-stained cells in the liver of 
a) b) 
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non-pregnant dwarf rats given an injection of bGH (270.3±9.4) was significantly 
higher than rats injected with saline (21.7±3.9, P<0.001). Furthermore, the number of 
positive cells in livers of pregnant dwarfs was lower (211) than the number of 
positively stained cells in non-pregnant dwarf rats (270). 
 
4.3.2 GH response in normal (AS) pregnant rats 
It was also important to test whether GH responses could be seen in tissues in normal 
(AS) pregnant rats. Figure 4.15 shows liver and placenta sections stained for 
phosphoStat5 for AS pregnant rats. In both the liver and placenta a dose dependant 
response to bGH was again seen, as in pregnant dwarf rats. Note that there was a 
greater number of positive cells after the saline injections in the AS rats than had been 
seen in the dwarf rats, this is shown particularly in the example liver section (a1), and 
evident although not as clearly, in the image of the placenta in rats treated with saline 
(b1). The few positive cells observed in the liver of saline treated AS rats is not 
unexpected given the presence of endogenous GH pulses seen in normal rats. 
Nevertheless, it is encouraging that although this method has been developed for 
analysis mainly in the GH-deficient model a positive response to exogenous GH can 
still be confirmed in the liver of normal i.e. GH-intact rats.  
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Figure (4.15) PhosphoStat5 Immunostaining for liver and placental sections 
from pregnant normal (AS) rats treated with varying bGH doses, or saline 
 
 
Nuclear pYStat5 staining in liver (panel a) and placenta (panel b) from pregnant wild-type 
rats treated with a single injection of (1) saline, (2) 2.5µg bGH, (3) 25µ  bGH and (4) 100µg 
bGH/100g bodyweight. Example images shown at x40, (n=6). 
 
Figure 4.16a shows the mean nuclear staining intensity in liver sections from pregnant 
AS rats. There was no significant difference between the saline injected group and the 
group injected with the lowest dose of bGH. There was a small but significant 
increase, however, in the mean nuclear staining intensity for the higher doses of 
injected bGH over saline controls (54.5±3.3 for 25µg bGH/100g bodyweight and 
57.8±2.8 for 100µg bGH/100g bodyweight, compared to saline, 44.83±0.03; P<0.05 
and P<0.01, respectively). Figure 4.16b also showed no significant difference 
between the saline injected group and the group injected with the lowest dose of bGH 
for mean number of positive cells counted in the liver. However, there was a 
a) 1 2 3 4 
b) 1 2 3 4 
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significant dose-dependant increase in the mean number of positive cells between the 
two higher doses of bGH and the saline group (P<0.01 for both). 
 
Figure (4.16) a) Nuclear staining intensity for pYStat5 b) number of positive 
(pYStat5) nuclei for liver from pregnant AS rats treated with varying bGH 
doses, or saline 
 
 
Saline vs varying bGH dose, ANOVA followed by Dunnett’s test, *P<0.05, **P<0.01. 
  
 
 
a) 
b) 
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There was no significant difference in either the mean nuclear staining intensity or 
number of positive cells between the saline-injected animals and those given the 
lowest bGH dose (2.5µg/100g of bodyweight). This contrasts with the previous results 
in dwarf rats, in which the same dose of GH in pregnant dwarves induced a 
significantly higher response than hepatic Stat5 seen in the saline group. An obvious 
explanation for this difference in dose sensitivity would be that the level of 
endogenous GH present in the AS rat causes some basal signalling and reduces 
sensitivity to a further GH challenge. Therefore even after an injection of saline I 
expected to see some level of pre existing cellular response (due to endogenous GH), 
and a shallower dose response curve. Later experiments in this thesis provided some 
support for this notion. Finally, it was also shown in both a) and b) of Figure 4.16 that 
the highest two doses of bGH, generated lower mean nuclear staining intensity and 
fewer positive cells than I saw in pregnant dwarf rats. Thus I conclude that the 
response to a single injection of bGH in pregnant AS rat liver is not as strong in 
pregnant dwarf rat liver. Again, I suspect this is most likely to be desensitization due 
to the endogenous GH present in normal rats, as also reported previously by Gevers et 
al (2009) [282].  
 
4.3.3 GH responses in the placenta of normal AS rats 
Figure 4.17a and 4.17b show that the placenta from AS rats also showed a dose-
dependent response to GH, though the dose response for staining was quite shallow. 
Despite this, I found a significant increase in mean nuclear staining intensity for all 
doses of bGH compared with saline injections, (P<0.01). There was also a similar 
dose dependent increase in the mean number of positively stained cells, compared to 
saline controls (P<0.01), with a more pronounced dose-dependent relationship. 
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Clearly therefore, the normal (i.e. non-GHD) placenta responds to GH with a pYStat5 
response. Thus if anything the evident response might suggest that the placenta is less 
susceptible to the desensitization response of endogenous pituitary GH, which could 
be interesting if true, as it may be more continuously exposed to a paracrine source in 
humans at least. 
 
Figure (4.17) a) Nuclear staining intensity for pYStat5 b) number of positive 
(pYStat5) nuclei for placenta of normal rats treated with varying bGH doses, or 
saline 
 
Saline vs varying bGH dose, **P<0.01. ANOVA followed by Dunnett’s test. 
a) 
b) 
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4.4 Visualizing the response to GH in the liver and placenta of growth hormone 
deficient (GRF-M2) and wild-type mice 
I felt it was important to see if I could obtain similar results in at least one other GH-
deficient rodent model, to exclude it simply being a property specific to the dwarf rat.  
Similar experiments were therefore repeated in GH-deficient transgenic (GRF-M2) 
mice, and compared to non-transgenic (wild-type) mice. Figure 4.18 shows 
immunoassaying for phosphoStat5 in mouse liver and placenta. As before, individual 
images are shown first followed by figures summarizing the group data in the next 
few figures. The data essentially confirm the results I obtained in dwarf rats. 
 
Figure (4.18) PhosphoStat5 Immunostaining for liver and placental sections 
from pregnant GRF-M2 mice treated with varying bGH dose or saline 
Nuclear pYStat5 staining in liver (panel a) and placenta (panel b) from pregnant wild-type 
mice treated with a single injection of (1) saline, (2) 0.25µg bGH, (3) 2.5µg bGH and (4) 
50µg bGH/100g bodyweight. Example images are shown at x40, (n=6). 
 
 
 
 
a) 1  2  3  4 
b) 1  2  3  4 
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I observed a response in the mouse liver to bGH and, importantly, confirmed Stat5b 
response to GH in the mouse placenta. Again, this is the first time this has been 
reported in this tissue in this species.  
Figure 4.19a shows that there was a significant increase to all doses of bGH in mean 
nuclear staining intensity in the liver compared to saline injections (P<0.001). Figure 
4.19b shows no significant difference in number of positive cells in the saline group 
and the lowest bGH dose (0.25µg bGH/100g bodyweight), but a significant difference 
between the saline controls and higher doses of bGH (though the dose response 
relationship at these doses for staining (a) was quite shallow). The result for the low 
GH dose were interesting, with a significant increase in staining intensity, but not 
number of responding cells. One suggestion is a differential dose effect revealed in 
these mice experiments, initially increasing staining in already responsive cells, 
subsequently recruiting more responsive cells (Fig 4.19 a vs b), as the GH doses is 
increased, but without increasing the intensity of the response further. It is also 
possible the responses are more “all-or-none” in the mouse. 
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Figure (4.19) a) Nuclear staining intensity for pYStat5 b) number of positive 
(pYStat5) nuclei from liver of GRF-M2 mice injected with varying bGH doses, 
or saline 
 
Saline vs varying bGH dose, ANOVA followed by Dunnett’s test, **P<0.01. 
 
In the same experiments, Stat5b response to a single injection of bGH was clearly 
observed in the placenta. Figure 4.20a suggest that the initial dose of 0.25µg bGH 
initiated a significant response in the placenta when compared to the saline group 
(20.0±0.5, compared to 10.0±0.8, P<0.01). Figure 4.20b, also shows that the group 
receiving, the lowest bGH dose showed a higher number of positive cells compared 
with the saline injected group (1.7±0.2 vs 3.7±0.2, P<0.01). Moreover, the higher 
a) 
b) 
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doses showed highly significant dose dependent trend for both mean nuclear staining 
intensity (39.5±.02 and 142.1±5.7) and the number of positive cells (61.5±3.8 and 
124.0±3.2), for 2.5µg and 50µg, respectively. This clearly establishes the mouse 
placenta as a direct target for GH action. 
 
Interestingly, there appeared to be higher nuclear staining intensity in the livers of 
GRF-M2 mice compared to dwarf rat liver. This might have been due to the mouse 
model being functionally more GH   - deficient than the dwarf rat model, therefore the 
response shown to a GH injection would be more intense with the reduction of 
background (endogenous GH) interference. However, the degree of pituitary 
deficiency with dwarfs is similar, so this is unlikely. Other reasons for the difference 
in species may include the difference of the amount of Stat5 or the density of cells in 
the liver of both models. Also, one cannot rule out technical differences that may have 
arisen during the handling and processing of tissue in different experiments rendering 
direct comparisons risky. The results obtained for nuclear staining in the placenta 
showed a higher number of positive cells in rat placenta, compared to mouse. Again, 
it is quite probable that many differences in both species, including size of rodent and 
placenta may contribute to the degree of responses to GH. Overall however the 
important point is that both rodents show placental Stat5b phosphorylation response 
to a single GH injection, which is the hallmark of a GH-responsive tissue. 
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Figure (4.20) a) Nuclear staining intensity for pYStat5 b) number of positive 
(pYStat5) nuclei for placenta from GRF-M2 mice injected with varying bGH 
doses, or saline 
Saline vs varying bGH dose, ANOVA followed by Dunnett’s test, **P<0.01. 
 
4.4.1 Pregnant non-transgenic mice have a similar dose dependant response to 
GH as   transgenic model 
As before, I wished to test whether these responses could also be seen in pregnant 
wild-type mice (with an intact pituitary GH axis). Accordingly, figure 4.21 illustrates 
immunostaining for phosphoStat5 from wild-type mice given saline and varying bGH 
doses (1-4) in liver panel (a) and in placenta (b). Both tissues showed dose dependent 
effects in the level of staining intensity and the number of positive cells recorded in 
a) 
b) 
        ** 
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response to GH. A low basal signalling could be detected in the saline-injected group, 
but the responses were faint. 
 
Figure (4.21) PhosphoStat5 Immunostaining for liver (panel a) and placental 
sections (panel b) from pregnant non-transgenic, wild-type mice treated with 
varying bGH doses, or saline 
Nuclear pYStat5 staining in liver (panel a) and placenta (panel b) from pregnant non-transgenic wild-type mice 
treated with a single injection of (1) saline, (2) 0.25µg bGH, (3) 2.5µ bGH and (4) 50µg bGH/100g bodyweight. 
Example images were created using x40, (n=6). 
 
The hepatic responses for all the animals are summarized in fig, 4.22. There was no 
significant difference in mean nuclear staining intensity (Fig 4.22a) in the livers of 
animals injected with saline and those injected with the lowest dose of bGH 
(0.25µg/100g bodyweight), 11.7±0.4 compared to 24.0±0.7. This indicates that, as in 
wild-type rats, in wild-type mice the level of response measured in the lowest dose of 
bGH is difficult to distinguish from response to prevailing endogenous GH levels. 
However, there was a significant increase in mean nuclear staining intensities for 
further increasing doses of bGH compared to saline, (45.8±3.2 and 94.5±7.1 
compared to 11.7±0.4, P<0.01). Figure 4.22b shows a similar pattern in mean number 
 
a) 1 2 3 4 
b) 1 2 3 4 
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of positive cells. There was no significant difference between the saline and the 
lowest bGH injected animals (2.8±0.5 vs 5.2±1.0). However, a dose dependent 
increase was found with the higher doses of GH (64.8±4.4 and 120.5±2.1 vs saline 
(2.83=±0.5), P<0.01). 
 
Figure (4.22) a) Nuclear staining intensity for pYStat5 b) number of positive 
(pYStat5) nuclei for liver from non-transgenic, wild-type mice injected with 
varying bGH doses, or saline 
 
 
Saline vs varying bGH dose, ANOVA followed by Dunnett’s test, **P<0.01. 
 
 
a) 
b) 
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Figure 4.23 simply summarizes the placental responses to GH in these normal mice. 
Figure 4.23a shows that the placenta had the same dose-dependent responses as the 
liver. Again, there was no significant difference between the saline and lowest bGH 
dose for the mean nuclear staining intensity, 14.0±0.7 compared to 13.2±0.8. 
However, a significant increase in nuclear staining intensity was seen in higher doses 
of bGH, compared to the saline group (37.0±4.5 and 58.7±4.2 compared to 14.0±0.7, 
P<0.01). There was a significant increase in the mean number of positive cells (Fig 
4.23b) with increasing bGH doses compared to saline. Thus, normal mouse placenta 
was clearly a target for GH, and the response was not confined to dwarf GHD 
animals, but also evident in GH-normal animals. 
 
Again I noted that there appeared to be a lower level of GH-induced nuclear staining 
intensity, and number of positively stained cells, in both the liver and placenta of 
wild-type mice compared to GRF-M2 mice. This was also seen in pregnant wild-type 
rats compared to dwarf rats. As for normal rats, I felt the most likely explanation is 
that wild-type mice have prevailing endogenous GH signaling, which could blunt the 
response to an acute GH challenge  
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Figure (4.23) a) Nuclear staining intensity for pYStat5 b) number of positive 
(pYStat5) nuclei for placenta from non-transgenic, wild-type mice injected with 
varying bGH doses, or saline 
 
 
  
 
Saline vs varying bGH dose, ANOVA followed by Dunnett’s test, *P<0.05 and **P<0.01. 
 
 
 
 
 
 
a) 
b) 
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4.5 Discussion 
 
My results from experiments in non-pregnant dwarf rats have reproduced the pYStat5 
responses to GH previously described by Gevers et al (2009) [291], who originally 
developed this method, to show a single acute injection of GH, in a GH-deficient 
animal, through visualization of phosphorylated Stat5. What I have added to the 
method is an analytical semi-automated process that allows this response to GH to be 
analyzed using a relatively objective set of quantification parameters, applicable to 
large numbers of sections, for high throughput, and affording statistical comparisons 
between groups. As expected non-pregnant dwarf rats clearly showed higher nuclear 
staining intensity for pYStat5 and an increased number of positive cells in response to 
GH, compared to animals injected with saline. This adds to previous data mostly 
obtained in male rats, but my main aim was then to test whether a response to GH, if 
any, could be detected in the liver in pregnant females, and in particular, whether 
responses could also be detected in this placentae. I also wished to test this in another 
GHD rodent species.  
 
My results are the first to show that pregnant dwarf rats given an acute injection of 
GH, exhibit an increase in both staining intensity, and number of positive cells, 
compared to saline injected animals, in placenta as well as liver. Importantly, the 
responses to GH appeared to increase according to GH dose in the liver, and suggests 
that both the responding tissue and the method of analysis was able to detect changes 
in staining intensity and the recruitment of responding cells, with increasing GH dose. 
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The level of nuclear staining intensity observed in pregnant liver appeared higher than 
that recorded for liver from non-pregnant dwarfs, however, the number of responding 
cells were appeared the same. This suggests that the same number of GH responsive 
cells is present, and that additional cells are not recruited in pregnancy. It is unclear 
why this might be, though it is possible there is more Stat5 present (to be 
phosphorylated) or a higher Jak kinase activity. An important conclusion however, is 
that there may be  “silent” GH-responsive cells which become “visible” only at higher 
GH doses. 
 
The same observations were made in AS rats, in which I observed a significant 
response to GH, compared to rats injected with saline, however, there was a less 
obvious dose dependant pattern to GH shown, compared to that evident in dwarfs. 
The obvious explanation I have advanced for this is that endogenous GH is present, 
which makes it more difficult to record a clear response to an acute injection of GH in 
the AS rats. This could be by desensitization of the response acutely, as more long-
term adaption of the JAK/Stat system in the presence of normal GH. I performed 
some GH infusion experiments, described in chapter 5, which lends some support to 
this idea. Further evidence for this is the higher level of background staining in the AS 
livers, compared to that in dwarfs. There are other ligands that can activate Stat5 (e.g. 
IFN) [348] so I cannot rule out that some of this staining, may be due to Stat5 signal 
unrelated to GH. It can also be that washing during the immunohistochemistry wasn’t 
as effective, though this would be the same for all sections in the batch, treated and 
untreated. Nevertheless, due to the subtraction of background, there will likely have 
been some loss of true staining, which could have reduced the signal recorded for 
nuclear staining intensity, though why this should differentially affect AS livers is 
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unclear. However, it is important to note that the number of positive cells in the AS 
rats did increase with dose, to similar numbers shown in the dwarf livers. Despite the 
level of response within AS liver being lower, the number of responding cells per 
section was similar between dwarf and normal animals.  
 
The main novel finding addressing my main aim in convincing fashion, was that in 
the same pregnant animals direct GH-induced YStat5 responses were clearly evident 
in placenta, and that the placenta from both dwarf and AS rats does represent a direct 
target for GH. It was obvious however that, unlike the liver, responding cells were 
confined to one given area and structure of the placenta, which appears to be 
syncytiotrophoblast cells. As with liver, the placentae from dwarfs showed a 
significant increase in both nuclear staining intensity, and number of positive cell, 
according to an increase in dose. Similar results were seen in placentae from AS rats, 
however, both nuclear staining intensity and number of positive cells recorded were 
lower than for dwarfs placenta. This implies that the placenta from AS rats may be 
subject to the same difference as seen in responses in the liver from AS rats, i.e. less 
responsive to an acute injection of GH. Again, it is reasonable to assume that 
endogenous GH levels in AS rats contribute to this desensitization, also in the 
placenta. 
To show that this was not a unique property of dwarf (GHD) rats, the same 
experiments were carried out in a transgenic GH-deficient mouse model (GRF-M2). 
When GH injection experiments were repeated in these mice, liver from both GRF-
M2 and non-transgenic mice showed significant increases in nuclear staining 
intensity, as well as, number of positive cells. Interestingly, the non-transgenic mice, 
like AS rats, showed lower levels of staining intensity, compared to GRF-M2 mice, 
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consistent with their endogenous GH being much higher. Furthermore, the number of 
positive cells recruited with varying dose in the non-transgenic mice, were similar to 
numbers recorded for GRF-M2 mice, again consistent with my results in GHD rats. 
This indicates that non-transgenic mice may be similar to AS rats, in that the levels of 
intensity of response is reduced due to spontaneous GH, however, in this case, this 
didn’t appear to alter the number of cells responding. However, it is also important to 
note that the high levels of background observed for AS rat liver was not equally 
observed for wild-type mouse liver, so not all the results can be directly extrapolated 
between these species.  
 
Gratifyingly, I was able to confirm placental Stat5b responses to GH response in 
mice. Placenta from both GRF-M2 and non-transgenic mice showed responses in the 
same syncytiotrophoblast regions, with dose dependent increases in nuclear intensity 
and number of positive cells recorded. I can therefore conclude that the mouse 
placenta is also a direct target for GH in the mouse. As in the liver from non-
transgenic mice, placenta from non-transgenic mice also showed much lower levels of 
staining intensity, and number of positive cells, compared to GRF-M2 mice, again 
implying a contribution of endogenous GH levels to placental responsiveness to an 
acute action of GH. I noted that the placenta and liver in GRF-M2 mice also showed 
much higher levels for nuclear staining intensity, and number of positive cells, 
compared to dwarfs. This differs from normal rodents, which showed similarities in 
these tissue responsiveness to GH, but I am cautious extrapolating this, as there are 
differences in the origin, severity, and cellular basis of GH-deficiency in my two 
models of GHD.  
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The quantification package I developed proved helpful for analysis of tissue responses 
in both mice and rats, but some comments are warranted about the difficulties 
encountered when analyzing the two tissue types. One difference observed for the 
placenta, compared to the liver, was the higher levels of non-specific staining. The 
non-specific staining shown in the placenta also had an edge like effect, outlining 
several structures, which were more troublesome for analysis given the relative 
heterogeneity of the placenta compared to the rather more homogeneous hepatic 
sections. This kind of non-specific edge staining was not observed in the liver. I 
cannot rule out that this type of “background” staining is in fact specific, however, it 
is not characteristic of the nuclear pYStat5 staining shown in the liver and the other 
parts of the placenta. Nevertheless, its removal during the analysis generates a 
potential underestimate of weakly responding cells, that get “subtracted” in the 
automated analysis, which would underestimate the overall response. Formally, I can 
thus describe positive cells as “responders”, but  “negative” cells may be missed as 
weak responders not “non-responders” as I classify them here. 
 
A second concern is that the cut off points for non-specific staining was set using the 
mean size of stained nuclei, so that any object size outside of the upper and lower 
settings would be discarded as non-nuclear and non-specific. However, edge-like 
nuclear staining in the placenta would lie within these settings, and therefore could 
have resulted in the creation of false positives. A way of reducing this would have 
been to set non-specific cut-off settings differently according to the tissue being 
analyzed, but I felt this risked introducing too much subjectivity into the analysis, I 
therefore preferred to accept the limitations as they are, and maintain unbiased 
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comparisons in the analytical settings. Nevertheless, this inhibits me from drawing too 
firm comparisons quantitatively between tissues, especially with lower doses of GH. 
 
Another difficulty is that some of the nuclear staining observed for the lower doses of 
GH was very faint, compared to staining achieved from higher doses. Visual 
inspection of some of these sections suggested that on occasion subtraction of 
background non-specific staining probably resulted in “missing” these fainter 
signalling nuclei.  In some sections a visible difference between lower GH dose and 
saline was apparent, however, following the automated processing the same images, 
for the responses lower GH doses were not significantly different to images from 
animals injected with saline. To over come this, the background subtraction values 
could have been changed to compensate for fainter signals, however, this would then 
introduce the problem of allowing some real non-specific staining to come through 
and it is always possible the visual impression is misleading.  Again, I felt the 
practical advantage of the higher throughput, semi-objective method, outweighed 
these errors, which would mostly be a problem at lower doses of GH, and it was better 
to accept these limitations. 
 
In summary, I have shown that the liver responds to bGH during pregnancy in dwarf 
rats. Furthermore, the results indicate that this response was much more accentuated 
during pregnancy compared to the liver of non-pregnant dwarf rats. A response to 
bGH has been documented for the first time in the placenta, which has been shown in 
both dwarf and GRF-M2 mice. Both the liver and placenta showed similar response to 
GH, in a dose dependent manner. A single injection of bGH was less effective in both 
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the liver and placenta in normal rodents, when compared to GH-deficient rodents, 
suggesting the latter are more sensitive to GH presented in this way. 
 
Finally, the quantification method devised to analyze GH responses proved to be 
effective and useful. It may require slight adjustments according to tissue type for 
more robust quantification of GH responses, but an acceptable compromise between 
false positive and false negatives allowed quantitative comparisons of GH responses 
and thus statistical evaluation to be performed on large numbers of images. 
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5. GH-signaling in pregnant rat liver and placenta: GH secretory 
pattern and nutrition 
 
 
5.1 Introduction  
 
Both the pattern of GH secretion [52] and changes in nutrition [349] alters the level of 
GH response in the liver, as reviewed in the Introduction. Having established a 
method for quantifying the responses to GH, I then performed experiments with the 
following aims: (i) to visualize potential differences in the hepatic response to GH 
given in different patterns in pregnancy, (ii) to look for changes in GH responses in 
the placenta, and (iii) to examine whether there are differences in response to GH, in 
the liver or placenta, under nutritional restriction. 
 
5.2 Experimental approach to investigating the effects of different GH patterns  
 
In the previous chapter, I showed that during pregnancy the liver and placenta responds 
to a single acute injection of GH, with increases in pYStat5. Whilst this single GH pulse 
is optimal for visualizing and identifying responsive cells, it is clearly not an appropriate 
physiological GH exposure shown during pregnancy, which is more continuous. To 
address this, I sought to test phosphorylation of Stat5 in pregnant dwarf rat liver and 
placenta after a 7-day exposure to GH, delivered by a subcutaneous osmotic pump in a 
continuous fashion. 
 
Growth in rats is dependent on the pattern of GH exposure [50]. A study by Gevers et 
al (1996) [78] generated comparative dose-response curves for dwarf rats treated with 
pulsatile or continuous intravenous infusions of GH. They showed that pulsatile 
infusions increased weight gain and bone growth, more than continuous infusions, for 
any given GH dose. The total duration of treatment in these experiments was 7 days, 
with a maximum dose of 200µg/day. Continuous infusion at this dose continued to 
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induce increased growth, with no observable plateau reached. In contrast, dose-response 
curves for dwarf rats treated with pulsatile treatment of GH began to plateau after doses 
above 72µg/day. In the same study, when mixed patterns of GH pulses superimposed 
on continuous GH exposure were given to animals, the pulsatile effect was predominant 
for growth, (though growth was stimulated to some degree by continuous component), I 
therefore decided to test a 7-day continuous infusion of 200µg/day bGH, which could 
more likely mimic physiological exposure during pregnancy. 
 
 
5.2.1 Effects of continuous GH exposure on hepatic pYStat5 responses 
 
Figure 5.1 illustrates images from the livers of pregnant dwarf rats treated with or 
without continuous bGH for 7 days, followed by an acute injection of saline or bGH, to 
test the pYStat5 response. Figure 5.1(a) shows an example of liver tissue from a dwarf 
rat treated with a 7-day continuous infusion of bGH (pump), followed by a single acute 
injection of saline alone i.e. no acute GH challenge.  I observed a number of nuclei with 
pYStat5 staining and an overall increased staining intensity with continuous GH 
exposure. Figure 5.1 (b) shows section of liver tissue from an animal treated with a 7-
day continuous bGH infusion, but also given a single acute injection of bGH, shortly 
before sacrifice. In these animals I observed more responding nuclei, which also 
appeared to have a higher level of staining intensity for pYStat5 when compared to (a). 
Figure 5.1 (c) shows an example of liver tissue from an animal not pretreated with 
continuous 7-day bGH infusion, and only given a single acute injection of saline 
(double control). In this example I observed a low number of pYSta5 nuclei staining, 
with less staining intensity, compared to (a) and (b). However, the strongest pYStat5 
response to GH is shown in the section in (Fig 5.1 [d]), taken from an animal treated 
with a single acute injection of bGH, without prior continuous GH exposure.  
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Figure (5.1) Liver sections from dwarf rats,  immunostained for Phospho 
Stat5,+/- 7 day bGH pump, followed by an acute iv injection of saline or bGH 
 
 
 
 
 
pYStat5 staining in the livers of pregnant dwarf rats treated (a) with continuous bGH 
infusion (pump) for 7 days and then with an acute injection of saline (b) with bGH. In (c) 
dwarfs received no pretreatment with continuous bGH, but given a single acute injection of  
saline, or bGH in (d). (n=6) for each group. 
 
 
 
 
The result of quantification of all the sections from groups of 6 animals with these 
treatments is shown in Figure 5.2. Figure 5.2a shows that the livers in pregnant dwarf 
rats were clearly responsive to continuous bGH infusion; nuclear staining intensity for 
groups treated with continuous bGH infusion was significantly higher (48±7.7) than 
that of the control group (14±0.1, P<0.001), which received no pre-treatment with 
continuous bGH infusion. Figure 5.2b shows a similar significant increase in the mean 
number of positive cells in the group that received continuous bGH infusion (35±8.6), 
compared to the control group (2±0.2), P<0.05. Giving an acute injection of bGH on 
top of continuous bGH treatment produced an apparent further increase in mean 
     7-Day bGH pump      No 7-Day pump 
Saline Injection 
a) c) 
b) d) 
GH Injection 
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nuclear staining intensity, though, this increase was not significant, compared to the 
group that only received continuous bGH infusion. However, there was a highly 
significant increase in the number of positive cells for the same group (100±12.2), 
compared to group treated with continuous bGH (35±8.6, P<0.001), Fig 5.2b. 
Furthermore, both the mean nuclear staining intensity and number of positive cells 
was lower in the group that received an acute injection of bGH following continuous 
bGH infusion, compared to the group that received an acute bGH injection alone 
(74±1.6 staining intensity and 133±81 positive cells ). These results show that the 
liver remains responsive to an acute GH challenge under continuous bGH exposure 
during pregnancy. However, as in non-pregnant animals, the liver shows a pattern 
dependent response to GH, as an acute injection of bGH superimposed on a 
continuous bGH infusion shows a smaller GH response than an injection of GH 
without pre-exposure to continuous GH. The continuous pre-treatment thus appears to 
desensitize the pYStat5 response to an acute challenge . 
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Figure (5.2) a) Nuclear staining intensity for pYStat5 b) number of positive 
(pYStat5) cells for liver from pregnant dwarf rats +/- 7 day bGH pump, followed 
with an acute iv injection of saline or bGH 
 
 
 
 
 
 
 
                  
        ANOVA followed by Student Newman Keuls test, *P<0.05, 
       ***P<0.001 
 
       
 
 
 
(a) 
(b) 
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5.2.2 Is the placenta also pattern dependent in its response to GH? 
 
 
Figure 5.3 shows images for the placenta from the same experiments in dwarf rats 
treated with or without continuous 7-day bGH infusion, and then challenged with an 
acute injection of saline or bGH.  
 
Figure (5.3) Placental section from dwarf rats, immunostained for phospho 
Stat5, +/- 7 day bGH pump, followed by an acute iv injection of saline or bGH 
 
 
 
 
 
 
pYStat5 staining in the placenta of dwarf rats treated in (a) with continuous bGH infusion 
(pump) for 7 days and then given an acute injection of saline or (b) with bGH. In the top 
right, (c) dwarfs received no pretreatment with continuous bGH, but given a single acute 
injection of  saline (c), or bGH in (d). (n=6) for each group. 
 
 
 
Figure 5.3(a) shows an example of a placental section from a dwarf rat treated with a 7-
day continuous infusion of bGH and then given a single acute injection of saline. I 
observed a large number of positive nuclei, although they appeared to have a lower level 
of staining, compared with hepatic responses. Figure 5.3 (b) shows a placental section 
      7-Day bGH pump No 7-Day pump 
a) c) 
Saline Injection 
bGH Injection 
b) d) 
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from an animal treated with a 7-day continuous bGH infusion and then a single acute 
injection of bGH. Several responding nuclei were evident which had a higher staining 
intensity, when compared to (a).  Figure 5.3 (c) shows a placental section from an 
animal not pretreated with continuous GH, and given only a single acute injection of 
saline (double control), a few faintly stained pYStat5 nuclei are seen. Again, the 
strongest pYStat5 response to GH was seen in animals treated with a single acute 
injection of bGH without continuous GH pretreatment, (Fig 5.3d). Placental images (b) 
and (d), from the same experiment appear to be very similar in their staining intensity, 
implying that continuous GH exposure has a lesser effect on placental response to acute 
GH challenge than in the liver of the same animals, but this needed quantification for all 
the groups (Fig 5.4) 
 
Figure 5.4a shows a higher mean value  for nuclear staining intensity in the placentaes 
of animals treated with continuous bGH infusion (52±13) compared to saline infused 
animals (29.0±0.2), but this difference did not reach statistical significance. However, 
figure 5.4b shows a significant increase in the mean number of positive cells 
(continuous bGH pretreated 40.0±6.5 vs untreated, 23.1±0.8, P<0.05). Giving a acute 
injection of bGH on top of continuous GH pretreatment, further increased the mean 
nuclear staining intensity and number of positive cells, but again this was not 
statistically significant. However, both mean nuclear staining intensity (62.0±6.12) 
and number of positive cells (52.3±5.3) were lower in the group that received an acute 
injection of bGH with continous GH pretreatment, compared to the group that had 
received an acute bGH injection with no pretreatment (103.1±5.7 staining intensity 
and 58.2±6.5 positive cells).   
 
 
 
 169 
Although there was no significant difference for mean nuclear staining intensity, a 
significant increase was shown for the mean number of positive cells following 
continuous GH, suggesting that the placenta (like the liver) is able to respond to GH 
when given in a pattern of continuous exposure, though less markedly so. This is 
important as continuous exposure is the more physiologically relevent exposure 
pattern during pregnancy. Furthermore, as in the liver, the placenta also shows a 
reduced response to an acute injection of GH following continuous bGH treatment. 
This suggests that the response to GH in the placenta also shows the same pattern 
sensitivity as in the liver, although greater pYStat5 responses can be obtained to a 
pulse of GH. This could occur earlier in human and rodent pregnancies before the 
pattern is “switched” to continuous. 
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Figure (5.4) a) Nuclear staining intensity for pYStat5 b) number of positive 
(pYStat5) cells for liver from pregnant dwarf rats +/- 7 day bGH pump, followed 
with an acute iv injection of saline or bGH 
 
                                                                                                                                                
 
 
ANOVA followed with Student Newman Keuls test, *P<0.05, 
**P<0.01, ***P<0.001. 
 
 
 
 
a) 
b) 
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Western blot analysis was carried out in the liver and placenta of pregnant dwarf rats 
treated with continuous bGH treatment or saline, to asses whether continuous bGH 
treatment made any changes in endogenous Stat5b, in Stat5b protein levels in the two 
tissues. Figure 5.5 shows an example of western blots for dwarf liver and placenta 
treated with continuous bGH or saline. Quantification of the blots for dwarf liver 
showed no statistical difference in Stat5b levels in continous bGH treated animals 
compared to saline treated group, when compared with the loading control (GAPDH). 
 
Interestingly, samples 1 and 2 from liver treated with continuous bGH showed 
stronger bands for Stat5b compared to samples 3 and 4, despite similar loading, 
suggesting that endogenous Statb levels vary in different animals. Signals were lower 
in the placenta of dwarf rats, and also showed no differences in groups treated with 
continuous bGH compared to saline treated, again, possibly due to the variation 
between animals. Although rather inconclusive it does not appear that GH alters the 
protein levels substantially in either tissue. Figure 5.5 suggests that there was higher 
amounts of Stat5b protein in the liver of pregnant dwarf rats treated with continuous 
bGH compared to the placenta (1.32±0.32 compared to 1.13±0.35, respectively). This 
could suggest higher steady state levels of Stat5b protein synthesis in the liver. 
However, it is important to bear in mind that these are Stat5b protein levels at a single 
time point and this may vary over the course of pregnancy in both tissues. I did not 
examine this. 
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Figure (5.5) Effect of continuous GH treatment on Stat5b in the liver and 
placenta of pregnant dwarf rats 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Stat5b in the liver and placenta of pregnant dwarf rats treated with continuous bGH 
(200µg/day) for 7 days or saline from day 16 of pregnancy. 
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5.3 The effects of fasting and insulin injections on GH responses 
during pregnancy 
 
5.4 Introduction 
 
As reviewed in the Introduction, previous studies on the acute insulin like actions of 
GH have included the ability of GH to decrease blood glucose concentrations, and to 
stimulate the uptake and transport of glucose in various tissues [133, 350] whereas 
more long-term, GH has anti-insulin like actions, inhibiting glucose uptake and 
promoting insulin resistance in tissues. It has been suggested this is due to a 
convergence and possible crosstalk between the GH and insulin signaling pathways 
[151, 351] and is quite complex. 
 
A major regulator of insulin is nutrition and several studies have shown both GH and 
insulin sensitivities vary during calorie restriction [162, 349, 352]. The aims of the 
experiments described in this section were (i) to look for changes in GH sensitivity 
(pYStat5 responses) in a known GH-target, the liver, following a 48-hour fast, and (ii) 
to test whether this was sensitive to the administration of insulin, during continuing of 
fasting. Preliminary evidence for this interaction had been obtained in normal male 
rats in the lab by Eveline Gevers (unpublished), so my aim was to see if this could be 
reproduced in pregnant liver and, or be demonstrated in the placenta. By using GHD 
models, I could investigate the potential interaction of fasting and insulin with GH 
signaling in pregnancies without the complication that fasting would altered 
endogenous GH production, as it does in normal animals. 
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5.5 GH responses in the liver of non-pregnant dwarf and AS rats, during a 48-
hours fast, +/- insulin injection 
Previous experiments by Beauloye [162] have shown that a 48-hour fast in male rats 
is sufficient to induce a state of GH resistance and was also the maximum length of 
time I was allowed to fast rats on my Home Office Licence. Beauloye showed a 
reduction in the phosphorylation of both JAK2 and GH-receptors, upon GH 
administration. Furthermore, the same fasted rats showed only a slight basal 
phosphorylated Stat5 signal in the liver, when compared to non-fasted animals [162].  
 
I began with positive controls by carrying out initial experiments in non-pregnant 
female rats (previous work was done only in males). I used both normal (AS) and 
GH-deficient (dwarf) female rats, as I wished to establish the effects of fasting on the 
response to GH, initially in the liver, under normal conditions. I expected clearer 
responses in GH-deficient rats, and that any effects of fasting and insulin might be 
most evident in the GH-deficient insulin sensitive condition, compared to intact 
control females. In subsequent experiments I then compared similar manipulations in 
pregnant animals, as well as examining placental responses. The dose of insulin 
administered to animals was chosen based on the observations of Evelien Gevers, and 
kept the same throughout all experiments. Choosing the correct dose of insulin was 
important, as I anticipated that after a 48 hour fast, blood glucose levels would be 
very low, and giving high doses of insulin during continued fast risked the induction 
of hypoglycemic shock, resulting in fitting and possible death of animals. All 
experiments were carefully monitored to ensure this did not occur. 
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Figure 5.6a shows the mean nuclear staining intensity for pYStat5 in liver sections 
from normal (non-pregnant) fasted AS rats.  Remarkably, there was no significant 
difference in the two fasted groups injected with saline or bGH. This clearly shows 
that fasting has a major effect to blocking the pYStat5 response to GH in the liver, 
confirming previous observations in males [291]. It is important to remember that 
some basal Stat5 activity could be expected in normal rats treated with saline, due to 
the endogenous GH, independent of what is administered to the animal. However, I 
would expect this activity to be low, since fasting in rodents causes a reduction in GH 
secretion (though this has mostly been tested in males) [80]. A much more surprising 
result was the restoration of a significant increase in mean nuclear staining intensity, 
following an acute injection of insulin prior to bGH (25±7 vs 55±7, P<0.05). Despite 
continuing fasting, insulin reversed the fasting-induced GH resistance independent of 
nutrient restoration. 
 
Figure 5.6b shows the number of cells positive for pYStat5 in this experiment. There 
was no significant difference between the two fasted groups, injected with bGH or 
saline, confirming that fasting powerfully blocks the GH responsiveness. Again, as for 
mean nuclear staining intensity, the number of positive cells increased following an 
acute injection of insulin prior to bGH (15.0±0.5 vs. 120±13, P<0001). Clearly 
therefore, the fasting induced GH resistance in the female liver can be reversed (at 
least in terms of pYStat5 phosphorylation) by an acute insulin injection.  
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Figure (5.6) Response to GH in livers of 48 hour fasted female non-pregnant AS 
rat’s +/- Insulin (a) nuclear staining intensity for pYStat5 (b) number of positive 
(pYStat5) cells 
 
                 
                       Fasting saline vs Fasting bGH, +/- Insulin, *P<0.05, ***P<0.001. 
        ANOVA followed by Student Newman Keuls test. 
 
 
(a) 
(b) 
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Figure 5.7 shows the results of similar experiments, but in female dwarf GHD rats. 
Here, the nuclear intensity (Fig 5.7a) following GH injection did increase 
significantly (95±11) when compared to fasted saline injected animals (20±12), 
P<0.001. This was different from the normal animals, and suggests that GHD females 
are less sensitive to the fasting effects on hepatic GH responsiveness. A further 
difference was that in these GHD animals an acute injection of insulin resulted in a 
reduction of mean nuclear staining intensity (45±2), P<0.001. This was not a direct 
effect of insulin as no significant difference in response to GH was shown between 
fasted saline group and fasted saline groups injected with insulin prior to saline. 
Figure 5.7b shows the mean number of positive cells measured in the same liver 
sections. The mean number of positively stained cells in the livers of fasted non-
pregnant dwarf rats injected with bGH, was significantly higher (96±20) than that in 
the saline injected group (7±6, P<0.001). Furthermore, as shown with mean nuclear 
intensity, addition of an insulin injection, prior to bGH, showed a significant 
reduction in number of positive cells (19±3 vs 96±20, P<0.001).  
 
It would appear that the higher GH responsiveness in GHD animals is less sensitive to 
fasting, and if anything, inhibited by insulin. It is not obvious why such differences 
are apparent in GHD animals but one possibility is that GHD rats are already more 
insulin sensitive than normal rats, and their basal nutritional intake is much lower. 
 
 
 
 
 
 178 
Figure (5.7) Response to GH in livers of 48 hour fasted female non-pregnant 
dwarf rats +/- Insulin (a) nuclear staining intensity for pYStat5 (b) number of 
positive (pYStat5) cells 
 
                
                          
          Fasting saline vs Fasting bGH, +/- Insulin, ***P<0.001. 
        ANOVA followed by Student Newman Keuls test. 
 
 
(a) 
(b) 
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5.5.1 GH responses in the liver of pregnant AS rats during a 48-hour fast, +/- 
insulin injection 
The same fasting experiments were then performed in pregnant rats beginning with 
normal (i.e. GH-intact) rats. Figure 5.8a shows the mean nuclear staining intensity in 
liver sections from pregnant wild-type (AS) rats. A significantly higher nuclear 
pYStat5 staining was observed in fasted rats given a bGH injection (85±5) vs saline 
injected (19±1, P<0.001). Interestingly, an injection of insulin at the 40th hour of a 
48-hour fast, prior to an injection of saline, resulted in a significant increase in mean 
nuclear staining intensity, compared to fasted animals not injected with insulin (45±5 
vs 19±1, P<0.001). In contrast, insulin pretreatment reduced the mean nuclear staining 
intensity response to GH (71±2), compared to fasted animals injected with bGH 
without prior insulin injection (85±5), P<0.01. This was reminiscent of the results in 
the non-pregnant dwarf females. Fasted pregnant rats injected with bGH showed a 
significantly higher number of pYStat5 responding cells (20±3) compared to saline 
injected fasting pregnant rats, who had very low basal signaling, (3±08), P<0.001. 
Taken together, this suggests that whilst fasting may reduce the number of cells 
responding to GH, the response in the pregnant liver is diminished to a much lesser 
extent by fasting, than that in non-pregnant AS rats (Fig 5.6a). 
 
Figure 5.8b shows the results in terms of the number of positive cells. An injection of 
insulin prior to GH challenge was able to further increase the number of positive cells 
responding to GH from 20±3 in non-insulin injected group, to 108.1±0.8 in insulin-
injected group, P<0.001, as in AS non-pregnant rats (Fig 5.6b). No significant 
increase in these parameters was seen in fasted rats given insulin alone, without a GH 
challenge. 
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Figure (5.8) Response to GH in livers of 48 hour fasted pregnant AS rat’s +/- 
Insulin (a) nuclear staining intensity for pYStat5 (b) number of positive 
(pYStat5) cells 
 
 (a) 
 
 
    Fasting saline vs Fasting bGH, +/- Insulin, **P<0.01, ***P<0.001. 
     ANOVA followed by Student Newman Keuls test. 
 
(b) 
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5.5.2 GH responses in the livers of pregnant dwarf rats during a 48-hour fast, +/- 
insulin injection 
The same experiments were then repeated in groups of fasted pregnant GHD dwarf 
rats (Figure 5.9). A significant increase in mean nuclear staining intensity in response 
to a single injection of GH (19±2) was found compared to saline injected controls 
(4.1±0.4), P<0.001. An injection of insulin without GH challenge also increased 
nuclear staining (Fig 5.9a) and greatly enhanced the response to GH, (64±3), 
compared to fasted animals given GH without prior insulin injection (19±2), P<0.001. 
This suggests that in these fasting pregnant GHD rats, insulin pretreatment increases 
basal GH responses, and has an even greater effect in the fasted state. Figure 5.9b 
shows the mean number of positive cells recorded for the liver sections of fasted 
pregnant dwarf rats with essentially the same trends, though the rise in the number of 
positive cells in the controls, or following an injection of GH did not reach statistical 
significance. However, an acute injection of insulin prior to GH challenge did produce 
a significant increase in the number of GH responding cells (117±6), when compared 
to fasted dwarfs injected with bGH alone (4.0±0.8), P<0.001.  
Overall, I interpret my results from these experiments to indicate that giving insulin 
prior to GH administration during fasting is able to increase the GH responses in the 
fasting pregnant liver, but the magnitude is highly dependent on prevailing 
endogenous GH tone. Fasting does reduce pYStat5 responses to GH in both pregnant 
and non-pregnant liver and is somewhat counteracted by insulin pretreatment, but this 
response is dependent on the GH-status of the rat. 
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Figure (5.9) Response to GH in livers of 48 hour fasted pregnant dwarf rats +/- 
Insulin (a) nuclear staining intensity for pYStat5 (b) number of positive 
(pYStat5) cells 
 (a) 
  
 
     Fasting saline vs Fasting bGH, +/- Insulin, ***P<0.001. 
       ANOVA followed by Student Newman Keuls test. 
 
 
 
  
(b) 
 183 
5.5.3 GH responses in the placenta of AS and dwarf rats during a 48-hour fast, 
+/- insulin injection 
As I have shown earlier that the placenta is directly responsive to GH, I also tested 
whether I could detect a similar change in sensitivity to GH in this tissue (like in the 
liver) following fasting, using placental tissues from the pregnant rats in the 
experiments described in the previous section. Figure 5.10a shows the mean nuclear 
staining intensity for placenta from fasted AS rats. There was no significance in 
pYStat5b responses difference between the fasted groups given bGH or saline, 
suggesting that, as in liver, the response to GH seen in the normal placenta is lowered 
by fasting. Injection of insulin had no effect on basal nuclear pYStat5 staining, but 
significantly increased mean nuclear staining in response to GH, when compared to 
the fasted group given bGH without insulin pretreatment (13±02 vs 17.0±0.8, 
P<0.01). This effect was relatively small, but nevertheless consistent with what was 
seen in liver in these rats. 
 
Figure 5.10b shows the number of positive cells recorded for fasted AS rats. There 
was small but significant increase (14.1±1.6) in the number of cells responding to GH 
in the fasted placenta compared to saline controls (3.0±0.8), P<0.001. This could 
indicate that whilst fasting reduces the intensity of response to GH in the placenta, 
some new responding cells, with possibly low staining intensity are still recruited. 
Interestingly, administration of insulin prior to GH, significantly reduced the number 
of positive cells (4.0±0.3), P<0.001, down to control values. It was unusual to see a 
divergence between staining intensity and cell number responding, and the reason is 
not obvious, thought the signals in placenta are much lower overall. No significant 
changes were observed in the groups given insulin prior to saline challenge.  
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Figure (5.10) Response to GH in placenta of 48 hour fasted pregnant AS rat’s +/- 
Insulin (a) nuclear staining intensity for pYStat5 (b) number of positive 
(pYStat5) cells 
 
 
Fasting-saline vs Fasting bGH, +/- Insulin, **P<0.01, ***P<0.001. 
                             ANOVA followed by Student Newman Keuls test. 
 
 
 
(a) 
 (b) 
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I also tested the placental responses to GH in fasting pregnant dwarf rats. Again, 
nuclear pYStat5 staining in dwarf placenta was low, but Figure 6a shows staining 
intensity to be slightly but significantly higher (15.0±0.8) in fasted animals given GH, 
compared to saline injected controls (10.1±1.6), P<0.01. Figure 5.11a also shows that 
an acute injection of insulin prior to saline challenge in these fasted animals increased 
mean nuclear intensity when compared to fasted dwarfs given saline alone (13±4 vs 
10.1±1.6, P<0.01), and the same was true for GH responses (19.1±0.4 vs 15.0±0.8, 
P<0.001), but the increase was no larger than for saline alone, suggesting the main 
effect was on basal pYStat5 signaling, rather than GH-induced responses. 
Figure 5.11b shows results for the numbers of positive cells recorded for placenta 
from these experiments in fasted pregnant dwarf rats. During fasting few cells 
responded to GH. However, an acute injection of insulin prior to bGH or saline 
challenge, revealed a marked increase in number of positive cells, in both groups 
(13±1 and 11±2, compared to 2.1±0.3 and 1±0; P<0.001 for both cases) respectively. 
Again, this implies the main effect of fasting and reversal by insulin is in basal 
pYSta5 signaling. Despite the small responses, I feel able to conclude for the first 
time that the placenta from dwarf rats, as from normal AS rats, shows small but 
significant changes in response to GH following fasting, and that the magnitude of the 
response is altered by insulin treatment during fasting. However, a major effect in 
placenta may be in basal pYStat5 signaling, upon which small GH responses are 
superimposed. It is also important to note that the number of cells responding to GH is 
fewer in the placenta, compared to the liver. As previously argued, placenta is a very 
heterogeneous tissue, with only a small area showing cells responsive to GH, relative 
to the more homogenous liver. Nevertheless, clearly responding cells are clearly 
present.  
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Figure (5.11) Response to GH in placenta of 48 hour fasted pregnant dwarf rats 
+/- Insulin (a) nuclear staining intensity for pYStat5 (b) number of positive 
(pYStat5) cells 
 (a) 
 
(b) 
        
Fasting saline vs Fasting bGH, +/- Insulin, **P<0.01, ***P<0.001. 
ANOVA followed by Student Newman Keuls test. 
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5.6 GH responses in the livers of pregnant Non-transgenic (Wild-Type) mice, 
during a 48-hour fast, +/- insulin injection 
Because of these somewhat divergent results in GHD pregnant rats I decided to repeat 
similar experiments in another GHD model available in the lab, namely the GH-
deficient (GRF-M2) mice. I was curious whether mice would demonstrate a different 
response to GH, following fasting, compared to rats. Figure 5.12a shows the mean 
nuclear staining intensity in the liver sections from fasting pregnant wild-type mice. A 
significant increase in mean nuclear staining intensity in response to a single injection 
of GH (38.1±2.1) was found, compared to saline injected controls (25.0±2.4, 
P<0.001). Insulin pretreatment before an injection of saline in fasted mice showed no 
further changes in pYStat5 nuclear staining, however, the insulin pretreatment before 
an injection bGH showed a significant increase in pYStat5 staining (50.0±4.4 vs 
38.1±2.1, P<0.01).  
 
Figure 5.12b shows a significant increase in the number of positive cells recorded for 
fasted animals injected with bGH (138.1±5.7) compared to saline (53.0±4.9), 
P<0.001. However, there was no further increase in the number of positive cells, 
following pretreatment with insulin prior to saline or bGH, when compared to fasted 
animals that had received bGH or saline alone. Nevertheless, fasted mice pretreated 
with insulin prior to bGH showed significantly higher positive cell numbers 
(136.0±8.5) compared to mice given saline after insulin pretreatment (62.2±5.3), 
P<0.001. These results show that a hepatic pYStat5 response to GH can still be 
observed during fasting in normal mice, but there is a significant increase in the level 
of response following insulin treatment, as in rats. However, unlike in my rat 
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experiments, the number of cells responding was not further increased by insulin 
pretreatment in these fasting mice.  
 
Figure (5.12) Response to GH in livers of 48 hour fasted pregnant Wild-Type +/- 
Insulin (a) nuclear staining intensity for pYStat5 (b) number of positive 
(pYStat5) cells 
 
Fasting saline vs Fasting bGH, +/- Insulin, **P<0.01,***P<0.001. 
ANOVA followed by Student Newman Keuls test. 
(a) 
 (b) 
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5.6.1 GH responses in the livers of pregnant GRF-M2 mice, during a 48-hours 
fast, +/- insulin injection 
When analogous experiments were repeated in GHD mice, (Figure 5.13), both mean 
nuclear staining intensity (55±2) and number of positive cells (25±4) in fasted livers 
of pregnant GRF-M2 mice, injected with bGH was significantly higher than that of 
saline (40±2 and 14±2, P<0.001, P<0.01 respectively). Fasting clearly does not 
abrogate GH-signaling in these GHD mice. However, an injection of insulin, during 
fasting, 8 hours prior to an injection of bGH, significantly increased both mean 
nuclear intensity (95±2) and mean number of positive cells (120±2) in the liver, 
compared to animals injected with bGH alone (55±2 and 25±4, P<0.001 in both 
cases), respectively.  
 
These results are particularly interesting because the responses to GH and insulin 
induced restoration of GH responses, are more clearly observed in GH-deficient mice, 
compared to the wild-type littermates. Whilst many explanations may be possible, the 
simplest is that, as in rats, the prevailing GH exposure from endogenous secretion has 
a profound effect on GH sensitivity to fasting and insulin reversal. It again 
emphasizes the importance of prevailing GH tone on the tissue responses to acute 
challenge with or without nutritional deprivation. 
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Figure (5.13) Response to GH in livers of 48 hour fasted pregnant GRF-M2 +/- 
Insulin (a) nuclear staining intensity for pYStat5 (b) number of positive 
(pYStat5) cells 
 
   (a) 
 
 
Fasting saline vs Fasting bGH, +/- Insulin, **P<0.01, ***P<0.001. 
ANOVA followed by Student Newman Keuls test. 
 
   (b) 
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Lastly, I addressed the same important question as in my rat experiments: In the 
placenta of pregnant mice, could I see GH responses and alterations during fasting 
and would this differ between normal and GH-deficient pregnant mice? 
 
5.6.2 GH responses in the placenta of Non-transgenic (Wild-Type) mice, during a 
48-hour fast, +/- insulin injection 
Figure 5.14a shows a small but significant increase in mean nuclear staining intensity 
between fasted normal mice injected with bGH (57±6) compared to saline injected 
pregnant fasting mice (40±5), P<0.05, though no further significant increase in mean 
nuclear staining intensity was observed in any group following an acute injection of 
insulin. Figure 5.14b shows a significant increase in positive cell number in fasted 
mice injected with bGH (71±6), compared with saline injected (47±6), P<0.05.  
An acute injection of insulin appeared to blunt this GH response, but the data were not 
significantly different from the group not receiving insulin prior to GH (Fig. 5.14b). 
Overall, fasting reduced, but did not block the placental response to GH in normal 
mice, and this was unaffected by insulin pretreatment. 
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Figure (5.14) Response to GH in placenta of 48 hour fasted Wild-Type mice, +/- 
Insulin (a) nuclear staining for pYStat5 (b) mean number of positive (pYStat5) 
cells 
  
  (a) 
 
 
Fasting saline vs Fasting bGH, +/- Insulin, *P<0.05. 
ANOVA followed by Student Newman Keuls test. 
 
 
(b) 
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5.6.3 GH response in the placenta of GRF-M2 mice, during a 48-hours fast, +/- 
insulin injection 
In the placenta from fasting GRF-M2 mice, Figure 5.15a shows that there is a clear 
GH response in staining intensity (71±1) compared to saline injections (49±5), 
P<0.001. Note that as in the liver responses, the mean nuclear staining intensity is 
lower, when compared to placenta from non-fasted bGH injected GRF-M2 mice. A 
highly significant increase was found in number of positive responding cells in the 
placenta from fasting animals given bGH compared to that of saline (57.1±4.4 vs 
13±0.8, P<0.001). Again this suggests that GHD background makes it easier to detect 
GH responses in mice, as in rats, and that fasting does not block this in GHD animals. 
 
An acute injection of insulin during fasting did not increase the mean nuclear staining 
intensity (48±4), or number of positive cells (21±2), in the placenta compared with 
fasted mice given bGH without insulin pre-treatment (71±1 and 57.1±4.4), 
respectively; the response was completely blunted. This was rather unexpected, but 
similar to that seen in GHD rats, where basal signals went up but additional GH 
responses were not seen with insulin pretreatment. It is also remarkable that both the 
nuclear staining intensity and number of positive cells in fasted, bGH injected animals 
are higher in the placenta compared to the liver in the same fasted mice (71±1 and 
57.1±4.4 compared to 55±24 and 25±4, respectively). This suggests to me that in 
mice, the effects of fasting on blocking GH response are less profound in the placenta 
than the liver, and might explain why the restorative effects of insulin are less clearly 
observable in this tissue. 
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Figure (5.15) Response to GH in placenta of 48 hour fasted GRF-M2, +/- Insulin 
(a) nuclear staining intensity for pYStat5 (b) number of positive (pYStat5) cells 
 
 
Fasting saline vs Fasting bGH, +/- Insulin, ***P<0.001. 
ANOVA followed by Student Newman Keuls test. 
 
 
 
  (b) 
(a) 
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5.7 Discussion 
(i) GH patterns 
Results from this experiment confirmed that a pulsatile pattern of  GH is more 
effective in activating phosphorylation of Stat5 than a more continuous pattern [353] 
but this is shown here for the first time in the placenta. My results also indicate that 
both the liver and placenta continue to be responsive to GH during pregnancy, 
regardless of the pattern of GH given. They also show that the liver during pregnancy  
(as in non-pregnant rat [291]) shows the highest level of Stat5 activity when given a 
pulse of GH. Liver Stat5b is known to be strongly and repeatedly activated in 
response to incoming plasma GH pulses [353], while a more continuous presence of 
GH leads to substantial down regulation of Jak2-dependent signaling to Stat5b [354]. 
However, earlier studies have shown cytoplasmic Stat5b and Jak2 expression to be 
similar in female and male liver [355, 356].  I showed that a single injection of GH is 
able to evoke a higher Stat5 response, in the liver of untreated pregnant dwarf rats, 
compared to those pre-treated with continuous GH infusion. This is true for both 
mean nuclear staining intensity and the number of positive cells. The reduction in the 
both mean nuclear staining intensity and the number of positive cell in the group 
treated with continuous bGH with or without an acute injection of bGH, suggests that 
continuous GH exposure down-regulates the Stat5 response to an acute challenge with 
GH.  
 
Mine are the first experiments to show that the placenta is also able to respond to GH, 
with continuous exposure. Like in the liver, the placenta from dwarf rats also appears 
to show higher Stat5 activity in response to a single acute injection of GH, compared 
to continuous GH infusion, for both mean nuclear staining intensity and number of 
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positive cells. The quantification in placenta only showed a statistically significant 
difference for the number of positive cells, when comparing animals pretreated vs not  
pretreated with continuous GH. This might be explained by smaller signals relative to 
higher background in this tissue. As mentioned earlier, some cells with very low 
staining intensity could be discarded during the background subtraction process. It is 
also important to note that this method used to detect responding nuclei and levels of 
intensity seems to give clearest results with GH pulse exposure, where the acute 
response can be easily distinguished above background. In contrast, in groups 
pretreated with continuous GH the increment of further pYStat5 nuclear staining in 
response to an acute challenge is smaller, making it more difficult to detect changes in 
the intensity of signal after background subtraction.  
 
The importance of a GH pulsatile pattern has been outlined in previous studies [63, 
357] with particular emphasis on its effectiveness on stimulating weight gain and 
body growth. However, the importance of continuous GH secretory pattern seen in 
female rodents is less clear. The potential effects of different GH patterns on the 
placenta and possible role during pregnancy, remains to be elucidated, but are likely 
to be most relevant for continuous exposure. Given the weaker responses, it is likely 
to be less powerful than in the liver, at least from circulating GH. Whether locally 
produced continuous GH exposure is more effective on the placenta in humans 
remains an attractive possibility, but would not be the case in rodents that lack 
placental GH. Concentrations in human placenta will be much higher than those 
reaching the liver after dilution in the circulation. 
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Both hepatic GH receptors and plasma GHBP levels are sensitive to the pattern of GH 
exposure. Male rats show much lower levels of GH receptor expression as well as 
GHBP levels when compared to females [107]. Furthermore, pulsatile GH infusion 
has very little effect on GH receptor expression, whereas continuous GH exposure 
leads to increased GH receptor and increased GHBP levels [54, 55, 357]. These 
findings suggest that (i) continuous GH exposure doesn’t impair the ability of the 
liver to respond to GH, as there isn’t any reduction in GH receptors, and (ii) up-
regulation of GH receptor expression and GHBP levels may be a mechanism to deal 
with the changes in GH pattern. However, there is a paradox that higher levels of 
GHR in female rat liver are associated with reduced responses and growth rate. 
Nevertheless, continuous GH given to hypophysectomized rats, although not being as 
effective as administration of pulses, does stimulate appropriate growth [48]. Some 
authors have suggested that high GHBP levels may act as a method of protecting 
tissues from high levels of GH that may not be beneficial, by competitive binding of 
GH to reduce the signaling effect of GH [358, 359]. Conversely, high levels of GHBP 
could also serve as a reservoir to prolong the time of low-level GH exposure [360] 
reducing GH clearance. Fairhall et al (1992) [111] shows that pre-incubation of 
recombinant human GH and human GHBP, 60 minutes before being injected into 
guinea pigs, also prolongs the in vivo clearance of both proteins greatly. 
 
However, it is important to remember that female rats do grow normally, and do show 
some pulses, these being more frequent and irregular than in males [79, 361] 
superimposed over a higher baseline. This more continuous irregular pattern of GH 
exposure is clearly growth promoting in females. Other studies carried out in the rat 
have shown that continuous GH exposure at various baseline levels can be more 
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involved in the metabolic actions of GH and regulating the expression of several GH-
sensitive proteins [76, 362] and to increase lipolysis [139]. Nevertheless, there has 
been no study that has looked at pattern dependent effects of GH on GH receptors and 
gene expression during pregnancy, the only physiological condition in which GH 
secretory pattern is notably more continuous. Such experiments could help with 
understanding of the potential functions of a more continuous pattern of GH on, for 
example, metabolism in pregnancy.  
 
(ii) Nutrition and Insulin 
A number of studies in fasted rats report a dramatic reduction of GH release [80, 159, 
363] along with a state of GH resistance, which is responsible for a reduction in IGF-1 
levels [161]. My results obtained from fasted non-pregnant, AS rats were consistent 
with these findings, in that I showed a state of GH resistance, with reduced hepatic 
GH responses. The results for non-pregnant dwarf rats did not parallel those obtained 
in AS rats. The dampening effects of fasting on hepatic GH response was not as clear 
in the non-pregnant dwarf rats. Although, there was a reduction in hepatic GH 
response compared to non-fasted female dwarf rats, a significant response to a 
challenge of GH is still observed with an increase in pYStat5 during fasting. This was 
a surprising result, as reported in a previous study, GHR mRNA levels in dwarf liver 
are significantly lower than in normal rats [364] so one might have expected there to 
be very low hepatic GH responses in dwarf rats during fasting compared to normal 
rats. However, hepatic GHR binding (i.e. protein level) in dwarf rats are similar to 
normal rats [364, 365]. Furthermore, although dwarf rats produce smaller amounts of 
GH, they still maintain a sexually dimorphic secretory pattern [301] and are very 
sensitive to low doses of GH. This would suggest that the GH deficiency doesn’t 
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affect the sensitivity of hepatic GH receptors to GH, and that dwarf tissue are adapted 
to low levels of GH occupancy and signaling. The reduction of hepatic GH response 
in both the normal and dwarf rats during fasting implies a reduction in GH binding, 
under these circumstances. This is in agreement with other studies that show that 
nutritional deprivation causes decreased GH binding in the liver [163, 365] in rats. 
 
Since hepatic GH receptors are sensitive to GH exposure patterns, another explanation 
for the observed GH response with such low levels of GH in dwarf rats could imply 
that hepatic GH receptors are sensitive to these differences in the plasma GH pattern 
at low circulatory GH concentrations. So the amount of GH required, to evoke a 
hepatic response in dwarfs to an acute pulse might be much lower than in normal rats. 
This would also imply that rather than simply the number of GH receptors, the level 
of GH response may be determined by other factors, such as the rate in which GH 
receptors become coupled to Jak2, or their turnover. The mechanisms involved in the 
down-regulation of the different components of the GH signaling pathway are not 
entirely clear, however, in fasted male rats GH stimulated JAK2 phosphorylation is 
severely blunted [162] with only a slight phosphorylated Stat5 signal being observed. 
Furthermore, over-expressed SOCS3 blunts Jak-Stat activation [366] and has been 
described in cases of fasting and GH resistance [367, 368]. It is also important to note 
that it is more difficult to assess the level of repression of endogenous GH response 
caused by fasting in dwarf rats, as the level of basal GH is already very low prior to 
fasting in these GHD animals. 
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 In the same experiments pretreatment with insulin prior to a GH challenge during 
fasting showed restored hepatic GH response in the liver of dwarf rats. It is well 
accepted that GH modulates tissue responses to insulin [133, 143]. GH deficiency is 
associated with increased insulin sensitivity, decreased insulin secretion and 
decreased fasting glucose concentrations [144, 145]. Nevertheless, it is remarkable 
that a single insulin pretreatment can reverse the inhibiting effects of fasting, despite 
continued nutritional deprivation. Insulin pretreatment in both the pregnant normal 
and dwarf rats was able to reverse the effects of fasting, showing an increase in the 
number of GH responding cells when given prior to GH. Some of the metabolic roles 
of GH promote gluconeogenesis and lipolysis, resulting in the release of glucose and 
energy sources to the body. I envisage there could be high demand for this during 
fasting in pregnancy, for fetal growth and maternal health. The direct effects of 
insulin are opposite to GH, in that it promotes the storage of glucose as glycogen in 
the liver, and inhibits lipolysis.  
 
The crosstalk of insulin and GH signaling via phosphorylated substrates could result 
in insulin enhancing GH-initiated signaling, resulting in the activation of GH like 
metabolism and a reduction in GH resistance. One explanation for the restoration of 
hepatic GH responses only in the dwarfs could be due to the increase in the 
abundance of insulin receptor (IR) in their liver, which could imply a receptor up 
regulation due to hypoinsulinemia. This is supported by a study that shows increases 
in insulin receptor abundance in GHR knockout mice [150]. In contrast, exposure to 
chronic GH excess leads to hyperinsulinemia, which in turn produces a down-
regulation of IR in liver, shown in transgenic mice over expressing GH [369]. I 
suspect that the restorative effect of insulin I observed during fasting is somehow 
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exerted on the cross talk between the GH and insulin pathways, rather than simply 
enhancing nutrient uptake, since fasting continued throughout any experiments. Both 
in vitro and in vivo studies show that GH can promote the tyrosine phosphorylation of 
IRS-1 and IRS-2 and their association with PI 3-kinase [146-149]. Furthermore, 
studies have also shown Stat5b to be a substrate for the insulin receptor [370]. Chen et 
al (1997) [371] identified Stat5b as a substrate of the insulin receptor using the yeast 
two-hybrid system and found that Stat5b interacts through its SH2 domain with 
receptor phosphotyrosine 960 localized in the cytoplasmic domain of the insulin 
receptor. The extent of such cross-talk could well depend on prevailing endogenous 
GH status, which might go some way to explain the dependence of this insulin effect 
during fasting on the GH status of the models used. For example the same 
observations made in the liver of normal pregnant rats showed that fasting had less of 
an effect in diminishing the hepatic GH response compared to non-pregnant fasted 
rats. Furthermore, hepatic GH responses were still evident in fasted pregnant dwarf 
rats.  
 
Many other factors could regulate this, one of which is estrogen, a major regulator of 
GH binding in the liver. Female rats have 2-3 fold more liver GH binding sites than 
male rats [365] with estradiol implants in male rats resulting in the increase of liver 
GHR expression and GH binding protein [114]. Estrogen production increases during 
pregnancy [372] and may result in an up-regulation of GHR expression in the liver, 
thus altering the effects of fasting in pregnancy. This could also be something 
particularly more pronounced in females as most experiments that have looked at 
GHR expression in fasted rats, report a reduction of GHR mRNA [161, 373]. It is 
unclear how estrogen and fasting would interact. 
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My results showed the placental response to GH in both normal and dwarf rats were 
sensitive to fasting. The reduction in GH response was particularly evident in the 
dwarf placenta, in which no new pYStat5 positive cells were seen following a GH 
challenge. Nutrition is obviously important for the progression of normal pregnancy 
[374] and the placenta has a central role in nutrient transfer, as well as being a source 
of IGF-1 production [375, 376], therefore I thought that nutritional restriction could 
potentially have potent effects on GH responses in the placenta. Under fasting, an 
interesting observation was that the level of signal recorded from responding cells, 
was generally more faint, compared to non-fasted animals. This was to be expected if 
the level of response to GH was reduced due to GH resistance. An explanation for the 
GH resistance observed in the placenta as well as the liver could be due to the down 
regulation of Jak2 initiated phosphorylation and the up regulation of suppressors of 
cytokine activity. A study by Miquet et al (2005) [390] showed a 3-fold increase in 
cytokine-induced suppressor (CIS) protein content in the liver of pregnant mice, 
compared to virgin animals. CIS has been implicated in the desensitization of GH-
Stat5b signaling by continuous GH levels [377] and has also been considered a post 
receptor mechanism partially responsible for hepatic GH resistance shown in the later 
part of rodent pregnancy, when elevated GH and hepatic GHR expression is 
accompanied with a reduction in hepatic IGF-1 production [313].  
 
It was important to test my results by fasting another rodent GHD species. Both 
normal and GH deficient (GRF-M2) pregnant mice showed a reduced GH hepatic 
response compared to non-fasted animals, however, both normal and GRF-M2 mice 
do still respond to an acute challenge of GH. An interesting observation was that 
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insulin in GRF-M2 mice (as in dwarfs rats) appeared to restore the GH hepatic 
response more markedly than in normal mice. This adds further support to my idea 
that reversibility of the effects of fasting by insulin on hepatic GH response could be 
more evident in a GHD background. Since insulin sensitivity is clearly elevated in 
conditions of low GH, it is more likely that the GHD rodents are more sensitive to 
insulin and thus the response to the pretreatment is more marked than in normal 
rodents whilst the GH response in the placenta of normal and GHD mice were lower 
than in to non-fasted animals, they were still able to show a response to an acute GH 
challenge.  
 
Interestingly, in both normal and GHD deficient mice the placental response to GH 
was blunted by insulin pretreatment. Insulin resistance in normal human pregnancy is 
a critical physiological adaptation designed to limit maternal glucose uptake, to ensure 
that an adequate supply of nutrients is shunted to the growing fetus [378]. The 
resistance of the placenta to insulin pretreatment in my results may be an example of 
this protective mechanism. Furthermore, transgenic mice over expressing human 
placental growth hormone in the liver show severe insulin resistance with insulin 
levels 4- to 7-fold greater than those in their wild type littermates [379]. On the other 
hand, I had to consider that I only used a single dose of insulin, and it may have not 
been as appropriate in the GHD animals as in GH intact animals. 
 
The hepatic GH responses in general were not so dissimilar between rats and mice. 
What stands out in my experiments is that the GH responses were reduced in pregnant 
GHD rodents during fasting compared to normal counterparts. This could be 
explained simply in the difference in their body size. The GHD rodents have smaller 
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body mass, less energy reserves compared to normal rodents. This difference could be 
another factor that dictates the severity of the effects of fasting, causing a higher level 
of GH resistance in a GHD background. Smaller animals generally have a higher 
relative body mass reduction during fasting compared to larger animals, normal mice 
show a 7% reduction in body mass, compared to 5% reduction in normal rats [380]. 
Another interesting finding in my results is that the placental response to GH was less 
affected by fasting in mice than in rats. This was a surprise to me as the smaller body 
size of mice led me to believe that the placenta would be more affected by fasting. 
Studies that assess the effects of fasting on placenta in different sized animals are 
scarce, but it appears that the placenta in my mice experiments was less affected by 
effects of fasting, at least in terms of acute pYStat5 response to GH. GHD mice have 
less food intake than normal mice, so restriction may have different effects on nutrient 
partitioning via the placenta, for the purpose of protecting the fetus from the effects of 
fasting. Is this why the effects of fasting appear less evident on the GH response in the 
placenta of GHD mice, compared to maternal liver? 
 
In summary, I have for the first time examined the effects of fasting on GH 
sensitivity, in the pregnant liver and the placenta of rats and mice. Furthermore, I 
showed that the administration of a single acute injection of insulin is able to restore 
the response to GH in these tissues under the continuing state of fasting in normal, but 
not GHD rodent placenta. This demonstrates the crosstalk between the GH and insulin 
signaling pathways, which in turn, could mediate the up-regulation of local IGF-1 
generation, counteracting the fall of IGF-1 caused by fasting and GH resistance. The 
system however, shows quite variable responses, and one key factor is the GH status 
in the different models, I used. 
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6. Placental gene expression in pregnant dwarf rats treated with 
continuous GH or acute GH injection: A preliminary Microarray 
study 
 
 
 
6.1 Introduction 
GH is thought to exert many of its effects on cellular metabolism, proliferation and 
differentiation by regulation of gene expression. My work so far has been limited to 
the initial events in the GH signaling cascade. For biological responses, clearly there 
must be downstream targets of the GH-induced pYStat5 response. Whilst it is 
possible that the range of effects on placenta may be similar to those in other tissues 
(e.g. metabolic, lipid mobilizing, protein anabolic, insulin antagonizing), in the time 
available, I decided to concentrate on a preliminary approach to identifying, potential 
initial direct gene targets for GH. The possibility to use microarray to explore 
expression data of thousands of genes, across a multiple of experimental paradigms, 
was the obvious route to pursue. Numerous microarray studies have already been 
carried out to analyze changes in gene expression in rat liver following GH treatment. 
Most of these experimental designs have focused on gender and the action of specific 
hormones on gene expression profiles [381-383]. I decided to use this approach to try 
to identify preliminary potential candidate targets for direct GH action in the placenta.  
 
In this chapter, I present my preliminary microarray data and analysis of gene 
expression profiles obtained for dwarf rat placenta, following administration of GH to 
pregnant GHD animals. Two objectives of this work were (i) to characterize the 
effects of GH on global gene expression in the placenta, and (ii) to try to identify GH- 
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responsive genes that might be sensitive to the GH secretory pattern. Many GH 
regulated genes have been identified from studies of liver tissue from rats deficient in  
GH, which have provided information on the consequence of a lack of GH on gene  
expression, highlighting candidate genes that may be directly or indirectly regulated 
by GH. Therefore using GH-deficient rats I manipulated the pattern of GH exposure, 
by continuous vs intermittent GH treatment in an attempt to identify genes responding 
to GH, in a pattern specific manner. Administration of continuous GH infusion to 
normal pregnant rats (likely having an continuous endogenous secretory pattern of 
GH) would create a state in which GH continuous signaling would be in excess. In 
these conditions, changes in gene expression would be a result of abnormally 
increased GH levels, rather than continuing pattern per se, but might have increased 
the chances of detecting weakly responding genes.   
 
I took three directed approaches to analyze my results, using both biased and unbiased 
approaches. First, I focused on genes known from the literature to be regulated by GH 
in other tissues. Second, I sought to identify genes in silico, reported to be expressed 
in placenta, to see if any had identifiable Stat5b response elements, as these could 
reasonably be direct targets for GH actions. Finally, I used standard software to 
identify those genes that showed the greatest change in response to GH (which could 
of course be secondarily affected by GH), using a more unbiased approach. 
 
6.2 Animals and experimental treatments 
 
Three groups of three pregnant dwarf rats were used, of which group 1 was the 
control, injected with saline only, group 2 received two individual intravenous 
injections of 100µg bGH/100g bodyweight, 24 hours apart, and group 3 received 48 
hour continuous bGH infusion by subcutaneous osmotic mini pump. The bGH 
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infusion was given at 200µg/day for 48hrs, as my previous experiments have shown 
that a 200µg/day infusion of GH is an adequate dose to achieve a pYStat5 response to 
GH in the placenta; this was also the dose previously used by Gevers et al (1996) 
[78]. The time duration for culling of 48 hours was set for all treatment groups, as it 
was considered a reasonable time to expect to see significant transcriptional changes. 
The bGH injected group 2, was treated with two acute injections of bGH, as I was 
concerned that the GHD state may require a first injection to activate the GH 
signaling cascade i.e. recruitment of transcription factors and phophorylation events, 
and thus the second injection might be predicted to activate more downstream events 
such as gene transcription, once the cells were primed with factors recruited with the 
initial GH injection. Finally due to cost constraints, I restricted the experiment to three 
animals per experimental group, which should be an adequate number to allow for 
some variation amongst individual animals but I hoped would still show the strongest 
consistent responses. Four hours after the final GH injection or 48hrs after infusion, 
animals were culled, placentae dissected and stored at -80 until RNA extraction was 
performed (see methods). Extracted RNA was sent to the array services at the  
Institute of Child Health, UCL, by Affymetrix analysis. Data files generated for gene 
transcript levels were then returned to me and initially processed by our local 
bioformatics expert, Dr A Sesay, who kindly assisted me with the analysis of these 
studies, using his expertise with GeneSpring software (GX 9.0).  Table 6.1 lists some 
well-characterized GH regulated genes and the evidence/studies that were the source 
of this data. It is important to note that the well-characterized GH target genes in 
Table (6.1) are widely diverse in their documented functions. I felt it possible that any 
identified genes to be responsive to GH in the placenta, may also follow a similar 
diverse trend of functions. 
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Table (6.1) Known GH- target genes identified in GH-deficient rat liver 
 
The lists of genes shown have been identified in the rat liver as a result of rapid increases in mRNA, following 
GH administration, (Mathews et al., 1986, Lemmey et al., 1997 and Ooi et al., 1997). Genes in bold have more 
recently been identified, also in the liver, to be upregulated by GH, (Barry et al., 2002). 
 
 
GENE APPREVIATION FULL NAME REFERENCE/FUNCTION 
IGF-1 Insulin-like growth factor 1 Mediator of the growth-promoting 
effects of growth hormone, Le-Roith et 
al., 2001 
IGFBP-3 Insulin-like growth factor 
binding protein 3 
Modulator of IGF bioactivity, Ferry et 
al., 1999. 
ALS Acid-labile subunit Stabilizer of IGFBP3/IGF complex in the vascular compartments and extends 
the half-life of IGFs in the circulation, 
Leong et al., 1992. 
FABP Fatty Acid Binding Protein Cytosolic proteins that enhance 
intracellular transfer of fatty acids and 
involved in the processes of fatty acid 
metabolism, Bennett et al., 1994.  
Spi2.1 Serine peptidase inhibitor, 
clade A, member 2.1 
Inhibitory actions on caspase-
independent cell death. 
EGFR Epidermal Growth Factor 
Receptor 
Cell signaling molecules involved in 
diverse cellular functions, including cell 
proliferation, differentiation, motility, 
and survival, and in tissue development, 
Wang et al., 2004. 
SOCS Suppressor of cytokine 
signaling  
Negatively regulate this signal 
transduction, Hilton et al., 1998. 
c-fos c-fos gene Growth related transcriptional control. 
c-fun Protooncogene - 
IRF-1 Interferon Regulatory 
Factor 1 
Regulation of type I interferon gene 
expression, Myamoto et al., 1988. 
HNF-α Hepatocyte Nuclear Factor-
1 alpha 
Required for hepatocyte-specific 
transcription of the genes, Courtois et 
al., 1987. 
Fibrinogen β   Blood plasma protein that plays a crucial role in hemostasis, Gonçalves et 
al., 2006. 
Gap130  Signal transducer, associated with JAK1, Lutticken et al, 1994. 
Stat3 Signal transducer and 
activator of transcription 3 
Transcription factor that plays a role in 
induction of gene expression during 
acute phase response, Akira et al., 
1994. 
p28MAPK - - 
GADD45 Growth Arrest and DNA 
damage –Inducible gene  
Involved in DNA replication and repair. 
APEN  - 
MTI-MMP Membrane type-1 matrix 
metalloproteinase 
Remodeling of tissue,  McCawley et 
al., 2001.  
 
MCT1 Monocarboxylate 
transporter 1 
Up regulation of transporters involved 
in brain metabolism, Cains et al., 2008 
18S Tetrapod ribosomal RNA  - 
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6.2.1 Micoarray data normalization and Quality control 
The initial part of the microarray analysis required normalization and quality control 
of all gene array data, combining the intensities of multiple probes within a probe set, 
across all chips into one measure of gene expression, and attempts to compensate for 
systematic technical differences between chips. My analysis used the PLIER 
algorithm, to generate a single summarized value for expression of genes represented 
on a chip by several probe sets, (comprising perfect match (PM) or mis-match (MM) 
probe sets). PLIER separately measures the strength of both (PM) and (MM) probe 
sets, applies dynamic weighting of the most informative value probes, resulting in a 
single value for each probe set, with the subtraction of (MM) probe sets. 
The advantages of PLIER, is (i) a higher reproducibility of signal (lower coefficient of 
variation) without the loss of accuracy, and (ii) it retains accuracy and higher 
differential sensitivity for genes with lower expression values.  
 
Using the integral Affymetrix GeneChip quality controls two separate assessments 
were performed: assessment of known hybridization controls on the chip, and a 
principle component analysis (PCA) to identify variation amongst replicate chips in 
individual experimental group. These are shown for my chip data in Figs 6.2 and 6.3 
Figure 6.2 shows the signal recorded for each individual control for all nine individual 
chips, showing very similar responses on all chips, with the same lowest signal 
(indicating assay sensitivity) as well as the same increase in signal, (reflecting the 
increase in the concentration of controls). This provided reassurance that (i)  
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hybridization to the chip was of high quality, and (ii) there was low variation in 
hybridization efficiency between chips. Figure 6.2 shows a screen shot of the PCA 
plot for all nine individual chips as separate data points. A color code identifies the 
two separate treatment and saline (control) groups. The data points were 
mathematically rotated in relation to one another to maximize the visibility of 
variability amongst the three separate groups. An ideal result in this display would 
show the clustering of replicates (colors) in individual treatment groups. Figure 6.2 
shows good clustering of individual data points in the groups treated with bGH 
injection or saline. The clustering for the data points in the continuous bGH treatment 
group is less obvious but still present. This may suggest a difference in the quality of 
samples in this dataset and not necessarily a true biological variation within the group 
and is thus a caveat. Nevertheless the consistency of these quality control tests was 
encouraging, and allowed me to proceed with analysis. 
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Figure (6.2) Hybridization controls plot 
 
The X-axis in this graph represents the controls used and the Y-axis, the log of the 
normalized signal values. 
 
 
Figure (6.3) Principle Component Analysis (PCA) plot 
 
The PCA components are numbered 1 and 2 according to their decreasing significance 
and can be interchanged accordingly between the X and Y-axis. 
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6.2.2 Microarray data analysis 
The rat 230 2.0 array used contains oligonucleotide probe sets corresponding to 95% 
of the rat genome. Figure 6.5 shows the distribution of the intensity of values of the 
probe sets within the three experimental groups (each group consists of 3 replicate 
chips), following normalization of data using PLIER. In this plot, normalized values of 
0 represent a baseline level of probe set intensity values, values greater than 0 
represent up-regulated probe sets, and values less then 0 represent down-regulated 
probe sets. The distribution of values was relatively tight indicating that the level of 
up regulated and down regulated genes was not vastly different between chip 
replicates. It is apparent that the group treated with saline shows values to be more 
widely dispersed when compared to other treatment groups, implying that some 
individual replicates in this treatment group are numerically more distant from the 
majority of data, in other groups. Again overall, this data suggests no major 
inconsistencies in the data sets. 
Figure (6.5) Box Whisker Plot for probe set values for individual treatment 
Groups 
 
The normalized and baseline transformed data are all centered around zero. The Y-axis represents normalized intensity values,  
X-axis shows each treatment group, which consists of three replica chips. 
   Saline 
bGH Pump 
 
 bGH Injected Saline 
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6.2.3 Filtering Data 
All microarray data sets provide huge amounts of data, and generally require filtering. 
I employed several criteria to generate lists of genes that appeared to be down or as up 
regulated, and I was also interested to observe which genes had changed expression 
differentially between the two GH treatment patterns. I first filtered the data to 
remove probe sets representing genes not expressed in any of my samples, using 
GeneSpring GX9.0. I chose an arbitrary threshold for the intensity of values obtained 
for each probe set at the 20th percentile. Values below this were considered as low 
intensity signals and largely (but not completely) represented genes that I thus 
“defined” as not significantly expressed.  The importance of removing these signals 
was to minimize the occurrence of false positives, but I am aware that low abundance 
transcripts could be missed. Larger significant changes in gene expression between 
groups were then identified using a one-way ANOVA. To assess the magnitude of 
change, a fold change analysis was also carried out on the probe set values, identifying 
differentially expressed genes, with a minimum fold change of 1.42. Again, any fold 
change below this value, was discarded, to reduce data load. Appendix 1 contains all 
the gene expression values from the three experimental groups. 
 
Strikingly, following comparative statistical analysis of gene expression values 
amongst the various groups, none of the GH-target genes identified in hepatic array 
studies had expression values that were statistically different in GH treated groups or 
even in some cases above the threshold fold change value (exact values are given in 
Appendix 2).  
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Although somewhat disconcerting for genes like IGF-1 that are known to be expressed  
in the placenta, it would appear that GH responsive genes in the placenta did not 
emerge as significant signals that have been described in the liver using this unbiased 
approach. Because this was unexpected, and I was concerned it could have related to 
too severe filtering, I nevertheless felt it of interest to see what changes, if any, 
occurred in the level of expression in some of these genes in the placenta even if only 
to document “negative” results.  
 
Placental gene expression values for three of these key GH responsive genes, in the 
three different experimental groups are shown in Figure 6.7 a-b. Figure 6.7a shows 
that expression of Stat5b was numerically higher in GH injected animals (0.084) 
compared to saline injected (0.033), this could be expected as pulsatile exposure of 
GH is documented to accompany Stat5b activation [61]. However, this is was not 
consistent within the group of GH injected animals. It was interesting that Stat5b gene 
expression values were lower in animals treated with continuous GH (-0.054) 
compared to both saline and GH injected groups, but there also was no consistency 
amongst the group. Figure 6.7b shows gene expression for IGF-1 in the three 
experimental groups. As discussed in chapter 1, IGF-1 is known as the classic 
mediator of the effects of GH, in the GH injected animals IGF-1 gene expression 
shows a steady increase (0.062) compared to saline injected animals (-0.090). In the 
continuous bGH treated animals there appears to be a huge increase in IGF-1 gene 
expression in one of the three animals (0.414) compared to both saline and GH 
injected groups but again it was not consistent in the others. Thus continuous GH 
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treatment could be effective in activating IGF-1 gene expression in the placenta, but 
my data does not allow me to draw this as a significant conclusion. This was 
disappointing, but was only a pilot study it should be repeated as it could be quite an 
important difference with respect to the liver. 
 
Figure 6.7c shows the gene expression for SOCS3 in the three experimental conditions.   
The Jak/Stat pathway activated by GH is negatively regulated by the suppressors of 
cytokine signaling (SOCS)/cytokine-induced suppressors (CIS) proteins [384, 385], 
CIS proteins have also been implicated in the desensitization of GH-Stat5b signaling 
by continuous GH levels [386], though the role of SOCS in conditions of continuous 
GH exposure is less clear. In this figure the most striking observation is the reduced 
expression of SOCS3 in all three animals injected with GH (-0.013), this implies that 
pulsatile reduces expression of this gene. In the continuous GH treated group the 
expressions of SOCS3 is less consistent amongst the animals but show strong up 
regulation in one (0.124), implying that continuous GH treatment is more effective in 
up regulating SOCS3 gene expression. 
 
Overall, the pooled data do not generate significant data for these targets, but with 
such variability, not obviously explained, it is premature to draw the conclusion that 
these genes are not targets for GH. Perhaps with more numbers of replicates, and 
attempts to make the experimental paradigms more consistent (or with different time 
points studied), different results might have emerged 
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Figure (6.7) Placental gene expression values for (a) Stat5b (b) IGF-1 and (c) 
SOCS3 in dwarf rats treated with saline, GH injections, or continuous GH 
(pump) treatment 
 
 
 
(a) 
(c) 
(b) 
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Examination of candidate genes known to be expressed specifically in the placenta, 
and to contain Stat5b response elements, also showed no statistical differences in 
expression amongst the treatment groups (expression values can be seen in Appendix 
2). This result can of course be affected by a number of technical and fundamental 
issues, which will be discussed later, but it would appear that this in silico approach 
did not provide me with the hoped for short-cut to experimentally manipulate directly 
GH responsive genes. Of course the presence of response elements does not 
automatically imply their use in any tissue, but this approach failed to outline any 
new GH targets in the placenta. I was therefore left with the third approach, 
identifying genes that were regulated by GH using an unbiased analysis of expression 
difference.  
 
All the differentially expressed gene data following the two GH treatments, compared 
to saline, and to one another, are summarized in Appendix 1. There were 19 
differentially expressed genes in the placenta of dwarf rats treated with continuous 
GH that showed a significant up regulation compared with the saline group. Placental 
gene expression in dwarf rats treated with GH injections showed a significant up 
regulation of a larger number (55) genes when compared to the saline group. Finally, 
comparison between the GH injected vs continuous GH treated groups showed 193 
genes to be differentially regulated. Genes showing the highest fold changes have been 
summarized in Tables 6.2-6.4. To attempt to cluster these genes in a meaningful way 
all genes showing differential expression were then analyzed using Ingenuity pathway 
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analysis, as this could help identify the canonical pathways that may be enriched in 
responding genes.  
The genes and their categorized functions for all three experimental groups are listed 
in Tables 6.5-6.7. As often the case, the list contained a mixture of potentially 
interesting, unknown, and unlikely candidates, and I would have needed to pick and 
confirm them by qPCR before attempting to speculate on their involvement. There 
wasn’t time to do this at the end of my practical work. 
 
Table (6.2) Differentially expressed genes from rat placenta for analysis based 
on GH injection vs saline injected (control) rats. 
GENE ABBREVIATION, NAME FUNCTION FOLD CHANGE 
RGD1306603 predicted Transcribed locus 2.80 
Dscr1, Down syndrome critical region homolog 1 - 1.74 
Man1c1, Manosidase - 1.67 
Pcdh21, MT-protocadherin 
 
- 1.65 
Tubb6, Tubulin 6 
 
 
- 1.64 
Rn.212222 
 
- 1.57 
RGD1308967_predicted - 1.53 
Grtp1 - 1.52 
Rn.24461 
 
- 1.52 
Capn8 - 1.52 
Rn.205554 - 1.46 
Fxyd6 Encodes the protein 
phosphohippolin and is part of a 
family of 7 FXYD genes 
(Kadowaki et al., 2004) 
1.45 
Klf2_predicted - 1.45 
Uhrf1, Ubiquitin-protein like containing PHD and 
ring finger domain 1. 
- 1.44 
Abcb1a  - 1.43 
Tagln, Transgelin Expressed exclusively in smooth 
muscles. 
1.43 
Bok, BCL2-related ovarian killer Highly expressed in the ovary. 1.43 
Rn.146945 - 1.43 
Atf3, activating transcription factor 3 Member of the mammalian 
activation transcription 
factor/cAMP responsive element-
binding (CREB) protein family of 
transcription factors 
1.41 
Slc7a1, solute carrier family 7 - 1.41 
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Table (6.3) Differentially expressed genes from rat placenta for analysis based 
on GH continuous treated vs saline treated (control) rats. 
 
Table (6.4) Differentially expressed genes from rat placenta for analysis based 
on GH injection vs GH continuous treated rats. 
GENE SYMBOL, NAME FUNCTION FOLD CHANGE 
Gap43, growth associated protein 43 Crucial component of an 
effective regenerative 
response in the nervous system 
4.83 
Arl4a,ADP-ribosylation factor-like 4A - 2.71 
Hsd11b2,hydroxysteroid 11-beta dehydrogenase 2 Glycoprotein enzyme-type II, is 
expressed predominantly in the 
kidney and placenta and 
catalyzes only the 11-beta-
dehydrogenation reaction 
2.29 
Mllt3,myeloid/lymphoid or mixed Highly expressed in normal 
hematopoietic stem cells. 
2.02 
Ampd3,adenosine monophosphate deaminase 3 Plays an important role in the 
purine nucleotide cycle. 
2.01 
Cuzd1,CUB and zona pellucida-like domains 1 - 2.01 
Add2,adducin 2 (beta) Role in assembly of the 
spectrin-actin lattice that 
underlies the plasma 
membrane. 
1.95 
Stag3,stromal antigen 3 High expression in zygotene 
cells and moderate expression 
1.94 
GENE SYMBOL, NAME FUNCTION FOLD CHANGE 
Hbe1_predicted, hemoglobin-epsilon locus Determines the epsilon, or 
non-alpha, chain of 
embryonic hemoglobin 
(originally known as Gower-
2) 
2.23 
Hbg1, hemoglobin gamma A Identified STAT3-like 
binding sequence in the 
promoter of gamma-A, 
(Foley et al.,2002) 
1.55 
Transcribed locus - 1.52 
Hpgd, hydroxyprostaglandin dehydrogenase 15 (NAD) Catalyzing the conversion of the 15-hydroxyl group of 
prostaglandins into a keto 
group. 
1.46 
Spna1, spectrin alpha 1 - 1.44 
Prl2b1/ PLP-K, Prolactin family 2 or Prolactin protein-K A member of the rodent 
prolactin family.  
1.41 
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in pachytene cells. 
Pklr,pyruvate kinase PKLR gene encodes pyruvate 
kinase a glycolytic enzyme that 
catalyzes the 
transphosphorylation from 
phosphoenolpyruvate (PEP) to 
ADP, yielding pyruvate and 
ATP. It is the last step of the 
glycolytic pathway and is 
essentially irreversible. 
1.92 
Ucp2,uncoupling protein 2 mitochondrial Glucose metabolism 1.91 
Hpcal1,hippocalcin-like 1 Hippocalcin-like protein 1.89 
Amelx,amelogenin X chromosome Highly conserved proteins 
secreted by ameloblasts, and 
constitute 90% of the enamel 
organic matrix 
1.87 
Gja1,gap junction protein Expressed in liver, (Li et al., 
1995) demonstrated that 
GAP43-like immunoreactivity 
in rat is mainly present in 
sympathetic and sensory nerve 
fibers as well as in perivascular 
nerve terminals. This peptide is 
axonally transported 
predominantly in sensory and 
adrenergic axons. 
1.86 
IL10 Interleukin 10 Involved in inhibiting the 
production of Th1 cytokine 
production (IFNγ, TNγ, & IL2). 
1.85 
Il18, interleukin 18 Involved in the development of 
Th1 cells and also in 
mechanisms of tissue injury in 
inflammatory reactions 
1.85 
Fxyd6,FXYD domain-containing ion Encodes the protein 
phosphohippolin and is part of 
a family of 7 FXYD genes 
(Kadowaki et al., 2004)  
1.85 
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Ak1,adenylate kinase 1 Muscle development in mice, 
(Jansson et al.,2000) 
1.81 
Prolactin family 2 - 1.75 
Mpst,mercaptopyruvate sulfurtransferase Catalyzes the transfer of a 
sulfur ion from 3-prime-
mercaptopyruvate 
1.75 
Nr1d1,nuclear receptor subfamily 1 Provide a direct link between 
signaling molecules and the 
transcriptional response 
1.75 
Hbz,hemoglobin-Zeta Locus Zeta is an early embryonic 
chain which is substituted for 
the alpha chain in Hb Portland-
1. 
1.75 
 
Table  (6.5) Up regulated placental genes from dwarf rats treated with 
continuous GH and enriched pathways 
 
 
 
 
 
 
 
 
 
 
GENE DESIGNATION COMMON NAME  CATEGORY/FUNCTION 
HPGD Hydroxyprostaglandin 
Dehydrogenase 
Cell growth proliferation/ 
Lipid metabolism 
HBE1 Haemoglobin epsilon 1 Organism survival 
HBZ Haemoglobin Zeta 
chain 
Organism survival 
BBC3 BCL2 binding 
component 3 
Cell morphology 
 222 
Table  (6.6) Up regulated placental genes in GH injected dwarf rats and enriched 
pathways 
 
 
Table  (6.7) Up regulated placental genes in continuous GH vs GH injected 
dwarf rats and enriched pathways 
 
GENE DESIGNATION COMMONE NAME CATEGORY/FUNCTION 
IL10 Interleukin 10 Molecular 
transport/canonical pathways 
IL-1 Interleukin 1 Canonical pathways 
NKαB  Canonical pathways 
IL-18 Interleukin 18 Molecular 
transport/Canonical pathways 
NFKBZ Nuclear factor kappa B Cell morphology 
ADDZ  Adducin 2 Molecular transport 
GAP1 Ras p21 protein activator 3  Molecular transport 
GAP43 Growth associated protein 43 Cell morphology 
HBE1 Haemoglobin epsilon 1 Organism survival 
HBZ Haemoglobin Zeta chain Organism survival 
FYN FYN tyrosine kinase 
protooncogene 
Cell morphology 
DCN Decorin Cell morphology 
AK1 Adenylate kinase 1 Cell morphology 
 
 
GENE DESIGNATION COMMON NAME CATEGORY/FUNCTION 
GJA1 Gap junction protein 1 Cell growth and proliferation 
KLF2 Kruppel factor 2                       “ 
UHRF1 Ubiquitin-like protein 
containing PHD and 
ring finger domains 1.  
                      “ 
ATF3 Activating 
transcription factor 3 
                      “ 
IL18 Interleukin 18                       “ 
MLLT3 Myeloid/lymphoid or 
mixed lineage 
leukemia, translocated 
to 3 
                      “ 
ADD2 Adducin 2                       “ 
RCAN1 Regulator of 
calcineurin 1 
                      “ 
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6.3 Discussion 
Oligonucleotide-based microarrays were used in my experiments to attempt to 
characterize placental gene expression in relation to GH secretory pattern. 
Traditional methods of analyzing GH regulated genes in microarrays have mainly 
employed GH deficient rodent models e.g. hypophysectomized rats, and have 
identified a number of genes (Table 6.1) as being dependent on GH for expression 
[381, 387] mainly in the liver. Other GH liver expressed genes include the GH 
dependent CYP enzymes, which are regulated by GH in a complex fashion, highly 
dependent on the temporal patterns of plasma GH [48]. DNA microarray analysis has 
been used to identify genes in rat liver that show sexual dimorphism [388]. 
Furthermore, microarray analysis has also outlined the important role of Stat5b in 
regulating the expression of these sex dependent liver genes [389].  
 
Given the time left for these studies, my goal was quite modest, to obtain a 
preliminary view of the placental gene expression responses to GH, and in particular, 
to ascertain whether GH, or its pattern of secretion is a major regulatory factor in gene 
expression in a newly identified GH target tissue. My findings failed to demonstrate 
that known GH target genes as well as genes containing Stat5b binding sites, known to 
be expressed in the human and rat placenta were differentially expressed in either GH 
injected or continuous GH treated animals.  
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There could be several reasons for this. Assessment of some of the expression values 
obtained for known (liver) GH target genes in the placenta, although not reaching 
statistical significance appeared interesting. Stat5b is directly activated in male rat liver 
in response to each incoming plasma GH pulse, whereas in female rats, the persistence 
of plasma GH stimulation leads to an apparent partial desensitization of the Stat5b 
signaling pathway and substantially lower nuclear Stat5b protein, compared to males 
[61]. What I might have expected was a increase in Stat5b gene expression in animals 
treated with single injections of GH compared to continuous GH, however, as well as 
not reaching the threshold set for significant expressional change, the values obtained 
in my results were also not consistent amongst animals. It could of course simply 
reflect that the main effect is on Stat phosphorylation, not Stat transcription. 
 
My results do highlight the importance of subject number in experimental groups 
Although, I showed the placenta to be directly responsive to GH with Stat5 activity 
(chapter 4), this does not imply that each animal will have the same level of Stat5b 
gene expression or protein turnover and thus show the same level of response to GH 
as one another, nor even how effective the Stat5 pathway is in placental cells. A major 
limitation was my decision to pick a single time point. With hindsight, it might have 
been better to try to run pairs of treatments at two time points, as I could have missed 
the peak mRNA changes. For example an experiment, using qPCR to obtain a time 
course for one target such as IGF-1 might have pinpointed a more optimal time. 
 
 225 
As discussed in chapter 1, IGF-1 is best known for mediating the effects of GH, and 
microarray studies in hypophysectomized rats show GH administration rapidly 
induces mRNA encoding IGF-1 [387]. Although not significant, my results show a 
steady increase in IGF-1 levels in GH injected rats, and this expression change tended 
to be higher in animals treated with continuous GH. In human pregnancy GH is 
shown to correlate with IGF-1 plasma levels [230] in rodents however, the continuous 
GH secretion from the pituitary is associated with lower IGF-1 plasma levels [173, 
311, 312]. 
 
However, it is important to remember that IGF-1 gene expression values shown in the 
placenta of rats treated with a 48-hour continuous GH pump, are only representative 
of a single time point following the 48-hour treatment. It is possible that the long-term 
effects of continuous GH treatment may be reflected in IGF-1 gene expression in later 
parts of pregnancy. Furthermore, it may also be probable that the continuous GH 
treatment of pregnant rats may have differentiated effects in different tissues i.e. 
showing a up regulation of IGF-1 in the placenta, which may have local effects, whilst 
inducing the down regulating of hepatic IGF-1 gene expression. Unfortunately, since 
these trends were not significant, in my data, I prefer not to put too much emphasis 
on this data. Gene expression for SOCS3 was low in the placenta of animals treated 
with both GH injection and continuous GH treatment. Since Jak2-Stat activity is 
initiated by a pulsatile GH pattern, a low level of SOC3 gene expression would have 
been expected in the GH injected animals, with possible high levels of expression in 
animals treated  
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with continuous GH. A study by Miquet et al (2005) [390] also reports a decrease in 
liver SOCS3 content in GH over expressing pregnant transgenic mice. These results 
imply, as in the liver, that SOCS3 may not be directly involved in the desensitization 
of the Jak-Stat pathway induced by continuous GH exposure in the placenta, at least 
at a transcriptional level. 
 
Due to the lack of significant change in Stat5 gene expression, I am unable to draw any 
firm conclusions about regulation of this gene in the placenta. It is possible that gene 
expression changes expected in response to GH may have been diluted amongst a high 
level of background, owing to non GH responsive cells in the placenta, unlike in the 
liver. Genes containing Stat5 response elements may be expressed only in a minority 
of specific cell types that make up some of the RNA, which could have contributed to 
clearer observation of small changes in gene expression. However, observing placental 
gene expression in isolated cell types may not be physiologically representative of 
what happens in the placenta. Furthermore, there could also be negative implications 
in gene expression when isolating cells from other near by cell types. Whatever the 
reasons, this approach via in silico “targeting” of Stat5 potential regulated genes did 
not provide me with the short cut to Stat5 regulated targets in my study. 
 
Although many sex-dependent liver genes are regulated by sex differences in pituitary 
GH secretion [301] such roles of GH secretory patterns in placental gene expression 
have never been shown, and although I have shown the pYStat5 response in the 
placenta to be sensitive to GH secretory pattern, this may not necessarily be 
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implicated in the expression of the same genes known to be pattern sensitive in the 
liver. It is also important to note that only one time point after both GH injected and 
continuous GH treatment was assessed in the placenta. It is quite possible that this 
specific time point may have not been adequate in observing the higher end of 
transcriptional changes in the placenta, since GH and IGF-1 levels progressively 
change during both human and rodent pregnancy. Finally, because in my studies, I 
identified GH response in the placenta by visualization of Stat5 activity, I hoped that 
genes with Stat5b response elements might show changes upon GH administration. 
However, its important to consider in this new GH target tissue, that there may be 
several other GH activated signal transduction pathways. Therefore, a number of 
genes transcriptionally responsive to GH, that emerged in the unbiased approach may 
not be directly regulated by Stat5 or indirectly regulated by other transcription 
factors, or even affected by other pathways such as AKT or MAPK. Thus, I was left 
with analyzing the genes that did show statistically significant changes in response to 
GH, from the unbiased approach.  
 
Administration of GH in the two secretory patterns did up-regulate several genes, of 
which some responded in common to both secretory patterns. The majority of these 
genes have unknown functions. All of the differentially expressed genes were also 
analyzed using enrichment pathway analysis, which resulted in some of the genes 
being categorized in several canonical pathways, as well as functions. However, 
possible involvement in growth or metabolism remain unclear due to a lack of 
experimental documentation, and whilst some are interesting (e.g. IL-10) others are 
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likely not to be very relevant (e.g. Hippocalcin-like protein). In all cases, to take this 
further I would need to confirm those changes independently in replicate experiments 
and by qPCR, and before attempting this it would be further beneficial to first check 
different time points. This would be a major study. 
 
My results do show that the Hydroxyprostaglandin Dehydrogenase (HPGD) gene is 
statistically up regulated in animals treated with continuous GH treatment compared 
to saline. The HPGD gene is expressed in the human placenta and its main function is 
to regulate contractility of the myometrium [391]. This gene has also been correlated 
with cases of pre-eclampsia, in which gene expression is reduced [392] if this is 
confirmed it might imply a potential role of continuous GH secretion in the regulation 
of a genes important for the progression of pregnancy to term. Also in the continuous 
GH treated group, there was a significant fold change in prolactin protein K (PLP-K). 
Rat PLP-K is part of the rodent prolactin family [393]. PLP-K expression is restricted 
to trophoblast cells within the labyrinth zone, expression has been reported to be 
initiated in trophoblast giant cells at midgestation and then extended to 
spongiotrophoblast and labyrinthine trophoblast cell types as gestation progressed 
[394] however, the nature of its physiological actions remain unclear. 
 
Interestingly, a member of the interleukin family is up regulated in animals treated 
with GH injections, compared to animals treated with continuous GH. Interleukin 10 
(IL-10) is involvement in the regulation of Jak-Stat signaling pathway [395] and has 
the potential role of activating other cytokine initiated pathways independent of 
Stat5. Stat3 was originally discovered as a factor activated by IL-6 through gp130 
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receptor [396]. However, Stat3 is also documented as being essential for the actions 
of IL-10 [397]. The importance of Stat3 in embryonic development is emphasized 
with the deletion of Stat3, resulting in embryonic lethality due to placental 
insufficiency in leukemia inhibitor factor (LIF) signaling [398]. Mice in which Stat3 
is deleted in a tissue and cell specific manner have been generated [398]. These mice 
have revealed critical roles of Stat3 in liver acute phase responses [399]. A study by 
Cui et al (2004) [400] also shows that the loss of STAT3 in the hypothalamus caused 
by RIP-Cre action interfered with normal body weight homeostasis and glucose 
metabolism. Thus, GH secretory pattern may be important in initiating other signal 
transduction pathways, independent from Stat5, which may be of great importance in 
the survival of a fetus from an early embryonic stage. Again, such speculation 
requires further confirmation of changes. 
 
In summary, a preliminary study to identify potential GH target genes in the placenta 
was justified on the basis that the placenta was (a) responsive to GH and (b) 
expressed genes known to contain Stat5b response elements. However, despite no 
known GH targets or genes containing Stat5b response elements showed statistical 
expressional change in response to GH or a change in secretory pattern, new genes of 
which a few, pose as potential candidates that could have some importance in growth 
during pregnancy. These results act as preliminary data that could prove useful if 
future, more thorough studies were to be performed.  
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7. General discussion 
I have discussed the detailed results in each chapter, so will finish with more of an 
overview of the work I accomplished. The characterization of a human growth 
hormone variant (GH-V) [227] whose sole source of production is the placenta [202] 
has provided another endocrine source of GH for systemic actions in the mother. 
However, evidence that the human GH receptor is also expressed in the placenta [229] 
raises the interesting question of whether the placenta itself could be a direct autocrine 
or paracrine target of growth hormone, as it is well recognized as a complex 
endocrine organ that mediates a number of events in adaption of maternal tissues to 
pregnancy. GH in the placenta could be acting constituting in an autocrine or 
paracrine fashion, and subject to regulation. Despite much circumstantial evidence for 
association between GH levels and various functions most of these were not related to 
placenta as a target. Thus all the evidence for this before I started my thesis work was 
indirect. 
 
My primary aim was to establish at a cellular and tissue level, whether there were 
cells directly responsive to GH in the placenta. The results I obtained were generated 
from both normal and rodent models of GH deficiency, characterized by others when 
I joined the Robinson lab. The advantage of using these well-characterized models of 
GH deficiency was that I was able to observe the direct effects of administered GH 
without the interference of existing GH. This also avoided creating conditions of 
excess GH, which would have otherwise lead to the problem of not being able to 
clearly define the effects of the GH being administered from the effects caused by a 
more pathological condition created with an excess of GH. Nevertheless it was 
important to me to confirm that results I obtained in these GHD models would be 
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reproduced in principle, in intact models. Using GH deficient rodent models gave me 
the possibility to vary the pattern of GH administered, to assess the changes in cellular 
response with the changes in GH secretion pattern in the placenta. Finally, using both 
rat and mouse models of GH deficiency enabled me to assess more than one rodent 
species. 
 
An obvious question is how relevant my observations in rodent pregnancy may be to 
humans. There is no ideal model for human pregnancy other than humans, however 
mice and rats have the practical advantage of having short generation times and large 
litters. Indeed, in choosing appropriate models for human pregnancy, one criteria 
might be how close they are to humans from a phylogenetic standpoint, the mouse 
appears to be reasonably close to primates, this is strongly supported by molecular 
phylogenetics reviewed by Springer et al (2005) [401], though this has been 
questioned by reports of unusually high rates of mutation [402]. Analogous cell types 
have been identified among human and rodent placenta, particularly in the 
trophoblastic linage including proliferative trophoblastic cells, invasive trophoblastic 
cells and cells differentiating into syncytium [274, 275, 403, 404]. 
 
One of the major differences in the human and rodent placentas lies in the difference 
in their endocrine function. In mouse, progesterone production by the corpus luteum 
is required throughout gestation [405] this is regulated in the first 8-9 days by mouse 
pituitary prolactin [406]. From around day 11 of gestation, mouse placental lactogen 
produced by the trophoblastic giant cells take over from pituitary production of 
prolactin. The lack of mouse pituitary requirement during late pregnancy is supported 
by studies that show the successful progression of pregnancy following 
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hypophysectomy in mice performed after day 11 [405]. In humans also, the pituitary 
gland is not required for the initiation or maintenance of pregnancy. Maintenance of 
the corpus luteum depends initially on hCG production by trophoblast cells, and after 
8 weeks of gestation, placental progesterone production by the syncytiotrophoblast 
cells is sufficient to maintain pregnancy even in the absence of ovaries [407, 408]. A 
more important difference for me, in human and rodent placental endocrine function, 
is the lack of any placental source of GH in rodent pregnancy. Such endocrine 
differences between rodent and human placenta may reflect the great fundamental 
difference in gestation length and the birth of altricial young in rodents. Many of the 
developmental processes that occur in humans during intrauterine life are postnatal 
events in rats and mice, so these timings are not strictly comparable.  
 
Taking into consideration the absence of a placental source of GH and the large 
production of placental lactogen by the rodent placenta, it is difficult to outline the 
possible functions of GH during rodent pregnancy. However, there is evidence that 
has shown the presence of GH receptors in both fetal and maternal compartments of 
the rat placenta [332] providing circumstantial evidence for the idea that the rodent 
placenta could be a direct target for GH. Furthermore, although the somatomedin 
hypothesis [85] favors the notion that most actions of GH is classically thought to be 
mediated via IGF-1, it is now recognized that GH has direct actions via the GH 
receptor, in a number of tissues [409]. When I began my thesis, work what was 
missing was a direct demonstration of GH activity. Since Gevers et al in the lab had 
produced a method that was suitable to the task, my main aim was to use this to obtain 
the direct evidence for a direct GH action in the placenta. My results showed this is 
indeed the case. 
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The secretion pattern of pituitary GH in pregnant rodents has been shown in several 
studies [81, 225, 226] to mimic the secretion pattern of GH-V in human pregnancy. 
The identification of GH receptors in the rat placenta and the documentation of such a 
GH secretory pattern change provided some evidence to suggest that the rodent 
placenta may act as a direct target of GH and be potentially involved with indirect 
mechanisms that may be favored by a more continuous pattern of GH. Thus, using a 
rodent GHD model with GH replaced in different patterns would be appropriate to 
shed some light on the possible functions of GH-V during both rodent and also human 
pregnancy and more importantly the possible importance of the GH secretory pattern 
change. 
 
At the start of my thesis plan, I wished to see if I could obtain preliminary evidence 
for this in human placental cells in vitro. This would bridge the species gap and 
perhaps led to early optimization of GH responses. Unfortunately, I was unable to 
detect any endogenous GH or GHR in either of the placental cell lines used, despite 
previous documentation [282]. Furthermore, although the placental cell lines were 
shown previously to be transfectable [292], my attempts to supply the cell lines with 
components of the GH signaling cascade (GHR and Stat5b constructs) resulted in 
minimal cell survival and inability of few surviving to respond to exogenous GH 
administration. These results proved likely to be a lack of appropriately differentiated 
cell type, since I readily obtained GH responses in Hep2 cells with the same method. 
A major frustration was that my original hope for in vivo studies was to use a mouse 
transgenic line already reported to produce an autocrine source of hGH in the placenta 
[410]. In hindsight, it would have been quicker to re-make the CYP19-hGH mouse, 
rather then wait for it to arrive (there were numerous difficulties in the Mendelson 
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lab), but by the time it was evident that this mouse model was not going to arrive in 
time for me, I decided it was too late to make my own transgenic. This would still be 
an interesting model to pursue, perhaps also using GH antagonist [411] to interrupt 
endogenous signaling in this mouse. 
 
In order to define responses to GH I wanted to exploit a method that would 
unequivocally identify activation of the GH signaling pathway. Using 
immunohistochemistry I was able to directly reveal individual nuclei that responded 
with Stat5b phosphorylation and nuclear translocation to a single acute injection of 
GH. This was shown for the first time in both the rat and mouse placenta. The 
reliability of this method is supported with previous studies, which have used this 
experimental approach to identify GH responding cells in a variety of other tissues 
(e.g. cartilage, liver, fat, heart, and muscle) [291, 412]. It has proved better than Jak2 
or other kinase markers (Gevers, personal communication). The response shown in the 
placenta following bGH is likely to be via the GHR. In rodents bGH binds only to GH 
receptors, while the use of human GH would show binding to both GH and PRL 
receptors [413]. This study by Kopchick showed that all analogues of bGH show 
ability to bind to GH receptors and exhibit somatogenic activity in vitro and in vivo. 
However, none of these bGH analogues show binding to PRL receptors or elicit 
detectable lactogenic response. However, there are a number of things that should be 
kept in mind when considering immunostaining of phosphoStat5 in GH signaling in 
the placenta. Firstly, this method only identifies Stat5 responses in cells, this doesn’t 
imply that the remaining cells not showing Stat5 phosphorylation are unresponsive to 
GH. There could be a number of pathways in the placenta that are activated by GH 
e.g. MAPK/ERK pathways, so several other methods would be needed to completely 
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dissect and outline the full repertoire of potential GH activated pathways in the 
placenta. Second, tissues were obtained only on day 16 of gestation, this day was 
chosen as it’s the time point in which GH levels peak in normal rodents [62]. It was 
therefore considered a time point in which tissues could be expected to be most 
sensitive to GH, thus chosen as the day to administer GH. However, day 16 of 
pregnancy may not be the peak time of phosphoStat5 responses. Nevertheless, a clear 
marked activation of Stat5 was shown in both the placenta and the positive control (liver) 
compared to saline injected control animals. Again, other cells could be responding at 
different times, and in future studies it could be interesting to determine when the 
placenta first shows GH responses. 
 
The level of response in all tissue sections was assessed using a novel quantification 
method. My analytical approach identified individual responding nuclei as well as 
calculating the level of response by individual staining intensity. As discussed earlier, all 
semi-automated methods tend to involve some compromise in settings. For example the 
thresholds set to exclude any non-specific or background staining may have been 
marginally too stringent or wide, allowing the discarding of some responding cells, or 
creating some false positives. There were large differences in background and non-
specific staining observed in some individual animals, therefore making it very difficult 
to apply arbitrary margins to all individual tissue sections. Despite these limitations the 
analysis showed significant difference between GH and the different doses 
administered, compared to saline injected animals, and was much more practical than 
subjective visual analysis of all the sections. 
 
To further demonstrate the direct action of GH, it was considered important to show the 
expression of GH receptors in the rat and mouse placenta. Although this has already 
been reported in rodents [414] and humans [229] I was unable to show any 
reproducible localized GHR expression in either the rat or mouse placenta using my 
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reagents. The antibody used has been designed to recognize the extracellular part of the 
human, rabbit, and rat GH receptor [22]. However, my protocol was probably not 
sensitive enough, particularly in cases of low GHR expression. In the case of the 
placenta there is no evidence to suggest the levels of GHR expression are higher or 
lower, compared to other tissues, but I believe that there was too little GHR expression 
to be detected by this antibody and method in hand.  Previous attempts to show GHR 
expression in other mouse tissues has been quite difficult, though data has been 
successfully reported for the growth plate [291]. The ability to detect antigen is 
dependent on the protein digestion step used in the immunhistochemistry protocol, as 
well as the method adopted to fix the harvested tissue. Despite several attempts to 
optimize these steps for placenta no improvement was observed in GHR staining.  
 
The effects of GH on the expression of many hepatic GH-dependent genes are known 
to be highly dependent on the pattern of exposure for the stimulation of growth in 
rodents [50, 362] and humans [415]. In rodents, this has been directly linked to the role 
of Stat5b, as deletion of the gene has resulted in compromised pattern of male-specific 
growth and expression of genes responding to pulses of GH [36]. In female rodents, 
GH secretion pattern is more continuous, this continuous GH secretory pattern is more 
pronounced during both rodent [81] and human pregnancy [219, 220], and generates 
different patterns of gene expression [37, 61]. I therefore decided to look at the effects 
of continuous GH exposure on Stat5b per se, and how such pre-exposure might alter 
the effects of a GH pulse. Given that in pregnancy, the predominant GH pattern is 
continuous, continuous GH infusion did increase the number of nuclei exhibiting 
phosphorylated stat5b under basal conditions, in both liver and placenta from rats and 
mice, but it tended to desensitize the system as there was very little difference when 
animals were given a further injection saline or GH. Overall, however, my results 
support previous studies that have used GH deficient rodents models to demonstrate the 
differential effects of GH on Stat5b [78, 362, 416] as well as confirms previous studies, 
which have also shown that continuous GH secretion blunts the acute effects of GH on 
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pYStat5 signaling [291, 412]. Although these findings demonstrate that continuous 
pattern of GH exposure can still evoke GH initiated Stat5b phophosphorylation in the 
placenta, its quite clear that this pattern of GH exposure is not best at revealing an acute 
effect of GH on pYStat5. Again it is important to recall that Stat5b mediated pathway 
may not be the only GH initiated pathway taking place in the placenta, as in other tissues 
[39]. It is possible that GH-GHR activation of Stat5b may be involved in activating more 
downstream targets that are then implicated in pregnancy, and of course IGF-1 will have 
Stat5 independent activities, with the known relationship between continuous GH 
secretion and circulating IGF-1. Continuous increasing GH exposure could alter the 
balance between direct and indirect (IGF-1 mediated) GH actions during pregnancy, and 
desensitize the tissue to acute changes in GH signaling. My result does not rule out the 
possibility that GH can also act indirectly (e.g. via IGF-1) on the placenta.  
 
 
In humans this could be via local paracrine activation of placental IGF-1, or via the 
circulation to elevate hepatic production. The pattern of GH secretion can also be 
important in the regulation of GH receptor expression itself in different types of tissues, 
which in turn, can regulate GH initiated pathways involved in pregnancy. This is 
supported with studies by Iida et al  (2004) [417] which have shown that excess GH in 
transgenic mice leads to increased levels of GH receptor expression in the liver but a 
decrease in expression levels in muscle tissue. However, no study has yet to report 
changes in GH receptor expression in the rodent placenta during pregnancy, and my 
results suggest this could be worth investigating, once GHR can be reliably detected. 
GHR expression and signaling is known to be reduced in fasting animals [80, 349] my 
findings also confirmed reduction in GH signaling via pYStat5 in both the liver and the 
placenta of animals fasted for 48 hours.  
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Remarkably, a single acute injection of insulin some hours prior to GH was also shown 
to restore a significant level of GH signaling in both the liver and placenta, even whilst 
fasting continued. I suggest that this is a direct effect of insulin independent of 
nutritional uptake, and suggest that signaling cascades may be able to integrate with the 
GH signaling pathway, thus potentially regulating metabolic activity of the cell. GH has 
been shown to regulate the IRS cascade directly via IGF-1 and also act indirectly on 
insulin signaling, [418]. This crosstalk of the GH and insulin signaling pathways, if it 
occurs in placenta, may be important in regulating an important balance between growth 
and metabolic responses. My results suggest the crosstalk with the insulin signaling 
pathway may be more important in cases of low GH, in which it could activate the 
metabolic reserve of the cell, enhance to the Stat5 signaling cascade and GH action. The 
cross over of the two pathways could also be debated in cases of excess GH, since 
insulin resistance is a hallmark of Type 2 diabetes in which high GH levels are 
ineffective. The importance of such a balance between the two signaling pathways could 
be implicated in cases of gestational diabetes, and the potential role of GH-V thus 
warrants further investigation [419, 420]. 
 
Finally, what might be the physiological role of placental actions of GH? Although I 
have shown the placenta to be a direct target of GH and sensitive to GH secretory 
pattern, I haven’t attempted to show any downstream effects, and how GH is implicated 
in pregnancy functionally is far from understood in any species.  My data in GH 
deficient models reveal some differences in the outcome of pregnancy in the absence of 
GH, when compared to normal rodent pregnancy, particularly in mice with a significant 
reduction in the number of pups born to each litter in both dwarfs and GRF-M2 mice. It 
is not clear how this would be directly caused by a lack of GH. It may be more likely to 
be the physiological deficits within the mother as a result of the absence of GH, but 
further experimental approaches will be needed to explore this further in animals. 
Contrasting findings in my results were seen in the individual pup weight data. Pups 
born to dwarfs showed similar weights to pups born to normal rats, however, pups born 
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to GRF-M2 mice showed a significant reduction in weight, compared to pups born from 
normal mice. It is well documented however that the direct actions of GH are not needed 
for fetal growth, as Laron dwarfs that have no functional GH receptors are born with 
normal weights [99]. Therefore, the reduction observed in pup weights could more likely 
reflect effects in the mother, affected by the GH deficiency, resulting in varied 
physiological changes that may then indirectly affect the growth of the individual pup, 
from complex metabolic stages to the more mundane restriction of smaller uterus [315, 
421-423]. 
 
One direction for future work lies in looking at the possible targets of GH in the 
placenta.  I only had time to perform preliminary experiments on this, but my initial data 
from microarray analysis carried out on placenta treated with continuous or pulsatilic 
GH points to some genes that may be targets of GH in the placenta, and that may also 
be sensitive to the pattern of GH. Obviously, until now, few studies have directly looked 
at changes in gene expression in the placenta in response to GH, most studies have only 
concentrated on using knockout mice to identify genes involved in placental 
development, or to look at GH responses in other target tissues such as liver, bone, 
muscle and fat [87, 133, 275, 424]. Given the shortness of time, I entertained two quick 
short cut approaches to attempt to identify potential new GH target genes in the placenta. 
The first was to check whether there were any changes in known GH targets genes 
[381] and the second was to look at any changes in genes expressed highly in the 
placenta [425] identified to contain Stat5b response elements from my in silico searches.  
 
Unfortunately none of the genes from these predicted lists were found to show any 
expression changes in any of the groups.  This was unexpected but given some of the 
technical limitations of the experimental setup, I concluded that this limited approach 
was not ideal for studying more obvious GH target genes, a particular area to consider 
would be the isolation of specific cell types in the placenta, to be able to observe smaller 
changes in particular genes, and to go directly for qPCR analysis. This has been feasible 
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in the study by Sood et al (2006) [425], who isolated the various tissue types that make 
up the placenta. I therefore fell back on an unbiased approach by looking at the most up-
regulated genes. Here I was able to identify few genes which could potentially have GH 
initiated roles in the placenta, however, these findings would initially need to be 
confirmed by repeat array studies, qPCR and western blot analysis, and was beyond the 
scope of my thesis work. The opportunity for further work would also arise from mouse 
models, specially expressing GH in the placenta [410]. The effects of having a placental 
source of GH could be then assessed and compared to normal rodents, which only have 
the pituitary source. Furthermore, comparative studies in these models could also be 
approached to look at differential placental gene expression in rats vs mice. Possible 
candidates would hopefully identify other GH initiated signaling pathways [29] that 
might also be present in the placenta and coupled to GH.  
 
In conclusion the findings of this thesis provides evidence for the first time that the 
placenta itself is responsive to GH, and as in the liver the activity of Stat5 in response to 
GH remains sensitive to pattern change and fasting. GH signaling in the placenta is 
clearly interactive with other pathways, however, the function relevance remains to be 
determined. It is evident that GH-V during human pregnancy remains important for the 
regulation of systemic IGF-1, an important mediator of the effects of GH, however, 
where these actions takes place remains unclear. My work suggests that the placenta 
itself could be a direct target for GH-N in rodents, and also an autocrine or paracrine 
target for this placental hormone in humans.  
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Appendix 1 
Microarray data for all experimental groups 
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Condition ()*S Sal ine Sal ine Sal ine bGH pump bGH pump bGH pump bGH inject bGH inject bGH inject
Replicate ()*S 1 2 3 1 2 3 1 2 3
SystematicFold changeF lags Raw F lags Raw F lags Raw F lags Raw F lags Raw F lags Raw F lags Raw F lags Raw F lags Raw Common Gene SymbolDescription
1379640_at 2.713P 10.77992P 13.85063P 8.690509A 3.702056A 3.703733A 4.79545A 5.430086A 7.174631A 7.021972 RGD:735110Ica69-related protein
1376702_at 2.557M 9.659397P 12.81154A 10.06989A 3.411409A 6.752596A 3.276613A 6.879062P 7.728528A 11.72254 Megalencephalic leukoencephalopathy with subcortical cysts 1 (predicted)
1396169_at 2.53P 13.62258P 14.76814P 12.01872A 5.545248A 6.154828A 4.427285A 12.63413P 17.03301P 16.16288 Similar to 4921510J17Rik protein (predicted)
1391860_at 1.952P 12.15528P 8.310773A 13.29561P 6.790933A 4.187118P 6.42303P 6.929717P 12.8683P 14.33306 Transcribed locus
1392749_at 1.947P 24.38401A 16.20874A 20.49417A 9.632067A 9.431266P 12.21927A 16.53331A 14.08324A 26.8714 RGD:1303100ciliary neurotrophic factor receptor
1385445_at 1.906P 10.7024A 13.15372P 13.39647P 7.732199P 4.600934P 7.748235P 15.52203P 8.989033A 5.735563 Similar to bM410K19.2.2
1385411_at 1.903P 29.67041P 28.42032P 26.94514P 12.84641P 17.23586P 15.0664P 19.36553P 17.21324P 33.27647 Usp43_predictedubiquitin specific protease 43 (predicted)
1383691_at 1.876P 6.566658P 10.80156P 6.937471A 3.595195A 3.664352P 5.721756P 4.550557A 4.269024A 3.084973 Atf2 Activating transcription factor 2
1391648_at 1.874A 6.023252A 7.570945A 10.1589A 3.578971A 3.613195P 5.509497A 5.447871M 9.114609P 4.5254 Transcribed locus
1380464_at 1.83P 11.28954P 11.44844P 16.91278A 6.509322P 7.288511P 7.607795P 10.54762P 16.03762P 6.50339 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 26 (predicted)
1381615_at 1.795P 17.47716P 12.02107P 16.18768P 9.712169P 9.983653A 6.132988P 12.18368P 9.994355P 11.68631 Transcribed locus
1380172_at 1.785P 26.11014P 35.75691M 26.47273P 16.84911P 15.36459P 17.00222P 14.78975P 30.7862P 25.06493 Kif5c_predictedkinesin family member 5C (predicted)
1394666_at 1.784A 15.16811M 17.83056A 11.29187A 10.01751A 6.816105A 7.969489A 10.21088A 14.76433P 9.770338 Nebulin (predicted)
1385010_at 1.768M 25.53792M 29.2675A 23.98879A 11.46529A 15.84628A 18.07081A 20.49326A 12.86926P 24.47604 RGD1306249_predicted ; RGD:1359595simila  to RIKEN cDNA 2310015J09 (predicted) ; type I hair keratin KA28
1378636_at 1.763P 16.98253P 22.12771P 17.55281A 12.90274P 11.17567A 8.450365P 17.28775P 17.96291A 9.276158
1396274_at 1.759A 17.45027P 14.90578P 10.81653A 9.02271A 7.249119M 7.997826A 20.87442A 10.82764A 12.41279 Transcribed locus
1380870_at 1.711P 8.630274P 7.536036P 5.637979M 4.541284A 4.230958A 3.852777P 7.446205A 2.509025P 5.292166 Similar to RIKEN cDNA 1700040L02 (predicted)
1368236_at 1.709P 10.07745P 13.08116P 13.28805A 8.018105A 7.520372A 5.885786P 14.59264A 6.65132A 10.99603 Mep1a meprin 1 alpha
1383537_at 1.708P 22.51845P 16.66369P 15.32968P 9.76761P 11.79727P 10.13645P 10.77893A 9.316725P 22.11298 Vascular endothelial zinc finger 1 (predicted)
1378197_at 1.694P 26.18667P 22.04568P 28.64405P 16.98094P 15.33375P 13.21018P 22.70922P 25.93513P 16.80478 KIFC2 kinesin family member C2
1372868_at 1.692A 40.87006A 33.80103P 41.41739A 29.61735A 19.12584A 21.11753P 27.39152A 29.14037A 33.72636 Tor3a_predictedtorsin family 3, member A (predicted)
1384680_at 1.678P 49.20684P 38.85346P 49.33643P 26.98219P 30.02099P 24.95429P 55.41842P 45.12899P 32.21533 Mtus1 Mitochondrial tumor suppressor 1
1379577_at 1.672P 15.57579A 11.61141A 15.13466A 8.370804A 6.643567M 10.65178P 14.42327P 11.08773P 13.72799 LOC500410similar to MIC2L1
1377305_at 1.67P 16.56571P 17.45681P 25.14481A 12.61299P 10.08337A 12.42522A 15.72174P 11.05621A 10.98244 Hypothetical LOC310764 (predicted)
1382186_a_at1.666P 17.40065P 21.23754P 15.95962P 10.16475P 10.96632P 11.586P 14.00376P 14.44578P 17.06826 RGD1311086_predictedsimilar to RIKEN cDNA 2610029K21 (predicted)
1377337_at 1.644P 7.107294M 9.805884P 9.886682P 5.680532A 4.193732A 6.588989A 7.080908A 8.175185P 12.41756 C-myc binding protein (predicted)
1384609_a_at 1.64P 28.13092P 22.53942A 33.8398P 16.68381A 14.24092M 20.71096A 20.91782P 19.57934P 20.36471 RGD1311456_predictedsimilar to RIKEN cDNA B230380D07 (predicted)
1396391_at 1.618P 16.6261P 12.77971A 13.88224A 10.42817A 9.563114A 7.069953P 11.65768P 18.06944A 16.95234 Similar to male sterility domain containing 2
1370816_at 1.611P 20.68779P 18.25483P 24.7642A 12.22181P 12.8124P 14.44397P 36.4526P 28.80547P 24.74142 Nr1d1 nuclear receptor subfamily 1, group D, member 1
1380964_at 1.598P 7.578685P 9.126699A 6.99791P 4.551585A 5.152765A 5.114914A 4.458827A 3.124033A 11.02285 Similar to dystrobrevin alpha isoform 1
1375386_at 1.575A 7.742448P 10.12062P 11.03664A 5.204338P 7.421891A 5.798077A 0.731894P 8.764554P 7.712946 Similar to mKIAA0804 protein (predicted)
1396280_at 1.571P 97.26368P 82.02874P 86.26887P 57.73856P 55.19386P 56.38005P 66.32711P 56.99611P 58.2047 LOC302560similar to G patch domain and KOW motifs
1396945_at 1.564P 13.03185P 13.25448P 10.16522P 9.54638P 6.2849P 7.745923A 0.414169P 5.047704P 8.052024 Transcribed locus
1397025_at 1.562P 35.96545P 44.74784P 49.55952P 28.5285P 29.60945P 25.09863P 22.75391P 43.02403P 30.51071 Trpc4 Transient receptor potential cation channel, subfamily C, member 4
1392561_at 1.561P 17.67608P 17.1528P 19.07759A 13.33744A 11.63529A 9.912245A 11.31089A 10.77174P 12.86178 Taf3_predictedTAF3 RNA polymerase II, TATA box binding protein (TBP)-associated factor (predicted)
1385332_at 1.561P 13.89666A 12.77755P 16.83784A 8.179605A 10.4486A 9.310978A 12.14819A 7.386911P 9.679131 Similar to protein similar to E.coli yhdg and R. capsulatus nifR3 (predicted)
1398688_at 1.555P 25.76145P 36.00822P 35.50203P 17.95619P 18.9164P 26.0994P 32.2333P 32.03446P 33.1511 Spink5_predicted ; LOC502158serin  protease inhibitor, Kazal type 5 (predicted) ; similar to Spink5 protein
1396518_at 1.547A 6.772035P 8.620581P 9.400674A 4.581282A 4.953663P 6.6042M 6.183833A 5.288638M 9.64873 FYVE, RhoGEF and PH domain containing 3 (predicted)
1376781_at 1.537P 120.1821P 120.5277P 121.3185P 75.50466P 83.43182P 77.79057P 86.84746P 118.9824P 103.8944 Glb1 Galactosidase, beta 1
1391684_at 1.534A 31.45784A 28.27786A 33.71306A 18.70006A 24.60668M 18.26019A 24.37549P 31.73697A 32.52305 Tmem14a_predictedtransmembrane protein 14A (predicted)
1385692_at 1.529A 47.09114A 38.35326M 40.15428A 28.75455A 23.95456A 29.823A 44.95573M 47.81514A 39.76297 Slc10a4_predictedsolute carrier family 10 (sodium/bile acid cotransporter family), member 4 (predicted)
1379648_at 1.524P 16.52596P 15.92761P 13.62533P 9.752743P 10.0744P 10.42781P 13.78924P 10.93379P 10.42577 Nfat5 Nuclear factor of activated T-cells 5 (predicted)
1368061_at 1.522P 16.94209P 20.80368P 18.32871P 11.50674P 10.58676P 15.21627P 17.92921P 10.62808P 14.08158 Kcnh1 potassium voltage-gated channel, subfamily H (eag-related), member 1
1380923_at 1.519P 70.58186P 62.92563P 52.47189P 39.71723P 38.48632P 44.03976P 67.86451P 62.45996P 71.59325 N-acylsphingosine amidohydrolase 3-like (predicted)
1368432_a_at1.517M 16.10072P 13.30107M 12.03697P 10.12853A 7.205982A 10.23038P 16.14782P 8.900972A 9.56637 Ros1 v-ros UR2 sarcoma virus oncogene homolog 1 (avian)
1398479_at 1.517P 20.55635A 16.13204P 18.42417P 12.22859A 12.08684P 11.99461P 20.04775P 16.69371A 8.694668 Transcribed locus, weakly similar to NP_996757.1 ryanodine receptor type 3 [Gallus gallus]
1381471_at 1.516P 42.06404P 38.65163P 44.8537P 29.1869P 30.29579P 23.93565P 28.05773P 33.9255P 54.83676 Transcribed locus
1391386_at 1.515P 6.447806A 6.329239P 6.214696A 4.734459A 3.678133A 4.241415P 7.20564A 6.95028A 4.965504 Chn1 Chimerin (chimaerin) 1
1367937_at 1.51P 66.7809P 67.76386P 69.31418P 44.97873P 42.66475P 48.00059P 61.01006P 69.07101P 60.81094 Miox myo-inositol oxygenase
1397154_at 1.502A 27.68131P 25.20919P 22.3262P 19.77136P 16.54128P 14.23295P 16.30015P 12.24069A 24.71881 Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila)
1370520_at 0.663P 22.84478P 19.74659P 15.89831P 31.92805P 23.61837P 32.97791P 22.52879P 16.84196P 16.9166 RGD:727791hippyragranin
1376180_at 0.663P 45.22917P 35.92415P 44.92118P 71.50909P 51.4601P 68.80343P 31.85651P 40.14759P 48.5204
1391571_at 0.658P 14.45683P 13.11981P 11.76632P 22.26706P 17.92402P 19.85225P 12.26607P 9.562852P 12.00377 Transcribed locus
1376403_at 0.658P 7.899254A 9.165625P 9.678021P 13.5218A 11.48969P 16.02577A 13.36984P 9.511164M 13.32318
1396993_at 0.657A 22.11608A 30.64543A 25.30629M 39.65807P 41.91699A 36.75429A 17.3666A 33.30005P 36.21574 Transcribed locus
1390950_at 0.657A 6.33572A 7.173213P 5.00602P 9.836214A 8.502183P 9.696831A 4.977945P 7.558811A 5.457897 Prdx3 Peroxiredoxin 3
1383384_at 0.654P 58.72894P 75.73902P 61.86374P 80.20663P 111.8061P 110.8856P 81.34615P 87.02633P 73.55166 TATA box binding protein-like 1 (predicted)
1395703_at 0.654P 13.39939A 9.507374P 11.46878M 16.81386A 19.73464P 15.95647A 14.46704A 15.93289A 18.60787 Transcribed locus
1373350_at 0.652P 42.7404P 44.89502P 40.53615P 69.90968P 57.04131P 71.17686P 32.93903P 44.7686P 43.2724 Psip1 PC4 and SFRS1 interacting protein 1
1389007_at 0.646M 19.74112A 20.39906A 17.73405P 30.99454A 26.52852P 32.64742A 24.73562P 21.83741A 15.13209 RGD1307524_predictedsimila  to Friedreich ataxia region gene X123 (predicted)
1376084_a_at0.645P 11.72057P 13.90163P 11.96186P 22.00271P 17.3167P 19.2781P 9.522137A 9.112554P 22.39788 Espl1_predictedextra spindle poles like 1 (S. cerevisiae) (predicted)
1386647_at 0.644A 16.29537M 21.98423A 16.0567P 32.23388P 30.31938P 22.29941A 21.86999A 24.88122A 17.77765 Mtap7_predictedmi rotubule-associated protein 7 (predicted)
1390126_at 0.639P 16.16669P 23.00833A 16.26274P 30.01127P 24.33312P 32.12049P 15.50596A 18.33153A 14.06883
1384410_at 0.635P 6.67689P 6.029502P 7.467504P 10.36876P 10.50402P 10.90396P 6.844388A 7.720983M 4.572625 Similar to sorting nexin 12
1389553_at 0.627P 11.41031P 14.58595P 11.39853P 22.1426P 16.56908P 21.28087P 17.98245P 9.427206P 12.37291 RGD:1359528dendritic cell inhibitory receptor 3
1393140_at 0.622P 19.16512P 18.57046P 25.13434P 30.25585P 35.72539P 34.7268P 22.30524P 27.24969P 35.69579
1380037_at 0.619A 13.95171A 11.95194M 15.17276P 19.897A 25.41308P 21.31351A 24.61616A 24.05559M 19.03213 MGC94040Hypothetical LOC292764
1379878_at 0.618P 15.36799P 11.6994P 10.39846P 23.88015P 19.34261P 17.35507P 12.67449P 15.31673P 15.76032 Transcribed locus
1370310_at 0.614P 39.45173P 52.79946P 56.41374P 84.49405P 71.16423P 85.27897P 64.69237P 48.90293P 40.04545 Hmgcs2 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2
1384309_at 0.614P 5.183973M 5.735261A 6.797849P 10.47112P 10.60018P 7.948514A 4.876275A 5.452471P 8.680175 Transcribed locus
1376784_at 0.61P 16.68219P 16.05684P 22.13428A 36.56663A 26.20017A 27.639A 26.69369P 21.39519P 22.689 LOC499775LOC499775
1386486_at 0.608A 26.06051P 24.39505P 32.5661P 44.18136P 49.4815P 42.73749M 31.94951P 39.90676A 22.5611 Rsn restin (Reed-Steinberg cell-expressed intermediate filament-associated protein)
1382576_at 0.607P 20.50295P 24.33367P 18.71252P 38.29654P 30.60168P 36.09693P 19.64275P 31.57876P 25.9088 CDNA clone IMAGE:7375616
1387408_at 0.605P 15.49428P 17.69748P 20.75498P 29.2922P 30.83562P 28.84386P 37.21759P 19.35643P 16.2496 RGD:620778seven in absentia 2
1391212_at 0.602P 17.16262P 22.42133P 14.03756P 32.164P 23.10067P 33.77628P 21.38269P 21.8146P 15.46015 Tceal1 transcription elongation factor A (SII)-like 1
1382902_at 0.6P 12.69383P 17.90398P 14.02534P 30.58025P 21.68639P 22.57047P 32.91943P 23.08282P 13.71616 Herc6 potential ubiquitin ligase
1385916_at 0.599A 7.920223P 8.017239A 9.596525P 13.65978P 14.79243P 14.19691A 7.409611A 9.719283P 15.49892 Transcribed locus
1392139_at 0.596P 14.59565P 23.24431P 18.79842P 29.61102P 34.74519P 29.64774P 18.50567P 32.57005P 40.96218 Transcribed locus
1382810_at 0.595A 3.912485A 4.445461A 4.134687P 6.941643P 6.879018A 7.226104A 5.360516A 3.594226A 7.45944 Similar to Eph receptor A4
1395294_at 0.593A 13.73278A 10.15828A 9.071011M 22.72715M 16.94693P 15.97153A 13.98234A 18.1217P 14.42248 Transcribed locus
1394922_at 0.593A 9.520434A 9.265462A 7.149046A 17.44643A 11.11964P 15.80715A 14.61597P 9.753514A 11.50115
1383211_at 0.592P 17.52883P 12.78016P 11.4147P 19.20081P 23.83607P 27.20473A 19.41585P 27.81611M 16.0278 Transcribed locus
1385580_at 0.577P 5.399708A 5.689971A 8.513547P 10.19006M 10.0953P 13.38691A 4.04119P 6.821384P 8.879457 Transcribed locus
1388170_at 0.572P 10.81966P 8.25322M 11.26203A 16.31209A 14.78421M 22.5617P 15.43295P 20.9104P 22.53628 Vad5 vitamin A-deficient testicular protein 5
1393739_at 0.562P 4.976151P 5.845766P 5.141604P 9.803797P 9.695179P 8.949806A 12.59934A 9.833208P 9.312375
1397512_at 0.553P 13.84526P 12.65714P 14.36303P 24.88096P 20.47119P 29.54292P 13.63555P 14.7383A 18.30126 LOC306991similar to Vps41 protein
1377261_at 0.551A 10.22221A 11.62831A 15.42538P 25.72573P 17.28331A 24.94986A 23.303P 15.16658A 24.04159 Transcribed locus
1387587_at 0.548P 12.39577P 19.66382M 18.34589P 33.51324P 22.73465P 36.02503A 18.28893P 27.98772P 21.841 Tnfsf6 tumor necrosis factor (ligand) superfamily, member 6
1391476_at 0.547P 16.47406P 21.30362P 12.88157P 34.18968P 22.7148P 35.91725P 21.55165P 23.22028P 27.10817 Transcribed locus
1383659_a_at0.546P 14.17709P 19.611P 13.50817P 26.3809P 28.44184P 31.15083P 14.55557P 15.84291P 20.39886 Similar to KIAA1183 protein
1392183_at 0.532A 9.702702P 13.96271P 10.14311P 27.60482A 15.80261P 21.11533P 13.61451P 15.99405P 14.01552 Homeo box C8
1398538_at 0.531A 6.917701A 6.131429A 8.501691P 10.66831P 12.26194M 18.68082A 9.995523M 10.33887A 1.923718 Abhd8_predictedabhydrolase domain containing 8 (predicted)
1379964_at 0.526P 7.997991P 8.413345P 9.644586P 20.48968P 12.82957P 17.15422P 8.290404P 14.63456P 7.781238 Transcribed locus
1379628_at 0.525P 7.95454P 6.595842A 6.394429A 10.99671P 13.9505P 15.28611A 3.594461A 9.128712A 8.015691 Transcribed locus
1385542_at 0.495A 4.734129P 8.618516P 7.298098P 11.90831P 16.70992P 12.4527P 7.715317P 7.79152P 12.58165 Transcribed locus
1382803_at 0.46A 5.048818A 5.668155A 3.928743M 10.60945A 10.10179A 10.88412A 13.29669P 17.71512A 12.13511 Map4k1_predictedmitog n activated protein kinase kinase kinase kinase 1 (predicted)
1392145_at 0.411A 3.612448A 8.241244A 4.803352P 10.36717A 10.62335P 18.94889P 7.478734A 4.916532A 1.374118
1394070_at 0.363A 3.302614A 2.101708A 3.092017P 7.597216P 5.672821P 10.49646A 7.777163A 6.734043A 2.579963 Transcribed locus
1391879_at 0.298A 4.851295P 5.235281A 3.367859P 13.05408P 12.94159P 19.35662P 9.969351P 10.86456A 1.806232 Transcribed locus
1395883_at 0.276A 2.104265A 3.525296A 1.63346M 10.66286P 9.453664A 5.762733A 1.789514A 6.052197A 8.301436 Similar to RIKEN cDNA 5730509K17 gene
1393377_at 0.25A 10.91696A 3.636218A 3.16572P 25.63876A 12.9535M 24.56443A 5.999729A 29.577A 24.65551
1386410_at 0.239M 3.117199A 1.713075A 0.849163A 9.141655P 4.80076M 7.685802A 6.187136A 3.230099A 5.789015 Transcribed locus
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Gene Title
tissue inhibitor of metalloproteinase 3 
Tissue inhibitor of metalloproteinase 3 
tissue inhibitor of metalloproteinase 3 
tissue inhibitor of metalloproteinase 2
Tissue inhibitor of metalloproteinase 3 
Tissue inhibitor of metalloproteinases-4
steroid 5 alpha-reductase 1
signal transducer and activator of transcription interacting protein 1
signal transducer and activator of transcription 5A
signal transducer and activator of transcription 1
signal transducer and activator of transcription 3
signal transducer and activator of transcription 3
signal transducer and activator of transcription 1
Signal transducer and activator of transcription 2
signal transducer and activator of transcription 6 (predicted)
signal transducer and activator of transcription 1
signal transducer and activator of transcription 5B
signal transducer and activator of transcription 2
signal transducer and activator of transcription 4
suppressor of cytokine signaling 2
suppressor of cytokine signaling 3
suppressor of cytokine signaling 1
Suppressor of cytokine signaling 1
suppressor of cytokine signaling 6 (predicted)
Suppressor of cytokine signaling 7 (predicted)
suppressor of cytokine signaling 7 (predicted)
muscle glycogen phosphorylase
muscle glycogen phosphorylase
muscle glycogen phosphorylase
A260_32.CELA260_1.CELA260_4.CELA260_7.CELUnigene(Avadis) Gene SymbolProbe Set ID A260_15.CELA260_17.CELA260_22.CELA260_27.CELA260_28.CEL
-0.1909 0.0710 -0.5323 -0.1682 Rn.119634 Timp31368989_at 0.0000 -0.0706 0.0208 0.2003 0.0088
-0.0591 0.0579 -0.0939 0.0097 Rn.119634 Timp31372926_at 0.0000 0.0251 0.0126 -0.0819 -0.0542
-0.1480 0.1010 -0.0110 0.0584 Rn.119634 Timp31375138_at 0.0000 0.0362 0.0048 -0.1730 -0.1778
-0.0525 0.0000 -0.3042 -0.0748 Rn.10161 Timp21386940_at 0.0291 -0.1336 0.1318 0.0686 0.0623
-0.1134 0.0169 0.0100 -0.0531 Rn.119634 Timp31389836_a_at0.0303 0.0000 0.0229 -0.1264 -0.1859
0.0997 -0.1643 0.0926 -0.1641 Rn.155651 LOC6801301377632_at 0.0000 0.0498 -0.0533 0.0313 -0.2678
-0.1937 0.0000 -0.0729 0.1908 Rn.4620 Srd5a11370420_at -0.0049 0.0556 -0.0486 0.6436 0.5552
0.0000 -0.0142 -0.0331 0.0749 Rn.25007 Statip11367533_at -0.0463 -0.0293 0.1652 0.0762 0.0717
-0.0385 0.0125 0.0015 -0.0731 Rn.154399 Stat5a1368231_at 0.0618 -0.1289 -0.2102 0.1166 0.0000
0.0064 -0.0742 0.0552 -0.0163 Rn.33229 Stat11368835_at 0.0605 0.0000 0.3097 -0.0658 -0.1084
-0.1194 0.0165 -0.0137 -0.3579 Rn.10247 Stat31370224_at 0.0760 0.0699 0.0570 0.0000 -0.0651
-0.1119 0.1922 0.1775 0.1309 Rn.10247 Stat31371781_at -0.0094 0.0611 0.0000 -0.1278 -0.0872
-0.1499 -0.1229 0.0253 -0.0118 Rn.33229 Stat11372757_at 0.0294 0.0000 0.1437 0.0959 -0.0913
0.0864 -0.1201 0.0154 -0.3431 Rn.24237 Stat21373670_at 0.0352 -0.0939 -0.1229 0.0000 0.0784
0.0303 -0.1239 -0.1579 -0.0990 Rn.6880 Stat6_predicted1382350_at 0.0240 0.0260 0.0286 -0.0664 0.0000
0.0380 -0.0669 -0.0539 -0.0129 Rn.33229 Stat11387354_at 0.0597 -0.1359 0.2629 0.1522 0.0000
-0.0827 -0.3270 0.0035 -0.1627 Rn.54486 Stat5b1387876_at 0.0404 -0.1228 0.1803 0.3339 0.0000
0.0767 -0.3112 0.0025 -0.3673 Rn.24237 Stat21389571_at 0.1088 0.0000 -0.0038 0.1277 -0.0059
-0.0380 0.0152 0.0000 -0.0441 Rn.137580 Stat41384111_at -0.0626 -0.2005 0.0464 0.1128 0.2070
-0.1602 0.1511 -0.0485 0.0000 Rn.205056 Socs21369577_at 0.0474 0.0106 -0.2227 -0.1039 0.1280
-0.2970 -0.1610 -0.0027 0.1244 Rn.127801 Socs31369584_at 0.0000 0.0612 -0.0667 0.0031 0.1031
0.0712 -0.1323 0.1430 0.1502 Rn.82754 Socs11371252_at 0.0404 -0.0012 -0.0579 0.0000 -0.0425
0.2191 0.0163 -0.0826 -0.0906 Rn.82754 Socs11375568_at 0.0000 -0.0829 -0.0277 0.0973 0.0103
-0.1642 0.0133 -0.1041 0.0000 Socs6_predicted1376666_at -0.1242 -0.1051 0.1666 0.1795 0.1733
0.1762 -0.1427 0.1363 0.0464 Rn.205543 Socs7_predicted1377131_at 0.0000 -0.2802 -0.0235 0.4723 -0.1386
0.1938 -0.1751 -0.1412 -0.4526 Rn.205543 Socs7_predicted1384888_at 0.0891 0.0548 -0.0446 0.0387 0.0000
-0.0551 0.0000 0.1595 -0.2806 Rn.11238 Pygm1370982_at 0.1434 0.0052 -0.1040 0.1925 -0.1168
0.1298 0.1321 -0.0109 0.1507 Rn.11238 Pygm1375476_at -0.0836 0.0000 0.1655 -0.2378 -0.0397
0.1968 0.0961 -0.0866 0.0420 Rn.11238 Pygm1383072_at -0.2132 0.0602 -0.1270 0.0000 -0.0991
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nitric oxide synthase 3, endothelial cell
nanos homolog 3 (Drosophila) (predicted)
metallothionein 1a
interferon regulatory factor 2 binding protein 1 (predicted)
interferon regulatory factor 1
interferon regulatory factor 3
Interferon regulatory factor 8
interferon regulatory factor 6 (predicted)
interferon regulatory factor 2 (predicted)
interferon regulatory factor 7
interferon regulatory factor 2 (predicted)
interferon regulatory factor 6 (predicted)
interferon regulatory factor 5 (predicted)
interleukin 6
interleukin 6 signal transducer
interleukin 6 receptor, alpha
insulin-like growth factor 2
insulin-like growth factor 2 receptor
insulin-like growth factor binding protein 2
insulin-like growth factor binding protein 3
insulin-like growth factor 1 receptor
insulin-like growth factor binding protein 1
insulin-like growth factor 1
insulin-like growth factor binding protein 5
insulin-like growth factor 2
insulin-like growth factor binding protein 7
insulin-like growth factor binding protein 4
insulin-like growth factor binding protein 6
c-fos induced growth factor
insulin-like growth factor 2 receptor
-0.0104 -0.4674 0.0183 -0.4040 Rn.44265 Nos31371166_at 0.1836 -0.1046 0.0337 0.1842 0.0000
-0.0656 -0.1725 0.2836 0.0168 Rn.161711 Nanos3_predicted1397827_at 0.0000 -0.2038 0.1405 -0.0952 0.0637
0.0000 -0.7602 -0.0101 -0.5047 Rn.54397 Mt1a1371237_a_at 0.1181 -0.4471 0.3966 0.4782 0.6535
0.0360 0.0308 -0.1334 0.0091 Rn.9129 Irf2bp1_predicted1367535_at 0.0000 0.0859 -0.1875 -0.0589 -0.0439
-0.2732 0.3080 0.0351 0.4525 Rn.6396 Irf11368073_at -0.0443 -0.0269 0.2112 0.0000 -0.2066
0.0615 -0.1511 0.0037 -0.3494 Rn.1499 Irf31371560_at -0.0591 -0.1280 0.0000 0.0147 0.1507
-0.2294 -0.3063 0.0791 -0.1127 Rn.3765 Irf81372097_at 0.0000 -0.3213 0.0518 0.3174 0.0877
-0.5504 0.0000 0.2178 0.4375 Rn.12385 Irf6_predicted1377379_at -0.4591 -0.1399 0.3012 0.2273 -0.1305
-0.0655 -0.0233 -0.2330 -0.1921 Rn.107887 Irf2_predicted1382503_at 0.0699 0.0000 0.0362 0.2542 0.0798
0.0566 -0.1457 0.2572 -0.1862 Rn.101159 Irf71383564_at 0.0000 -0.0408 -0.0780 0.0699 0.1402
0.0000 0.0026 -0.0126 0.1595 Rn.107887 Irf2_predicted1386518_at 0.1117 -0.0769 0.0846 -0.0976 -0.1481
-0.7636 0.0678 0.0000 0.2123 Rn.12385 Irf6_predicted1386568_at -0.5544 -0.3516 0.2621 0.0764 -0.1981
0.0000 0.2515 -0.0772 -0.0183 Rn.203787 Irf5_predicted1379563_at 0.0163 -0.0206 0.0484 0.1322 -0.1542
-0.1089 0.1039 0.1644 0.1178 Rn.9873 Il61369191_at 0.0209 -0.0627 -0.0487 0.0000 -0.0497
-0.2531 -0.2206 -0.1571 -0.3696 Rn.12138 Il6st1370957_at 0.0741 0.0567 0.0000 0.0264 0.0531
0.0000 0.3150 -0.3906 0.2093 Rn.1716 Il6ra1386987_at 0.0157 -0.1093 0.1228 -0.1501 -0.3641
-0.1769 0.0042 0.0022 0.0712 Rn.118681 Igf21367571_a_at-0.0829 0.0019 0.0000 -0.1501 -0.1558
-0.1679 0.1345 0.1199 0.2027 Rn.270 Igf2r1367636_at -0.0033 0.1424 0.0000 -0.0946 -0.1216
-0.1150 -0.1390 0.0000 -0.0503 Rn.6813 Igfbp21367648_at 0.1049 -0.0179 0.0927 0.1636 0.0282
-0.1029 -0.3945 -0.5676 0.1083 Rn.26369 Igfbp31367652_at -0.1171 0.1697 0.0000 0.2588 0.3531
-0.0032 0.1152 0.0551 -0.1127 Rn.10957 Igf1r1368123_at 0.0578 -0.0140 -0.0229 0.0000 0.1424
-1.4182 -0.4862 0.7773 0.3515 Rn.34026 Igfbp11368160_at -1.6178 -1.9061 0.0000 1.7249 0.4240
0.0924 0.4142 -0.1274 -0.0791 Rn.6282 Igf11370333_a_at0.0000 -0.2672 -0.0019 0.0349 0.0591
-0.3758 0.3548 0.0000 0.0090 Rn.1593 Igfbp51370960_at -0.2916 -0.2244 0.0277 0.0404 -0.2289
0.0000 -0.1378 -0.0564 -0.1224 Rn.118681 Igf21371206_a_at 0.1102 -0.0204 0.0509 0.1483 0.1930
-0.2055 0.2113 0.0151 0.3702 Rn.203012 Igfbp71371357_at 0.0000 0.1452 -0.0212 -0.1364 -0.1545
0.0705 -0.0296 -0.0064 -0.2055 Rn.160666 Igfbp41371462_at -0.0058 0.1083 0.0000 0.3008 0.1387
0.2007 -0.0034 -0.0336 0.0000 Rn.6431 Igfbp61372168_s_at-0.0134 -0.1627 0.3434 0.3317 0.2916
-0.2703 0.1304 -0.0960 0.1271 Rn.10796 Figf1373882_at 0.0713 0.0283 0.0000 -0.5366 -0.2821
-0.1278 -0.0017 0.1497 0.0000 Rn.270 Igf2r1386872_at 0.0947 0.0765 0.0138 -0.0899 -0.0836
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insulin-like growth factor binding protein 3
insulin-like growth factor binding protein 5
insulin-like growth factor binding protein 5
insulin-like growth factor binding protein 6
c-fos induced growth factor
insulin-like growth factor binding protein, acid labile subunit
insulin-like growth factor binding protein-like 1 (predicted)
insulin-like growth factor 2
insulin-like growth factor 2, binding protein 3
similar to IGF-II mRNA-binding protein 2 (predicted)
Similar to IGF-II mRNA-binding protein 2 (predicted)
IGFBP-2-Binding Protein, IIp45
insulin-like growth factor 2, binding protein 1
insulin-like growth factor 2, binding protein 3
Insulin-like growth factor 2, binding protein 3
insulin-like growth factor binding protein 5
insulin-like growth factor binding protein 5
hepatocyte nuclear factor 4, alpha
hepatocyte nuclear factor 4, alpha
similar to Pterin-4-alpha-carbinolamine dehydratase 2 (PHS 2) 
similar to Pterin-4-alpha-carbinolamine dehydratase 2 (PHS 2) 
GH regulated TBC protein 1
glypican 3
G-protein coupled receptor 12
putative G protein-coupled receptor snGPCR32
glypican 2 (cerebroglycan)
glypican 1
similar to Probable G-protein coupled receptor 62 (hGPCR8) (predicted)
glypican 4
0.0096 -0.4822 -0.4875 0.0593 Rn.26369 Igfbp31386881_at -0.1139 0.0000 -0.1032 0.2499 0.3364
-0.0721 0.0000 -0.0344 0.2202 Rn.1593 Igfbp51387347_at 0.1648 0.1748 -0.2389 -0.0061 0.2533
0.0107 0.0000 -0.0011 -0.2672 Rn.1593 Igfbp51387348_at 0.0151 0.0191 -0.3287 -0.0176 0.1864
0.2502 0.0000 -0.2234 -0.2375 Rn.6431 Igfbp61387625_at -0.1026 -0.1540 0.0016 0.2098 0.2827
0.1153 0.2118 -0.0770 -0.0657 Rn.10796 Figf1387709_at 0.2245 -0.0452 0.0000 -0.2303 0.0272
-0.5583 0.0000 0.3140 0.5831 Rn.7327 Igfals1387816_at -0.3111 -0.2328 0.5628 0.3294 -0.1053
0.0356 -0.0765 0.1161 -0.1025 Rn.32120 Igfbpl1_predicted1390715_at -0.0103 -0.0877 0.0000 0.0406 0.2791
0.0000 -0.1339 -0.2462 -0.2210 Rn.118681 Igf21398322_at 0.0320 0.0574 -0.3151 0.3526 0.1310
0.0000 0.2335 -0.2140 0.4692 Rn.100446 Igf2bp31377824_a_at-0.0418 0.1881 -0.0492 0.1925 -0.1385
0.1894 -0.1792 0.0055 -0.2248 Rn.17318 RGD1305614_predicted1382220_at 0.0000 0.0681 -0.0621 -0.0369 0.0558
0.1453 0.0000 -0.0364 -0.0766 Rn.17318 RGD1305614_predicted1382609_at -0.0425 0.0562 -0.1403 0.1682 0.0921
-0.0528 -0.1656 0.0446 -0.1053 Rn.27362 LOC2986431383925_at 0.0297 0.0000 -0.0144 0.0051 0.0037
0.0000 -0.0714 -0.0365 -0.0032 Rn.77572 Igf2bp11385469_at 0.0687 -0.0126 0.1939 0.1318 0.2210
-0.0682 0.0000 -0.0542 0.1897 Rn.100446 Igf2bp31390860_at 0.0512 0.1118 -0.2526 0.0641 -0.0510
-0.0576 0.0250 0.1001 0.1092 Rn.100446 Igf2bp31393202_a_at0.0000 -0.1112 0.0045 -0.1182 -0.0640
0.1265 -0.2456 0.0000 -0.0056 Rn.1593 Igfbp51396152_s_at0.0067 0.0116 -0.1248 0.1623 -0.1808
-0.0264 0.0319 -0.1266 -0.2205 Rn.1593 Igfbp51397830_at 0.0893 -0.0948 0.0445 0.3047 0.0000
-0.0750 0.0000 -0.1045 -0.2220 Rn.44442 Hnf4a1369289_at 0.0083 0.0981 -0.0200 0.0841 0.0627
0.1004 0.0078 -0.1198 -0.0552 Rn.44442 Hnf4a1382496_at -0.3026 0.0000 -0.0046 0.2372 0.1600
0.0000 0.0934 -0.1779 0.1965 LOC6833191379329_at -0.0055 0.0086 0.0725 -0.1564 -0.0981
0.0000 0.2138 -0.1438 0.2795 LOC6833191379330_s_at-0.0226 0.0079 0.1270 -0.1066 -0.0301
-0.1612 0.7262 -0.0265 0.8657 Rn.19589 Grtp11390918_at 0.0000 0.2974 0.4137 -0.4423 -0.5067
-0.5675 0.0663 0.0000 0.3003 Rn.9717 Gpc31368395_at -0.4079 -0.3981 0.1194 0.1781 -0.1814
0.0734 -0.0018 0.0549 -0.1518 Rn.88417 Gpcr121368786_a_at0.0000 -0.0058 -0.2014 0.2064 0.1494
-0.2342 0.2654 -0.0694 0.3818 Rn.64507 Edg71369055_at -0.2896 -0.2481 0.1961 0.2166 0.0000
0.0000 -0.0866 0.1242 -0.1985 Rn.88131 Gpc21370448_at 0.0334 -0.0495 -0.0528 0.1293 0.0733
0.0432 0.1469 0.1985 -0.2473 Rn.7044 Gpc11387039_at 0.0005 -0.0681 0.0000 -0.4101 -0.2968
0.2285 0.1951 -0.1453 0.1534 Rn.1410721378554_at -0.0376 -0.0118 -0.1206 0.0000 0.1909
-0.5618 -0.1005 0.0814 -0.3710 RGD1560166_predicted1379821_at -0.2353 0.0000 0.2050 0.0427 0.0948
-0.3302 0.1903 0.0332 0.1117 Rn.19945 Gpc41392888_at -0.0311 -0.1111 -0.1303 0.0234 0.0000
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growth arrest and DNA-damage-inducible 45 alpha
growth arrest and DNA-damage-inducible, gamma interacting protein 1
growth arrest and DNA-damage-inducible 45 beta
growth arrest and DNA-damage-inducible 45 gamma
fos-like antigen 1
c-fos induced growth factor
FBJ murine osteosarcoma viral oncogene homolog
fos-like antigen 2 /// FBJ osteosarcoma oncogene B
c-fos induced growth factor
Fos-like antigen 2
fibronectin 1
fibronectin type III domain containing 3B (predicted)
fibronectin type III domain containing 3B (predicted)
fibronectin type III domain containing 1
fibronectin type III domain containing 3B (predicted)
Fibronectin type III domain containing 3a (predicted)
fibronectin leucine rich transmembrane protein 3 (predicted)
fibronectin type III and SPRY domain containing 2 (predicted)
Fibronectin leucine rich transmembrane protein 3 (predicted)
fibronectin type III domain containing 3a (predicted)
fibronectin leucine rich transmembrane protein 3 (predicted)
fatty acid binding protein 3
fatty acid binding protein 4, adipocyte
fatty acid binding protein 9, testis
fatty acid binding protein 6, ileal (gastrotropin)
fatty acid binding protein 1, liver
fatty acid binding protein 2, intestinal
fatty acid binding protein 7, brain
fatty acid binding protein 5, epidermal0.0204 -0.0410 -0.0170 -0.0614 Rn.98269 Fabp51370281_at 0.1084 0.0000 -0.0476 0.0847 0.1436
-0.1145 0.0989 0.0000 -0.0530 Rn.10014 Fabp71370024_at 0.0201 -0.0743 0.0147 -0.0457 0.0463
-0.0911 0.0000 0.0317 -0.0674 Rn.91358 Fabp21369195_at -0.1937 -0.2941 0.2696 0.1901 0.1936
0.0498 -0.0417 -0.0511 0.0221 Rn.36412 Fabp11369111_at 0.0488 0.0000 -0.0292 0.1265 -0.1104
-0.1452 0.0427 0.0232 0.0213 Rn.10008 Fabp61368697_at 0.0238 -0.0681 0.0000 -0.0729 -0.1237
0.0690 0.0622 -0.1267 -0.0381 Rn.10078 Fabp91368630_at 0.0000 0.1845 -0.0509 -0.1134 0.0097
0.2974 0.1421 -0.2433 0.0000 Rn.4258 Fabp41368271_a_at 0.1509 -0.1205 0.0863 -0.0751 -0.0109
-0.0208 -0.0017 0.1720 0.1148 Rn.32566 Fabp31367660_at 0.0057 0.1426 0.0000 -0.1344 -0.0053
0.0000 0.0314 -0.2353 0.1642 Rn.95324 Flrt3_predicted1392863_at -0.0706 -0.0254 -0.1935 0.0763 0.1959
0.0469 0.0000 -0.0145 0.2625 Rn.100627 Fndc3a_predicted1383396_at -0.1328 -0.0575 0.2087 -0.0264 0.1294
-0.2050 0.1697 -0.1049 0.0226 Rn.95324 Flrt3_predicted1382638_at -0.1865 0.0963 0.0000 0.2456 -0.2232
-0.0240 -0.1002 0.1108 0.0244 Rn.41372 Fsd2_predicted1379921_at -0.2361 0.0325 -0.1188 0.0000 0.0363
-0.0898 -0.0558 -0.0942 0.0113 Rn.95324 Flrt3_predicted1378057_at 0.0078 0.0000 -0.1819 0.1858 0.1687
0.1088 0.0488 -0.1306 -0.1354 Rn.100627 Fndc3a_predicted1376823_at 0.0000 -0.0228 -0.0463 0.1263 0.1767
0.0736 -0.1531 -0.1321 0.0000 Rn.757 Fndc3b_predicted1376532_at -0.0471 0.0385 -0.0686 0.0167 0.0715
0.0000 0.3778 -0.1981 0.2913 Rn.20633 Fndc11374726_at 0.1154 0.1990 -0.1419 -0.0090 -0.2650
-0.1346 0.0642 -0.1591 0.1027 Rn.757 Fndc3b_predicted1373416_at -0.0526 0.1412 0.0000 -0.0165 0.1291
-0.0231 -0.0234 -0.0364 0.0413 Rn.757 Fndc3b_predicted1373206_at 0.0000 0.0747 -0.0021 0.0348 0.0234
-0.0194 -0.0556 0.0034 -0.0638 Rn.1604 Fn11370234_at 0.0000 -0.0269 0.0022 0.0687 0.0434
-0.3393 -0.3860 0.0165 -0.5003 Rn.163577 Fosl21383860_at 0.1543 -0.2991 0.0000 0.1811 0.0013
0.1153 0.2118 -0.0770 -0.0657 Rn.10796 Figf1387709_at 0.2245 -0.0452 0.0000 -0.2303 0.0272
-0.1452 -0.0326 0.0000 -0.0039 Rn.163577 Fosb /// Fosl21387530_a_at0.2838 -0.0161 0.4089 0.4766 0.2800
-0.2524 0.2200 -0.0541 0.2721 Rn.103750 Fos1375043_at -0.1094 0.0191 0.0000 0.0127 -0.0649
-0.2703 0.1304 -0.0960 0.1271 Rn.10796 Figf1373882_at 0.0713 0.0283 0.0000 -0.5366 -0.2821
-0.0182 -0.3795 0.0877 -0.2350 Rn.11306 Fosl11368489_at 0.0000 -0.3051 0.0543 0.3376 0.0992
0.0639 0.2103 0.0000 -0.0874 Rn.1735451380605_at 0.1088 -0.0872 0.0703 -0.0193 -0.0741
0.0000 0.0221 -0.1569 0.1285 Rn.16950 Gadd45g1388792_at -0.0772 -0.0530 0.0928 -0.1088 0.0058
-0.1336 -0.0189 0.1527 -0.0857 Rn.35886 Gadd45b1372016_at 0.0985 0.0762 0.1374 0.0000 -0.0707
0.1109 0.0000 0.0551 0.0099 Rn.161715 Gadd45gip11371896_at -0.0628 -0.0971 0.0442 -0.0260 -0.0062
0.0000 0.0244 -0.0339 0.0513 Rn.10250 Gadd45a1368947_at 0.0528 0.0201 -0.0627 -0.1091 -0.0473
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Suppressor of cytokine signaling 1
suppressor of cytokine signaling 6 (predicted)
Suppressor of cytokine signaling 7 (predicted)
suppressor of cytokine signaling 7 (predicted)
muscle glycogen phosphorylase
muscle glycogen phosphorylase
muscle glycogen phosphorylase
nitric oxide synthase 3, endothelial cell
nanos homolog 3 (Drosophila) (predicted)
metallothionein 1a
interferon regulatory factor 2 binding protein 1 (predicted)
interferon regulatory factor 1
interferon regulatory factor 3
Interferon regulatory factor 8
interferon regulatory factor 6 (predicted)
interferon regulatory factor 2 (predicted)
interferon regulatory factor 7
interferon regulatory factor 2 (predicted)
interferon regulatory factor 6 (predicted)
interferon regulatory factor 5 (predicted)
interleukin 6
interleukin 6 signal transducer
interleukin 6 receptor, alpha
insulin-like growth factor 2
insulin-like growth factor 2 receptor
insulin-like growth factor binding protein 2
insulin-like growth factor binding protein 3
insulin-like growth factor 1 receptor
insulin-like growth factor binding protein 1
insulin-like growth factor 10.0924 0.4142 -0.1274 -0.0791 Rn.6282 Igf11370333_a_at0.0000 -0.2672 -0.0019 0.0349 0.0591
-1.4182 -0.4862 0.7773 0.3515 Rn.34026 Igfbp11368160_at -1.6178 -1.9061 0.0000 1.7249 0.4240
-0.0032 0.1152 0.0551 -0.1127 Rn.10957 Igf1r1368123_at 0.0578 -0.0140 -0.0229 0.0000 0.1424
-0.1029 -0.3945 -0.5676 0.1083 Rn.26369 Igfbp31367652_at -0.1171 0.1697 0.0000 0.2588 0.3531
-0.1150 -0.1390 0.0000 -0.0503 Rn.6813 Igfbp21367648_at 0.1049 -0.0179 0.0927 0.1636 0.0282
-0.1679 0.1345 0.1199 0.2027 Rn.270 Igf2r1367636_at -0.0033 0.1424 0.0000 -0.0946 -0.1216
-0.1769 0.0042 0.0022 0.0712 Rn.118681 Igf21367571_a_at-0.0829 0.0019 0.0000 -0.1501 -0.1558
0.0000 0.3150 -0.3906 0.2093 Rn.1716 Il6ra1386987_at 0.0157 -0.1093 0.1228 -0.1501 -0.3641
-0.2531 -0.2206 -0.1571 -0.3696 Rn.12138 Il6st1370957_at 0.0741 0.0567 0.0000 0.0264 0.0531
-0.1089 0.1039 0.1644 0.1178 Rn.9873 Il61369191_at 0.0209 -0.0627 -0.0487 0.0000 -0.0497
0.0000 0.2515 -0.0772 -0.0183 Rn.203787 Irf5_predicted1379563_at 0.0163 -0.0206 0.0484 0.1322 -0.1542
-0.7636 0.0678 0.0000 0.2123 Rn.12385 Irf6_predicted1386568_at -0.5544 -0.3516 0.2621 0.0764 -0.1981
0.0000 0.0026 -0.0126 0.1595 Rn.107887 Irf2_predicted1386518_at 0.1117 -0.0769 0.0846 -0.0976 -0.1481
0.0566 -0.1457 0.2572 -0.1862 Rn.101159 Irf71383564_at 0.0000 -0.0408 -0.0780 0.0699 0.1402
-0.0655 -0.0233 -0.2330 -0.1921 Rn.107887 Irf2_predicted1382503_at 0.0699 0.0000 0.0362 0.2542 0.0798
-0.5504 0.0000 0.2178 0.4375 Rn.12385 Irf6_predicted1377379_at -0.4591 -0.1399 0.3012 0.2273 -0.1305
-0.2294 -0.3063 0.0791 -0.1127 Rn.3765 Irf81372097_at 0.0000 -0.3213 0.0518 0.3174 0.0877
0.0615 -0.1511 0.0037 -0.3494 Rn.1499 Irf31371560_at -0.0591 -0.1280 0.0000 0.0147 0.1507
-0.2732 0.3080 0.0351 0.4525 Rn.6396 Irf11368073_at -0.0443 -0.0269 0.2112 0.0000 -0.2066
0.0360 0.0308 -0.1334 0.0091 Rn.9129 Irf2bp1_predicted1367535_at 0.0000 0.0859 -0.1875 -0.0589 -0.0439
0.0000 -0.7602 -0.0101 -0.5047 Rn.54397 Mt1a1371237_a_at 0.1181 -0.4471 0.3966 0.4782 0.6535
-0.0656 -0.1725 0.2836 0.0168 Rn.161711 Nanos3_predicted1397827_at 0.0000 -0.2038 0.1405 -0.0952 0.0637
-0.0104 -0.4674 0.0183 -0.4040 Rn.44265 Nos31371166_at 0.1836 -0.1046 0.0337 0.1842 0.0000
0.1968 0.0961 -0.0866 0.0420 Rn.11238 Pygm1383072_at -0.2132 0.0602 -0.1270 0.0000 -0.0991
0.1298 0.1321 -0.0109 0.1507 Rn.11238 Pygm1375476_at -0.0836 0.0000 0.1655 -0.2378 -0.0397
-0.0551 0.0000 0.1595 -0.2806 Rn.11238 Pygm1370982_at 0.1434 0.0052 -0.1040 0.1925 -0.1168
0.1938 -0.1751 -0.1412 -0.4526 Rn.205543 Socs7_predicted1384888_at 0.0891 0.0548 -0.0446 0.0387 0.0000
0.1762 -0.1427 0.1363 0.0464 Rn.205543 Socs7_predicted1377131_at 0.0000 -0.2802 -0.0235 0.4723 -0.1386
-0.1642 0.0133 -0.1041 0.0000 Socs6_predicted1376666_at -0.1242 -0.1051 0.1666 0.1795 0.1733
0.2191 0.0163 -0.0826 -0.0906 Rn.82754 Socs11375568_at 0.0000 -0.0829 -0.0277 0.0973 0.0103
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G-protein coupled receptor 12
putative G protein-coupled receptor snGPCR32
glypican 2 (cerebroglycan)
glypican 1
1378554_at
1379821_at
1392888_at
1368947_at
1371896_at
1372016_at
1388792_at
1380605_at
1368489_at
1373882_at
1375043_at
1387530_a_at
1387709_at
1383860_at
1370234_at
1373206_at
1373416_at
1374726_at
1376532_at
1376823_at
1378057_at
1379921_at
1382638_at
1383396_at
1392863_at
1367660_at
-0.0376 -0.0118 -0.1206 0.0000 0.1909 0.2285 0.1951 -0.1453 0.1534 Rn.141072 Transcribed locus, strongly similar to XP_980173.1 
0.0057 0.1426 0.0000 -0.1344 -0.0053 -0.0208 -0.0017 0.1720 0.1148 Rn.32566 Fabp3 fatty acid binding protein 3
-0.0706 -0.0254 -0.1935 0.0763 0.1959 0.0000 0.0314 -0.2353 0.1642 Rn.95324 Flrt3_predicted fibronectin leucine rich transmembrane protein 3 (predicted)
-0.1328 -0.0575 0.2087 -0.0264 0.1294 0.0469 0.0000 -0.0145 0.2625 Rn.100627 Fndc3a_predicted fibronectin type III domain containing 3a (predicted)
-0.1865 0.0963 0.0000 0.2456 -0.2232 -0.2050 0.1697 -0.1049 0.0226 Rn.95324 Flrt3_predicted Fibronectin leucine rich transmembrane protein 3 (predicted)
-0.2361 0.0325 -0.1188 0.0000 0.0363 -0.0240 -0.1002 0.1108 0.0244 Rn.41372 Fsd2_predicted fibronectin type III and SPRY domain containing 2 (predicted)
0.0078 0.0000 -0.1819 0.1858 0.1687 -0.0898 -0.0558 -0.0942 0.0113 Rn.95324 Flrt3_predicted fibronectin leucine rich transmembrane protein 3 (predicted)
0.0000 -0.0228 -0.0463 0.1263 0.1767 0.1088 0.0488 -0.1306 -0.1354 Rn.100627 Fndc3a_predicted Fibronectin type III domain containing 3a (predicted)
-0.0471 0.0385 -0.0686 0.0167 0.0715 0.0736 -0.1531 -0.1321 0.0000 Rn.757 Fndc3b_predicted fibronectin type III domain containing 3B (predicted)
0.1154 0.1990 -0.1419 -0.0090 -0.2650 0.0000 0.3778 -0.1981 0.2913 Rn.20633 Fndc1 fibronectin type III domain containing 1
-0.0526 0.1412 0.0000 -0.0165 0.1291 -0.1346 0.0642 -0.1591 0.1027 Rn.757 Fndc3b_predicted fibronectin type III domain containing 3B (predicted)
0.0000 0.0747 -0.0021 0.0348 0.0234 -0.0231 -0.0234 -0.0364 0.0413 Rn.757 Fndc3b_predicted fibronectin type III domain containing 3B (predicted)
0.0000 -0.0269 0.0022 0.0687 0.0434 -0.0194 -0.0556 0.0034 -0.0638 Rn.1604 Fn1 fibronectin 1
0.1543 -0.2991 0.0000 0.1811 0.0013 -0.3393 -0.3860 0.0165 -0.5003 Rn.163577 Fosl2 Fos-like antigen 2
0.2245 -0.0452 0.0000 -0.2303 0.0272 0.1153 0.2118 -0.0770 -0.0657 Rn.10796 Figf c-fos induced growth factor
0.2838 -0.0161 0.4089 0.4766 0.2800 -0.1452 -0.0326 0.0000 -0.0039 Rn.163577 Fosb /// Fosl2 fos-like antigen 2 /// FBJ osteosarcoma oncogene B
-0.1094 0.0191 0.0000 0.0127 -0.0649 -0.2524 0.2200 -0.0541 0.2721 Rn.103750 Fos FBJ murine osteosarcoma viral oncogene homolog
0.0713 0.0283 0.0000 -0.5366 -0.2821 -0.2703 0.1304 -0.0960 0.1271 Rn.10796 Figf c-fos induced growth factor
0.0000 -0.3051 0.0543 0.3376 0.0992 -0.0182 -0.3795 0.0877 -0.2350 Rn.11306 Fosl1 fos-like antigen 1
0.1088 -0.0872 0.0703 -0.0193 -0.0741 0.0639 0.2103 0.0000 -0.0874 Rn.173545 Transcribed locus, strongly similar to XP_213842.2 
-0.0772 -0.0530 0.0928 -0.1088 0.0058 0.0000 0.0221 -0.1569 0.1285 Rn.16950 Gadd45g growth arrest and DNA-damage-inducible 45 gamma
0.0985 0.0762 0.1374 0.0000 -0.0707 -0.1336 -0.0189 0.1527 -0.0857 Rn.35886 Gadd45b growth arrest and DNA-damage-inducible 45 beta
-0.0628 -0.0971 0.0442 -0.0260 -0.0062 0.1109 0.0000 0.0551 0.0099 Rn.161715 Gadd45gip1 growth arrest and DNA-damage-inducible, gamma interacting protein 1
0.0528 0.0201 -0.0627 -0.1091 -0.0473 0.0000 0.0244 -0.0339 0.0513 Rn.10250 Gadd45a growth arrest and DNA-damage-inducible 45 alpha
-0.0311 -0.1111 -0.1303 0.0234 0.0000 -0.3302 0.1903 0.0332 0.1117 Rn.19945 Gpc4 glypican 4
-0.2353 0.0000 0.2050 0.0427 0.0948 -0.5618 -0.1005 0.0814 -0.3710 RGD1560166_predictedsimilar to Probable G-protein coupled receptor 62 (hGPCR8) (predicted)
0.0432 0.1469 0.1985 -0.2473 Rn.7044 Gpc11387039_at 0.0005 -0.0681 0.0000 -0.4101 -0.2968
0.0000 -0.0866 0.1242 -0.1985 Rn.88131 Gpc21370448_at 0.0334 -0.0495 -0.0528 0.1293 0.0733
-0.2342 0.2654 -0.0694 0.3818 Rn.64507 Edg71369055_at -0.2896 -0.2481 0.1961 0.2166 0.0000
0.0734 -0.0018 0.0549 -0.1518 Rn.88417 Gpcr121368786_a_at0.0000 -0.0058 -0.2014 0.2064 0.1494
 
 251 
 
1368271_a_at
1368630_at
1368697_at
1369111_at
1369195_at
1370024_at
1370281_at
1370699_a_at
1370830_at
1385413_at
1367988_at
1368155_at
1368468_at
1368636_at
1368738_at
1368739_s_at
1368990_at
1369136_at
1369264_at
1369275_s_at
1369424_at
1369444_at
1370241_at
1370269_at
1370475_at
1370495_s_at
1370497_at
1371076_at
1376667_at
1387123_at
0.0488 0.0000 -0.0292 0.1265 -0.1104 0.0498 -0.0417 -0.0511 0.0221
0.1509 -0.1205 0.0863 -0.0751 -0.0109 0.2974 0.1421 -0.2433 0.0000 Rn.4258 Fabp4 fatty acid binding protein 4, adipocyte
0.0000 0.1845 -0.0509 -0.1134 0.0097 0.0690 0.0622 -0.1267 -0.0381 Rn.10078 Fabp9 fatty acid binding protein 9, testis
0.0238 -0.0681 0.0000 -0.0729 -0.1237 -0.1452 0.0427 0.0232 0.0213 Rn.10008 Fabp6 fatty acid binding protein 6, ileal (gastrotropin)
Rn.10014 Fabp7 fatty acid binding protein 7, brain
Rn.36412 Fabp1 fatty acid binding protein 1, liver
fatty acid binding protein 2, intestinal
0.0201 -0.0743 0.0147 -0.0457 0.0463 -0.1145 0.0989 0.0000 -0.0530
Rn.37227 Egfr /// Pepd epidermal growth factor receptor /// peptidase D
0.1084 0.0000 -0.0476 0.0847 0.1436 0.0204 -0.0410 -0.0170 -0.0614 Rn.98269 Fabp5 fatty acid binding protein 5, epidermal
-0.3145 -0.2400 0.2001 0.1170 -0.0110 -0.2736 0.0714 0.0000 0.2603
Rn.37227 Egfr epidermal growth factor receptor
0.2342 -0.0383 -0.0354 0.0776 0.0343 -0.2331 0.2681 0.0000 -0.2253 Rn.37227 Egfr epidermal growth factor receptor
0.2990 -0.0448 0.0990 0.0000 -0.0637 -0.0637 0.1302 -0.2061 0.1417
Rn.2586 Cyp2c12
-0.5116 -0.5098 0.4797 0.7868 0.0000 -0.2896 -0.3307 0.0662 0.1668 Rn.2184 Cyp2c23 cytochrome P450, family 2, subfamily c, polypeptide 23
cytochrome P450, family 2, subfamily c, polypeptide 120.0861 -0.0412 -0.0578 0.0118 0.0116 0.0000 -0.1547 0.1466 -0.0528
Rn.10847 Cyp27b1 cytochrome P450, family 27, subfamily b, polypeptide 1
0.0799 0.0000 0.1524 0.0009 -0.2575 0.1280 -0.0942 -0.2308 -0.1754 Rn.1401 Cyp11a1 cytochrome P450, family 11, subfamily a, polypeptide 1
0.0000 -0.0255 0.0230 -0.1717 0.0838 -0.0177 -0.0144 0.0225 0.0633
Rn.198236 Cyp11b1 /// Cyp11b2 /// Cyp11b3cytochrome P450, family 11, subfamily B, polypeptide 2 , polypeptide 3 , polypeptide 1
0.0823 -0.1111 -0.0956 0.0000 0.0364 -0.1043 0.0272 0.1620 -0.1663 Rn.198235 Cyp11b1 cytochrome P450, subfamily 11B, polypeptide 1
0.0368 0.1239 0.0315 0.0000 -0.0644 -0.1354 0.0167 -0.1164 -0.1185
Rn.2063 Cyp2a3a cytochrome P450, family 2, subfamily A, polypeptide 3a
-0.0028 0.0635 0.0212 0.0000 0.2733 0.3023 -0.0437 -0.1989 -0.3639 Rn.10125 Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1
0.0208 -0.1603 0.0233 0.0424 0.1076 0.0000 -0.2185 -0.3179 -0.3485
Rn.9867 Cyp2a1 /// Cyp2a2 cytochrome P450 IIA1 
-0.0421 0.1396 -0.0611 -0.1468 0.0384 0.0000 0.0049 0.0506 -0.0400 Rn.161726 Cyp21a1 cytochrome P450, subfamily 21A, polypeptide 1
-0.0273 0.0617 -0.1428 -0.0027 -0.0662 0.1313 0.0938 0.0131 0.0000
Rn.21402 Cyp19a1 cytochrome P450, family 19, subfamily a, polypeptide 1
0.0000 0.0047 0.1426 0.0386 -0.0002 0.2579 -0.0002 -0.0002 -0.0002 Rn.9867 Cyp2a2 cytochrome P450, subfamily 2A, polypeptide 1
-0.1153 -0.1645 0.0252 0.0338 0.0484 0.0000 -0.0589 -0.0665 0.0386
Rn.10352 Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1
0.1879 0.0594 -0.2864 -0.3244 0.1088 -0.0949 0.1207 0.0000 -0.2239 Rn.1247 Cyp2c7 cytochrome P450, family 2, subfamily c, polypeptide 7
-0.0676 -0.2051 -0.0279 0.4732 0.5083 0.0175 -0.1119 0.3176 0.0000
Rn.82715 Cyp2c13 cytochrome P450 2c13
0.0491 -0.0438 0.2407 0.2919 -0.1354 0.1581 -0.0893 0.0000 -0.0042 Rn.4845 Cyp2b3 cytochrome P450IIB3
-0.0271 -0.0550 -0.1799 0.0914 0.2743 -0.2155 0.0011 0.0000 0.2019
Rn.91353 Cyp2b15 /// Cyp2b2 cytochrome P450, family 2, subfamily b, polypeptide 15, polypeptide 2
-0.0485 0.0681 0.0814 -0.0550 0.0163 0.0539 -0.0558 0.0000 -0.1702 Rn.198236 Cyp11b3 cytochrome P450, subfamily 11B, polypeptide 3
0.0554 -0.0860 0.0000 0.0780 0.2645 -0.1485 -0.0023 0.1779 -0.0055
Rn.10172 Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1
0.0000 -0.4174 0.0067 -0.0528 0.0649 -0.1118 0.3276 0.1508 -0.1670 Rn.19898 Cyp26b1 cytochrome P450, family 26, subfamily b, polypeptide 1
0.2472 -0.1063 0.2602 0.1158 -0.1609 0.0000 -0.0147 0.0607 -0.4130
-0.1937 -0.2941 0.2696 0.1901 0.1936 -0.0911 0.0000 0.0317 -0.0674 Rn.91358 Fabp2
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1387243_at
1387305_s_at
1387328_at
1387511_at
1387583_at
1387722_at
1387914_at
1387949_at
1387993_at
1378551_at
1384392_at
1369354_at
1369529_at
1369828_at
1371227_at
1371228_at
1373020_at
1388784_at
1379631_at
1380582_at
1380583_s_at
1382153_at
1382692_at
1386009_at
1392528_at
1397360_at
1372481_at
1370131_at
1372111_at
1393281_at
-0.0736 0.0989 -0.0966 -0.0475 0.0725 -0.1860 0.1559 0.3419 0.0000
Rn.22518 Cav1 caveolin, caveolae protein 1
0.0000 0.0323 -0.0990 -0.0341 0.0600 -0.1070 0.1606 -0.0655 0.2309 Rn.22518 Cav1 caveolin, caveolae protein 1
0.0000 0.0895 -0.1152 -0.1287 0.0623 -0.1566 0.2416 -0.2845 0.4642
Rn.22518 Cav1 caveolin, caveolae protein 1
0.0000 -0.2220 0.4455 0.2511 0.4987 0.1469 -0.4029 -0.2281 -0.2576 Rn.2721 Cd34_predicted CD34 antigen (predicted)
-0.0752 0.1155 -0.0080 0.0000 0.0261 -0.2153 0.2791 -0.5422 0.5955
Rn.82624 Clecsf1_predicted C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 1
0.1054 0.1318 0.0000 0.0063 -0.0550 -0.0002 0.2189 -0.1239 -0.2701 Rn.216620 Csf2ra Granulocyte-macrophage colony stimulating receptor alpha
0.0000 0.0737 0.0452 -0.0533 0.0807 -0.0442 -0.1258 0.0442 -0.0542
Rn.134664 Csf3r_predicted colony stimulating factor 3 receptor (granulocyte) (predicted)
0.1667 0.1048 0.1820 -0.0920 -0.0541 -0.0740 0.2159 0.0000 -0.0883 Rn.15743 RGD1565140_predicted similar to Clecsf12 protein (predicted)
-0.0142 0.0990 -0.1242 0.0187 0.0043 -0.1953 0.1304 -0.0937 0.0000
Rn.24032 Clecsf6 C-type (calcium dependent, carbohydrate recognition domain) lectin, superfamily member 6
0.0726 0.0832 -0.1144 -0.0222 0.1073 0.0108 -0.0477 0.0000 -0.2442 Rn.83632 Csf1 colony stimulating factor 1 (macrophage)
-0.1235 0.2176 -0.0129 -0.0370 0.0000 -0.1967 0.2079 0.0046 0.1807
Rn.83632 Csf1 colony stimulating factor 1 (macrophage)
-0.0902 0.1234 0.0000 -0.0110 0.2408 -0.4566 0.0560 -0.0391 0.1589 Rn.83632 Csf1 colony stimulating factor 1 (macrophage)
0.1466 0.0777 0.0000 0.1118 0.1163 -0.0036 -0.0278 -0.0503 -0.2263
Rn.72599 Csf1r colony stimulating factor 1 receptor
0.0020 0.0082 -0.1041 0.0305 0.0506 -0.1043 -0.1265 0.0000 -0.1154 Rn.144694 LOC679907 /// LOC687579similar to mitochondria-associated granulocyte macrophage CSF signaling molecule
0.0000 0.0301 -0.0391 -0.4358 -0.3435 -0.0211 0.2865 0.0364 0.0841
Rn.44285 Csf2 colony stimulating factor 2 (granulocyte-macrophage)
0.0886 0.0000 -0.1690 0.0008 0.0185 -0.1077 -0.0418 0.0138 -0.1159 Rn.44285 Csf2 colony stimulating factor 2 (granulocyte-macrophage)
0.2749 -0.0297 0.0234 -0.2109 -0.1051 0.0000 -0.0370 0.0488 0.0566
Rn.42930 Csf2rb1 colony stimulating factor 2 receptor, beta 1
0.1554 -0.4372 0.1481 -0.0837 0.0738 0.1726 -0.1034 0.0000 -0.0961 Rn.53973 Csf3 colony stimulating factor 3 (granulocyte)
0.1611 -0.0131 -0.2885 0.0077 0.1137 0.0994 -0.1221 0.0000 -0.0025
cytochrome P450, family 26, subfamily b, polypeptide 1
colony stimulating factor 1 (macrophage)0.0000 -0.2202 0.2189 0.5552 -0.0427 -0.0963 0.2080 0.4266 -0.0988 Rn.83632 Csf1
-0.2805 -0.3522 0.1840 -0.0249 0.3279 0.0000 0.5382 0.1078 -0.0535 Rn.19898 Cyp26b1
Rn.101629 Cyp20a1 cytochrome P450, family 20, subfamily A, polypeptide 1
0.0680 0.0000 0.1599 -0.0974 0.0090 0.0642 -0.1365 -0.0921 -0.1771 Rn.38261 Cyp2b21 cytochrome P450, family 2, subfamily b, polypeptide 21
-0.1581 -0.1159 -0.0059 0.0000 0.0418 -0.0792 0.1267 0.0859 0.1140
Rn.88025 Cyp2c22 cytochrome P450, family 2, subfamily c, polypeptide 22
-0.0679 -0.2633 0.4012 0.1428 0.0894 -0.2719 0.0000 -0.0281 0.2327 Rn.94956 Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1
-1.2063 -1.4705 0.4483 0.4797 0.0000 -1.0213 -0.3387 0.0356 0.2922
0.0947 0.0616 -0.1781 0.0000 -0.1499 0.1137 -0.0993 0.0535 -0.0903
Rn.10870 Cyp2c cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase)
Rn.144570 Cyp2b15 cytochrome P450, family 2, subfamily b, polypeptide 15
Rn.32107 Cyp2a1 cytochrome P450 IIA1 (hepatic steroid hydroxylase IIA1) gene
cytochrome P450, family 26, subfamily A, polypeptide 1Rn.81072 Cyp26a1
0.0270 0.0347 -0.2283 -0.0833 0.0625 0.0000 -0.1982 0.0424 -0.2745
Rn.5563 Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2
-0.0395 0.0000 -0.0793 0.2549 0.0298 0.1126 0.1638 -0.1583 -0.1372 Rn.198235 Cyp11b1 /// Cyp11b2 cytochrome P450, family 11, subfamily B, polypeptide 2,  polypeptide 1
-0.1882 0.0046 -0.1980 0.1699 0.0000 -0.0391 0.0011 -0.0408 0.0216
0.0000 -0.0255 -0.0952 -0.1118 0.1915 0.0612 0.2545 -0.4288 0.0560
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1388544_at
1383551_at
1377166_at
1386313_x_at
1398562_at
1381455_at
1383155_at
1384279_at
1367555_at
1367556_s_at
1370214_at
0.3000 -0.0265 0.3642 -0.0266 0.0862 0.0000 -0.0143 -0.0241 0.2345
Rn.204528 Bpgm 2,3-bisphosphoglycerate mutase
-0.0305 0.0288 -0.0288 -0.0496 0.0522 0.1683 0.2099 -0.1876 0.0000 Rn.204528 Bpgm 2,3-bisphosphoglycerate mutase
0.1119 0.0000 -0.0114 -0.0457 0.0551 0.2872 0.1223 -0.0139 -0.1097
-0.0006 0.0000 0.0322 -0.1048 0.0480 0.0179 -0.0105 -0.0723 0.0353 Rn.6408 Als2 Amyotrophic lateral sclerosis 2 (juvenile) homolog (human)
Rn.98599 Als2cr4_predicted amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 4 (predicted)
Rn.98599 Als2cr4_predicted amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 4 (predicted)
amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 4 (predicted)Rn.98599 Als2cr4_predicted
-0.0247 -0.0805 0.1136 -0.0220 -0.0689 0.0000 0.2494 0.2358 0.0740
Rn.8070 Als2cr13_predicted amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 13 (predicted)
0.0456 -0.2303 0.0213 -0.1206 0.0069 -0.0382 0.0887 0.0000 -0.0587 Rn.8070 Als2cr13_predicted amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 13 (predicted)
0.1391 0.0000 -0.0296 0.3322 -0.0581 -0.1160 0.2948 -0.0147 0.3831
Rn.202968 Alb albumin
0.0000 0.0040 -0.4016 0.2933 0.0943 -0.3539 -0.0303 0.2045 -0.2145 Rn.202968 Alb albumin
0.0744 0.0000 0.0336 0.0187 0.0483 -0.0061 -0.2153 -0.0195 -0.1422
parvalbumin-0.0495 -0.0906 0.0000 0.3272 0.2257 -0.0249 -0.0294 0.0994 0.0438 Rn.2005 Pvalb
0.0040 -0.2301 0.1461 0.0000 -0.1889 -0.0443 0.2154 -0.0211 0.1873
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